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 The primary cause of chronic myelogenous leukemia (CML) is the presence of 
the Philadelphia chromosome, resulting in the oncoprotein Bcr-Abl.  The constitutive 
tyrosine kinase activity of Bcr-Abl, localized intracellularly in the cytoplasm, activates 
numerous oncogenic signaling pathways.  Conversely, Bcr-Abl trapped in the cell 
nucleus induces apoptosis.  This work is aimed at turning the oncogenic Bcr-Abl 
signaling into apoptotic signaling through redirecting Bcr-Abl, found only in the 
cancerous cells, to the nucleus.    
 First, this work validated that Bcr-Abl could be directed to the nucleus with 
nuclear localization signals, and that nuclear Bcr-Abl does induce apoptosis.  Ectopic 
expression of a nuclear localized Bcr-Abl construct in CML cells activated apoptotic 
signaling.   
 Next, this worked focused on the design and isolation of Bcr-Abl binding 
domains.  The first approach was the rational design of the Bcr-Abl coiled-coil domain 
which led to identification of mutations that could be made to enhance the 
oligomerization properties with Bcr-Abl.  A nuclear translocation assay was then 
developed for studying protein interactions inside a live cell, and confirmed the 
modifications to the coiled-coil domain improved the binding to the wild-type coiled-coil 




to the nucleus, the improved oligomerization domain (CCmut2) was found to function as 
an inhibitor of Bcr-Abl.  A second generation modification to the Bcr-Abl coiled-coil 
domain, CCmut3, was found to exhibit even greater binding than CCmut2 and also 
inhibited Bcr-Abl.   
 As an alternative binding approach we used the intracellular antibody capture 
(IAC) methodology to isolate single domain antibodies (iDabs).  Two Bcr-Abl regions 
with potential implications in the cytoplasmic retention of Bcr-Abl were targeted in the 
iDabs screens, the actin binding domain and Dbl homology/Pleckstrin homology 
domains.  These screens produced ABI7, and when co-expressed with Bcr-Abl, caused a 
redistribution of the normal Bcr-Abl localization pattern.   
 Both CCmut3 and ABI7 were tested for their ability to translocate Bcr-Abl into 
the nucleus and together were found to efficiently redirect Bcr-Abl to the nucleus.  The 
culmination of this work is an established method to efficiently redirect Bcr-Abl from the 
cytoplasm into the nucleus where it is known to induce apoptosis. 
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 Proteins are essential to any organism due to their numerous biological roles 
including enzymatic reactions, structural integrity, and inter- and intracellular 
communication. These life dependent functions are both temporally and spatially 
regulated, and just as a mutated protein may not function, a protein in the wrong location 
may not function, or may have an alternate function in the new environment.  
Mislocalized proteins have been documented to be the cause of numerous diseases such 
as cancer, diabetes, schizophrenia, and cystic fibrosis (1-3).  The ability to control the 
localization of a protein is a remarkable tool that not only provides a method for studying 
the effects of protein localization, but also exhibits the potential to be used therapeutically 
to overcome the results of a mislocalized protein.  The control over the translocation 
between the cytoplasm and the nucleus has been previously optimized in the Lim 
Laboratory for the greatest nuclear translocation upon addition of ligand.  The resulting 
chimeric protein was called a “protein switch” (4), and allows for the reversible 
translocation between two subcellular compartments through the addition or removal of a 
ligand.  Although various other “protein switches” that translocate to other subcellular 
compartments have been constructed in the Lim Laboratory, the protein switch used in 
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the studies herein are based on the optimized nucleo-cytoplasmic shuttling protein switch 
and consist of the HIV Rev nuclear export signal (NES), the MycA8 nuclear localization 
signal (NLS), and the glucocorticoid ligand binding domain (LBD).  In the absence of the 
synthetic glucocorticoid dexamethasone (dex), the NES is dominant and causes the 
protein switch to localize primarily to the cytoplasm.  When dex is added, it induces a 
conformational change in the LBD, resulting in the NLS becoming dominant, and the 
protein switch translocates into the nucleus.  A simple method of conveying control over 
the subcellular localization of a protein of interest is to genetically engineer a fusion 
protein consisting of the protein switch and the protein of interest.  This fusion protein, 
and the ability to control its translocation between two compartments by adding or 
removing dex, allows for studying the function of the protein of interest in each of the 
compartments.  Although fusing a protein of interest to the protein switch is a useful 
method to study the correlation between function and location of a protein, the 
therapeutic application is limited to diseases which may be treated by restoring a lost 
protein function. Potential problems with a treatment involving a protein known to have a 
role in causing the disease state are a further limitation.  More broadly applicable is the 
ability to move an endogenous protein from one subcellular location to another.  Critical 
to achieving this goal is a way to bind the protein switch to the protein of interest, 
enabling the targeting of a disease causing protein. By incorporating into the protein 
switch a domain/protein that interacts with a protein of interest, a mislocalized protein 
can be redirected to the appropriate location as a means of therapeutic intervention (see 











Figure 1.1 Protein switch mechanism.  The PS, shown schematically (top diagram), 
consists of a NES, NLS, ligand-binding domain and binding domain.  When PS plasmid 
is transfected into cells, the expressed PS captures a PoI in the cytoplasm.  Upon addition 
of ligand, the PS-PoI complex translocates to the nucleus.  L: Ligand; NES: Nuclear 
export signal; NLS: Nuclear localization signal; PoI: Protein of interest; PS: Protein 
switch. (Reprinted by permission from Ther Deliv. 2010 Jul 1;1(1):169-193.) 
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 of interest so long as a binding motif to that protein has been identified or can be 
generated.  As an alternative to the traditional attempt to stop the undesired function of 
the mislocalized protein, the protein switch allows for the redirection of the protein to the 
appropriate location to not only stop the aberrant function in the wrong compartment, but 
also restore the proper function in the right compartment. 
 The oncoprotein Bcr-Abl is the primary cause of chronic myeloid leukemia due to 
unregulated signaling of the tyrosine kinase domain in the cytoplasm of the leukemic 
cells (5-7).  The constitutive activity of Bcr-Abl in the cytoplasm, which results in the 
uncontrolled cell proliferation, has the opposing role of inducing apoptosis in the nucleus 
(3, 5).  Prior to the protein switch, there was no way of exploiting the apoptotic abilities 
of Bcr-Abl as a mode of fighting the Bcr-Abl containing cells.  Moreover, the potential of 
using an active Bcr-Abl protein to induce apoptosis would be applicable to tyrosine 
kinase inhibitor (TKI) resistant cells (8-11) and even the cancer stem cells that are 
refractory towards TKI therapy (12-15).  This first chapter will describe the etiology of 
chronic myelogenous leukemia (CML) and the pathogenic role of Bcr-Abl in CML.  The 
protein switch concept will then be described in both the context of the application to 
escort Bcr-Abl to the nucleus for controlled induction of apoptosis in CML cells, as well 
as the context of the nuclear translocation assay.  As a binding motif is pivotal in using 






Background and Significance 
Chronic Myeloid Leukemia 
The Philadelphia Chromosome 
 The Philadelphia chromosome (Ph), named after the city where it was identified, is 
responsible for 90-95% (16-19) of chronic myeloid leukemia and 20% of adult acute 
lymphoblastic leukemia (19, 20), and was the first abnormal chromosome to be directly 
correlated to a specific disease.  The shortened chromosome 22 was first identified in 
leukocytes from people with CML by Peter Nowell and David Hungerford in 1960 (16, 
21, 22), but at this time it was not known whether the chromosomal abnormality was the 
result of a deletion or a translocation.  It was not until 13 years later that Janet Rowley 
was able to demonstrate the Ph was a result of a reciprocal translocation between 
chromosomes 9 and 22 (23).  Further work by others more fully characterized the 
translocation as t(9:22)(q34:q11), involving the fusion of the Abelson kinase gene (abl) 
from chromosome 9 onto the Breakpoint Cluster Region gene (bcr) of chromosome 22 
and the resulting expression of the oncoprotein Bcr-Abl (17, 24, 25).  In most patients 
with CML the breakpoints are located between exons 12 and 16 of bcr, termed the major 
breakpoint cluster region, and between exon Ib and Ia of the abl gene, which generate a 
210 kDa protein (p210Bcr-Abl) (26, 27).  Alternative breakpoints generate a 190 kDa 
protein (p190Bcr-Abl) commonly found in Philadelphia chromosome positive (Ph+) B cell 
acute lymphoblastic leukemia (B-ALL) and a 230 kDa protein (p230Bcr-Abl) found in 
chronic neutrophilic leukemia (28-30).  It has been demonstrated in a mouse model that 
expression of p210Bcr-Abl is sufficient to induce a myeloproliferative disorder typical of 
CML (31), directly indicating the Philadelphia chromosome provokes CML.   
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Disease Characterization and Progression 
 When a hematopoietic stem cell acquires the Ph, the resulting expression leads to 
an uncontrolled production of blast cells, and classification of CML into three distinct 
phases can be based on counts of these cells.  As defined by the World Health 
Organization, the chronic phase is characterized by the leukocytes in the blood and 
marrow being comprised of less than 10% blast cells (32).  Most CML patients are 
diagnosed in this chronic phase by the presence of the Ph after hypercellularity is 
detected in a medical examination as a periodic check-up or for an unrelated condition, a 
fact reflecting that this phase is not generally associated with noticeable symptoms.  If 
undiagnosed and untreated, the chronic phase typically progresses to accelerated phase 
within 3-6 years (33), defined by 10-19% blasts in the blood and marrow (32).  Even with 
treatment the chronic phase may advance to the accelerated phase due to additional 
chromosomal abnormalities, increased expression of Bcr-Abl, genomic instability, 
inactivation of tumor suppressor genes, and arrest of differentiation (34).  Patients in the 
accelerated phase typically exhibit thrombocytopenia, neutropenia, anemia, and 
splenomegaly, which result in infections, contusions, hemorrhages, fatigue, weight loss, 
and a general loss of well-being.  Within a couple months (untreated) the accelerated 
phase moves to blast phase (blast crisis) characterized by more than 20% blast cells in the 
blood and bone marrow (32).  In blast crisis there is an increase in severity of the 
previously mentioned symptoms, and results in similar effects as acute myeloid leukemia 
or, less frequently, acute lymphoid leukemia.  The fatal effects of blast crisis are 
primarily a result of the blast cells over whelming and limiting the number of mature and 
functional blood cells.   
7  
 
Prognosis and Treatment 
 It is estimated that approximately 5,000 people in the US will be diagnosed with 
CML in 2011, with the median age at diagnosis being 65 (35).  In 2010 it was estimated 
that 440 people in the US died due to CML (35).  Currently, the only cure for CML is 
allogenic stem cell transplantation, but this treatment is generally salvage therapy used 
for patients in accelerated phase, blast crisis, or otherwise resistant forms of CML.  The 
rationale for considering stem cell transplantation as salvage therapy is the effective 
management of CML with tyrosine kinase inhibitors (TKIs) coupled with the risk of the 
stem cell transplant.  Donor availability and recipient qualifications are also limiting 
factors.  Stem cell transplantations are not generally used for patients older than 60, and, 
with the high median age at diagnosis of CML, this curative approach is not an option for 
a large percentage of CML patients.  In addition, other factors such as phase of disease, 
matching of donor, and Bcr-Abl mutations affect the outcome and overall survival rate 
(36, 37).   
 The current first-line treatment of CML is one of three TKIs: imatinib (Gleevec®), 
nilotinib (Tasigna®), or dasatinib (Sprycel®).  The first FDA approved TKI, imatinib, not 
only altered the treatment and prognosis of patients with CML, but validated the 
approach to rationally design drugs (38-40).  Imatinib has exhibited astonishing results of 
97% hematological response (normalization of the white blood cell counts), and 82% 
cytogenetic response (absence of Philadelphia chromosome in 20 metaphases on classical 
karyotyping on bone marrow) (41, 42) when treating CML patients in the chronic phase.  
Both nilotinib and dasatinib have lower IC50 values than imatinib and have further 
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enhanced the treatment of CML (43).  However, in spite of the success observed with 
TKIs, they do not cure CML (44), and patients will require continual treatment to manage 
the disease.  If treatment is discontinued, the disease rapidly returns (45, 46).  The return 
of the disease is attributed the “residual disease,” or the inability of TKIs to eliminate all 
the Ph cells (47-49).  Specifically, TKIs do not induce apoptosis in the quiescent 
hematopoietic stem cells containing the Ph in spite of the over-expression of Bcr-Abl and 
the ability of the TKI to inhibit Bcr-Abl (50, 51).  Given that any remaining stem cells 
containing the Ph will generate more Ph blast cells, it is easy to see why relapse occurs if 
treatment is discontinued or resistance develops.  The inability to eliminate these 
leukemic stem cells underscores the necessity for alternative therapies with the ability to 
target these critical cells.   
 
Resistance and Adverse Events 
 It is estimated that as many as 28% of patients on imatinib will have to stop 
treatment due to intolerance or resistance (41, 52).  Resistance can be classified as 
primary resistance or secondary resistance.  Failure to achieve complete hematologic 
response within 3-6 months, a partial cytogenic response by 12 months, or a complete 
cytogenic response within 18 months is defined as primary resistance.  Secondary 
resistance, or acquired resistance, is the loss of response following an initial achievement 
of either complete hematologic or complete cytogenic response.  The development of 
point mutations in the kinase domain of Bcr-Abl is the leading cause of secondary 
resistance, but ranges from 40-90% of cases due to variations in the definition of 
resistance, the method used to detect the mutation, and the phase in which the resistance 
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develops (8, 53, 54).  Although more than 100 mutations have been identified in Bcr-Abl 
(54-56), all of these mutations can be treated with one of the approved TKIs except for 
T315I (57-59).  This mutation, termed the gate keeper mutation, prevents the TKI from 
forming a critical hydrogen bond with Bcr-Abl and adds steric block to the ATP-binding 
region.  The prevalence of this mutation is estimated to be up to 19% of patients with 
imatinib resistance (54, 60-62).  However, two third-generation TKIs have demonstrated 
the ability to inhibit Bcr-Abl with the T315I mutation, ponatinib and DCC-2036, and are 
currently in clinical trials (63-66).   
 Although imatinib was found to induce cell death in cardiomyocytes through 
activation of the endoplasmic reticulum stress response (67), leading to the fear that 
imatinib and other inhibitors of c-Abl would cause cardiotoxicity, the incidence of 
cardiotoxicity in CML patients so far has been minimal, <0.1% (41, 42, 68, 69).  There 
are, however, adverse events such as cytopenias, nausea, vomiting, fever, abdominal 
pain, and periorbital edema (42, 70).   
 
Dr. Abl and Mr. Bcr: Cytoplasmic Oncogenicity and Nuclear Apoptosis 
 Bcr-Abl primarily localizes to the cytoplasm where it activates numerous pathways 
which result in cell proliferation, increased cell motility, and oncogenesis (Figure 1.2).  
Bcr-Abl is a complex protein consisting of numerous functional domains, and the 
signaling through Bcr-Abl is the cumulative result of these domains.  As illustrated in 
Figure 1.2, the Bcr portion of p210Bcr-Abl contributes four domains; a coiled-coil domain 
(CC), serine/threonine kinase domain (S/T kinase), Dbl homology domain (DH), and 





Figure 1.2. Bcr-Abl domains and signaling.  Only some pathways affected by Bcr-Abl 
signaling are illustrated.  The dashed lines indicate intermediate steps that are not 
depicted in the diagram. 
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homology 3 domain (SH3), Src homology 2 domain (SH2), tyrosine kinase domain (Y 
kinase), DNA binding domain (DBD), and an actin binding domain (ABD).  The fusion 
of Abl onto Bcr relieves the autoinhibition of the Abl tyrosine kinase domain and 
generates a constitutively active protein (71) that signals cell proliferation, inhibition of 
apoptosis, and altered cell adhesion and motility (72-75).  The Bcr coiled-coil domain is 
responsible for the oligomerization of the oncoprotein into first a dimer, and subsequently 
a tetramer (76, 77), and has been shown to be both essential and sufficient to activate the 
tyrosine kinase domain of Abl (78).  Through the S/T kinase domain (specifically 
tyrosine 177) (79, 80), Bcr-Abl activates the Ras pathway which signals cell proliferation 
and transformation (78, 81-85).  The combination of the S/T kinase and Y kinase 
domains also activate the phosphatidylinositol-3 kinase (PI3K)/AKT pathway (81, 86) 
associated with inhibition of apoptosis and inhibition of inhibitors of cell proliferation 
(78-80).  As evident from the successes of imatinib, dasatinib, and nilotinib (tyrosine 
kinase inhibitors), the tyrosine kinase domain is of paramount importance in the 
oncogenesis of Bcr-Abl.  This domain is responsible for phosphorylating and activating a 
list of proteins (81, 87-95).  The SH3/SH2 domains play critical roles in regulating the 
tyrosine kinase activity and interacting with substrate proteins that are phosphorylated by 
the tyrosine kinase domain (96-98).  In short, the pathogenesis of CML induced by Bcr-
Abl is complex and is a cumulative effect of these various domains in concert.  
 The fusion of Abl onto Bcr results not only in the constitutive activity of Abl, but 
also an altered subcellular localization.  While c-Abl is known to shuttle between the 
cytoplasm and the nucleus (99), Bcr-Abl is primarily cytoplasmic (100, 101).  This 
subcellular localization is important in the regulation of the various functions of c-Abl 
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(99, 102).  In the nucleus, c-Abl can bind distorted DNA structures and A/T duplexes 
(103, 104), interacts with retinoblastoma (RB) protein (105, 106), and regulates p73 (107-
109) and RNA polymerase II (110-114).  c-Abl is involved in cell cycle regulation and 
induction of apoptosis (99, 102), and the tyrosine kinase activity of c-Abl has been shown 
to be activated by several apoptotic agents such as cisplatin (107), ionizing radiation 
(115), mitomycin C (116, 117), etoposide (117), TNF (117), and camptothecin (117).  
Cells with homozygous deletion of the c-Abl gene have also been shown to have a 
reduced apoptotic response to ionizing radiation (118).   
 The opposing roles of Bcr-Abl in cell proliferation and c-Abl in apoptosis are 
correlated to the subcellular localization of these two proteins.  The theory that  Bcr-Abl 
would also regulate apoptosis if located in the nucleus was initially validated by Vigneri 
and Wang who showed the nuclear accumulation of Bcr-Abl resulted in the induction of 
apoptosis (5) and subsequently by Aloisi et al. using samples from CML patients (3).  
The potency of the nuclear Bcr-Abl is evident by the induction of apoptosis by a small 
percentage of Bcr-Abl protein (20-25%) that became trapped inside the nucleus.  We 
have further demonstrated in this work that an exogenously added Bcr-Abl, with 
additional nuclear localization signals to direct it to the nucleus, induced apoptosis in 
leukemia cells (119).  The remainder of this work was aimed at identifying Bcr-Abl 
binding domains, and subsequently using those identified binding domains to translocate 
Bcr-Abl to the nucleus, as a means of exploiting this potent apoptotic potential as a novel 




Controlling Nucleo-Cytoplasmic Translocation of  
Bcr-Abl Using the Protein Switch 
 Since the pioneering work by Nobel Laureate Günter Blobel on signal sequences in 
proteins (120), numerous studies have been done to characterize these localization signals 
and use them to direct proteins, nucleic acid, and other macromolecules to a desired 
compartment within a cell (Figure 1.3).  Nevertheless, while much work has been done 
with localization signals, the protein switch exhibits the unique property of the 
localization being controlled through the presence or absence of a ligand (121).  Various 
ligand inducible transcription factors have been generated (122-127), and paved the way 
for the development of the bidirectional protein switch developed in our laboratory.  
Comprised of three components, the protein switch contains a nuclear localization signal 
(NLS), a nuclear export signal (NES), and a ligand binding domain (LBD).  In the 
absence of the ligand, the NES is dominant and the protein switch localizes to the 
cytoplasm.  When the ligand is added, it binds to the LBD and causes a conformational 
change that sends the protein switch to the nucleus.  Nuclear import and export signals 
have been extensively studied (121, 128, 129) and optimized as protein switches (4, 128) 
that exhibit the most nuclear increase upon ligand induction.  The optimized protein 
switch contains the NES sequence from the HIV-rev protein (LQLPPLERLTL), and the 
NLS sequence from the MycA8 protein (PAAKRVKADE) fused to the rat glucocorticoid 
receptor LBD containing the C656G mutation that renders it 10 times more sensitive to 
the agonistic ligand dexamethasone (130).  The HIV-rev NES fits the typical leucine-rich 
sequences that are recognized by the classical export receptor, chromosomal region 











Figure 1.3.  Drug targeting to cellular organelles.  Text on arrows indicate consensus 
targeting sequence (if available), example of targeting signal, or mode of targeting. ER = 




LX2-3LXJ, where X is any amino acid and J is leucine, valine or isoleucine (128, 129, 
131).  The MycA8 NLS sequence contains 3 basic residues which are common to 
sequences recognized by importin-α and then transported to the nucleus by the importin-
α/β heterodimer (132-134).  This optimized protein switch provides a controlled method 
of shuttling between the cytoplasm and the nucleus.  Representative images of the 
nucleo-cytoplasmic translocation of the protein switch are illustrated in Figure 1.4.   
 There are numerous examples in the literature of mislocalized proteins that result in 
diseases to which the protein switch would be useful (1, 134).  As described in the 
previous section, the oncogenic Bcr-Abl is one of these proteins, and through 
relocalization with the protein switch, can be converted from an oncoprotein to an 
apoptosis inducing factor. 
 
The Protein Switch Can Be Used to Study Protein 
Interactions in Live Cells 
 The main goal intended for the protein switch is the translocation of a disease 
causing protein for therapeutic intervention.  However, the ability to translocate a second 
protein to the nucleus can be used as a measurement of the interaction between the 
protein switch and the second protein.  This capability of the protein switch to monitor 
protein interactions has been termed the nuclear translocation assay, or NTA.  While 
there are numerous methods to study protein interactions, there are relatively few assays 
for quantifying the interaction inside a live cell under the biological conditions wherein 
the interaction occurs.  The NTA is a method of studying protein interactions in the 

















Figure 1.4. EGFP fused to the protein switch and transfected into 1471.1 murine 
adenocarcinoma cells. A) In the absence of ligand, the nuclear export signal (HIV NES) 
causes the protein switch to localize in the cytoplasm. B) The nuclear localization signal 
(MycA8 NLS) causes the protein switch to localize to the nucleus after the induction with 




strategy is relatively limited, the application of the protein switch to studying protein 
interactions inside cells is more applicable to a broad range of scientists.   
 As already described, the protein switch localizes in the cytoplasm in the absence of 
ligand, and translocates to the nucleus upon addition of ligand (Figure 1.4) (4).  A 
protein, or protein domain, can be fused to the protein switch through genetic engineering 
to grant control over the nucleo-cytoplasmic shuttling of that protein.  If nuclear 
accumulation of a second protein that is not fused to the protein switch and is not 
responsive to the ligand occurs upon addition of ligand, it is due to the interaction with 
the protein switch construct.  The translocation of both proteins is easily monitored 
through tagging one protein with EGFP, tagging the other with DsRed, and fluorescence 
microscopy.  Thus, not only does the NTA allow protein interactions to be assayed inside 
a cell, but is relatively simple and essentially only requires a fluorescence microscope.   
 
A Binding Domain Is Essential to the Protein Switch 
 As will be demonstrated in Chapter 2, it is possible to induce apoptosis by sending 
exogenous Bcr-Abl to the nucleus through the attachment of additional nuclear 
localization signals (119).  This demonstrates the ability to induce apoptosis when inside 
the nucleus, without cytoplasmic depletion of endogenous Bcr-Abl.  Further, this 
suggests the apoptotic signal from Bcr-Abl is greater than the proliferative signals in the 
cytoplasm, yet it is easy to speculate on the increased, and maybe even synergistic, effect 
when the removal of the cytoplasmic proliferative signal is combined with the nuclear 
apoptotic signal.  Thus, the translocation of endogenous Bcr-Abl from the cytoplasm into 
the nucleus may produce an even greater apoptotic response due to removal of oncogenic 
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signaling through cytoplasmic depletion combined with apoptotic signaling due to the 
nuclear accumulation.  Moreover, the delivery of exogenous Bcr-Abl to the nucleus may 
induce apoptosis in a wide range of cell types, not only CML cells. Altering the 
localization of Bcr-Abl, which is only present in the CML cells, is a way of specifically 
inducing apoptosis in only CML cells that express Bcr-Abl, and requires a binding 
domain that will efficiently bind Bcr-Abl to allow for nuclear translocation. 
 
Binding Bcr-Abl with CCmut2 and CCmut3.   
 With the goal of translocating endogenous Bcr-Abl into the nucleus along with the 
protein switch, it is essential that the protein switch exhibits some method of binding Bcr-
Abl.  One method of binding Bcr-Abl is through the coiled-coil domain (76, 77), which 
may be incorporated into the protein switch.  Nevertheless, incorporation of the wild-type 
coiled-coil domain into the protein switch would allow for protein switch dimerization, 
but would not preferentially oligomerize with Bcr-Abl over another protein switch 
molecule, potentially limiting the nuclear translocation of Bcr-Abl.  Improving the 
specificity of the coiled-coil domain so as to not cause the oligomerization of the protein 
switch was the goal in designing CCmut2 and CCmut3.  These design goals are 
illustrated in Figure 1.5.   
 
Binding Bcr-Abl through the ABD and DHPH Domains with iDabs 
 Another method of binding Bcr-Abl is through an antibody.  Antibodies specialize 








Figure 1.5.  Goals for the design of a mutant coiled-coil domain.  A) Depiction of the 
incorporation of the wild-type coiled-coil domain into the protein switch, and the 
resulting equal formation of protein switch homo-oligomers, Bcr-Abl homo-oligomers, 
and protein switch/Bcr-Abl hetero-oligomers.  B)  Improved equilibrium from a mutant 
coiled-coil domain incorporated into the protein switch.  Through introduction of charge-
charge repulsion the protein switch homo-oligomerization is reduced.  Through formation 
of additional salt bridges the hetero-oligomerization is improved.  Blue coil = wild-type 
coiled-coil domain, Red coil = mutant coiled-coil domain.   
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individual polypeptide chains held together through disulfide bonds (135).  These 
disulfide bonds are stable in oxidizing conditions, but are reduced inside cells and can 
result in the intracellular instability of antibodies (136).  This has been a major limitation 
in the usefulness of antibodies as therapeutics since most target antigens, including Bcr-
Abl, are present inside cells.  However, smaller antibody fragments have been identified 
that do not require disulfide bonds for their stability (135, 136).  The first generation of 
intracellular antibodies, single chain variable fragments (scFv), contains the variable 
fragments from the heavy and light chains held together by a small peptide linker (137-
139), and is roughly 250 amino acids (27 kDa), or one fifth the size of an IgG, and is 
stable inside cells.  Recently it has been shown that one variable fragment can bind to an 
antigen with similar affinity and specificity (140, 141), further reducing the size to one 
tenth of an IgG antibody.  The intracellular stability and minimal size make these single 
domain antibodies (iDabs) an ideal candidate for protein therapeutics.  Technology 
termed intracellular antibody capture (IAC) (142-145) has been established to isolate 
intracellular antibodies that bind a desired target.  The IAC protocol for isolation of 
single domain intracellular antibodies (iDabs) has been termed the third-generation 
intracellular antibody capture, or IAC3 (146).  The first report of the binding from iDabs 
isolated using IAC demonstrated binding to the Ras protein with affinities ranging from 
20 nM to 200 nM (147).  Unpublished data have also demonstrated iDabs to bind even in 
the picomolar range (personal communication with Dr. Terrence Rabbitts).  Recently 
IAC3 screening has produced iDabs binding LMO2, TP53, CRAF1, and Hoxa9 (148).  
Screening for single domain antibodies that bind Bcr-Abl at the actin binding domain 




Inhibition of Bcr-Abl through Oligomeric Disruption 
 While the original goal of studying the coiled-coil domain was to obtain an efficient 
binding partner for Bcr-Abl that could be used for nuclear translocation, an interesting 
alternative use is for the inhibition of Bcr-Abl through oligomeric disruption.  Bcr-Abl is 
found predominantly as a tetramer, and achieves this homo-oligomerization through the 
coiled-coil domain at the N-terminus of the protein (77).  The oligomerization through 
the coiled-coil domain is a critical part of the constitutive activity of the tyrosine kinase 
domain (149, 150).  This oligomerization allows Bcr-Abl to undergo a trans-
autophosphorylation wherein Bcr-Abl is activated.  Bcr-Abl constructs that lack the 
coiled-coil domain have reduced levels of phosphorylation and reduced transformation 
potential (149).  Interfering with the oligomeric state of Bcr-Abl prevents the activating 
trans-autophosphorylation and mimics the effects of a TKI.  However, disruption of the 
oligomeric state through binding the coiled-coil domain may have the advantage of not 
binding the SH3, SH2, or Y-kinase domains where the point mutations have been 
described.   
 The Bcr-Abl coiled-coil domain consists of two parallel-oriented α-helices and a 
short linker connecting them to form an “N” (77).  These helices interact with the helices 
from another coiled-coil domain in an anti-parallel orientation to form a dimer, which 
subsequently dimerizes with another dimer to form the tetramer (76).  The dimer 
interface is composed primarily of the second helices of the coiled-coil domain, residues 
28-67, while the first helices fold onto the backsides of the second helices in a swap-
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domain fashion.  Thus, helix two fits the typical α-helical coiled-coil model wherein 
residues at the “a” and “d” positions are hydrophobic and compose the hydrophobic core, 
and charged residues are found at the “e” and “g” positions where they can form salt 
bridges.  The α-helix has been highly studied and characterized, greatly facilitating the 
rational design of modifications to an existing α-helical coiled-coil domain such as the 
one found in Bcr-Abl (151-155).   
 We aimed to improve the oligomerization between a modified coiled-coil domain 
and the Bcr-Abl coiled-coil domain, in attempt to reduce the homo-oligomerization of the 
mutant and increase the hetero-oligomerization with Bcr-Abl (the same concept 
illustrated in Figure 1.5 for the incorporation of the coiled-coil domain into the protein 
switch).  The design of the coiled-coil domain focused on the helix at the dimer interface, 
helix two.  In a simple fashion, uncharged residues in a position to form a salt bridge with 
a charged residue on the opposing helix were mutated to the appropriately charged 
residue to increase the number of salt bridges in the hetero-dimer.  To decrease the homo-
oligomer stability, residues were mutated to charged residues in positions in close 
proximity to the same-charged residue on the opposing helix in the homo-dimer.  
Through this simple approach the oligomerization properties were improved. 
 
Therapeutic Potential of Nuclear Bcr-Abl 
 The introduction of tyrosine kinase inhibitors has revolutionized the treatment of 
CML and improved the prognosis and quality of life of CML patients.  Nevertheless, the 
only cure for CML, allogenic stem cell transplantation, is not an option for the majority 
of patients due to age and donor availability.  Moreover, resistance to TKI therapy (8-11), 
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the inability of TKIs to achieve a sustainable response for patients in advanced stages of 
the disease (156-162), and ineffectiveness of TKIs towards CML stem cells (13, 163-166) 
all remain major problems in CML therapy.  More CML research is currently being done 
to generate additional TKIs that are efficacious against resistant cells and the CML stem 
cell niche.  Yet, all indications from TKI therapy thus far indicate an inability to use this 
type of approach against leukemic stem cells.  In addition, development of alternative 
TKIs that bind the kinase domain in distinct regions will create new selective pressures 
and may lead to resistance and identification of previously uncharacterized mutations.  
This work aims to induce apoptosis through translocating Bcr-Abl into the nucleus using 
a mutant form of the Bcr-Abl coiled-coil domain (alone or in combination with another 
Bcr-Abl-binding domain such as the iDab ABI7).  Due to the essential role of 
oligomerization through the coiled-coil domain in activating Bcr-Abl, mutations affecting 
the oligomerization would alleviate the kinase activity driving the oncogenicity.  Thus, by 
targeting Bcr-Abl through the coiled-coil domain, mutations leading to resistance to this 
type of therapy would be limited to mutations that only affect the hetero-oligomerization 
between Bcr-Abl and the therapeutic coiled-coil while not affecting the homo-
oligomerization of Bcr-Abl.  Whether or not such mutations are possible remains to be 
determined, but seem far less likely than mutations in the kinase domain that lead to 
increased transformation potential in addition to avoidance of the therapeutic interaction.  
Furthermore, the translocation of Bcr-Abl into the nucleus using a coiled-coil domain or 
iDab is not likely to be affected by any of the mutations generating TKI resistance, and is 
likely to be equally effective in all of the currently described mutant forms of Bcr-Abl 
including the T315I mutation.   
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 In addition to the mutational advantages, sending the endogenous Bcr-Abl to the 
nucleus would also reduce oncogenic signaling from the cytoplasmic Bcr-Abl (167, 168).  
Cytoplasmic depletion of Bcr-Abl combined with the apoptotic signaling through nuclear 
Bcr-Abl will be a more potent therapeutic strategy.  This approach is more likely to 
induce apoptosis in CML stem cells where inhibition of Bcr-Abl alone is not sufficient to 
induce apoptosis (13, 164, 166).  Thus, the nuclear accumulation of at least 20-25% of 
Bcr-Abl (5) through the controlled translocation with the protein switch has the potential 
to address the two biggest problems with treatment of CML, and would be progress 
towards a possible cure for patients who do not have transplantation as an option. 
 
Summary 
 In addition to demonstrating progress in the generation of a novel therapeutic, this 
work also demonstrates the ability to control the localization of an endogenous protein 
through an exogenously added protein.  Both the oncoprotein Bcr-Abl and the disease 
CML are highly characterized and provide an ideal model system for validating this type 
of approach.  The establishment that cytoplasmic Bcr-Abl is oncogenic and nuclear Bcr-
Abl induces apoptosis was also critical in choosing Bcr-Abl as the target for this work.  
However, there are numerous other examples of proteins wherein the localization is a 
factor in the development of a disease (169-173), and where an alternate localization of 
that protein would relieve the disease causing conditions.  Thus, the proof of concept 
demonstrated herein is not only applicable to CML, but a host of other diseases as well.   
 The translocation of other proteins by the protein switch can also be useful as an 
assay for intracellular protein-protein interactions relevant to the biochemistry field in 
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general.  Currently, intracellular protein-protein interaction assays are limited, and 
alternative approaches to validate the interactions are needed.  Hence, the significance of 
this work is the establishment of widely applicable methodology to alter the subcellular 
localization of an endogenous protein to alter the function, including a new biochemical 
assay for intracellular protein-protein interactions (nuclear translocation assay described 
in Chapter 3). 
 
 In summary, this dissertation is organized into the following chapters: 
1. (This chapter) Background and significance.  Some figures used in this 
chapter were taken from: 
Mossalam M, Dixon AS, Lim CS. Ther Deliv. 2010 Jul 
1;1(1):169-193. “Controlling subcellular delivery to optimize 
therapeutic effect.” 
2. Demonstration that Bcr-Abl can be directed to the nucleus and that it 
does induce apoptosis when inside the nucleus 
Dixon AS, Kakar M, Schneider KM, Constance JE, Paullin BC, 
Lim CS. J Control Release. 2009 Dec 16;140(3):245-9. 
“Controlling subcellular localization to alter function: Sending 
oncogenic Bcr-Abl to the nucleus causes apoptosis.” 
3. Use of the protein switch for studying protein interactions (the nuclear 
translocation assay) 
Dixon AS, Lim CS. Biotechniques. 2010 Jul;49(1):519-24. “The 
nuclear translocation assay for intracellular protein-protein 
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interactions and its application to the Bcr coiled-coil domain.” 
4. Design of CCmut2 and demonstration of the inhibitory effects on Bcr-
Abl and CML cells 
Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, 
Cheatham TE 3rd, Lim CS. J Biol Chem. 2011 Jun 9. [Epub ahead 
of print] “Disruption of BCR-ABL coiled-coil oligomerization by 
design.” 
5. Design of a second generation coiled-coil mutant, CCmut3, and 
demonstration of the inhibitory effects on Bcr-Abl and CML cells 
Dixon AS, Miller G., Bruno, BJ, Woessner DW, Constance JE, 
Cheatham TE, Lim CS. “Second generation modifications to the 
Bcr coiled-coil domain: further mutant homo-dimer 
destabilization for enhanced oligomerization with Bcr-Abl.” In 
preparation for submission to Mol. Pharmaceutics. 
6. Isolation of iDabs for binding Bcr-Abl, and use of binding domains for 
translocation of Bcr-Abl to the nucleus 
Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS.  
“Rationally designed Bcr-Abl capture motifs for escort to the 
nucleus.”  In preparation for submission to J. Control. Release. 
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CONTROLLING SUBCELLULAR LOCALIZATION TO ALTER 
 
FUNCTION: SENDING ONCOGENIC BCR-ABL TO 
 





 Altering the subcellular localization of signal transducing proteins is a novel 
approach for therapeutic intervention. Mislocalization of tumor suppressors, oncogenes, 
or factors involved in apoptosis results in aberrant functioning of these proteins, leading 
to disease. In the case of chronic myelogenous leukemia (CML), cytoplasmic Bcr–Abl 
causes oncogenesis/proliferation. On the other hand, nuclear entrapment of endogenous 
Bcr–Abl (in K562 human leukemia cells) causes apoptosis. The goal of this study was to 
determine whether ectopically expressed Bcr–Abl could cause apoptosis of K562 cells 
when specifically directed to the nucleus via strong nuclear localization signals (NLSs). 
A single NLS from SV40 large T-antigen or four NLSs were subcloned to Bcr–Abl 
(1NLS–Bcr–Abl or 4NLS–Bcr–Abl). When transfected into K562 cells, only 4NLS–Bcr–
Abl translocated to the nucleus. Bcr–Abl alone was found to localize in the cell 




localized with actin. Apoptosis induced by 4NLS–Bcr–Abl was evaluated 24 h post-
transfection by morphologic determination, DNA staining, and caspase-3 assay. This is 
the first demonstration that altering the location of ectopically expressed Bcr–Abl can kill 
leukemia cells. Multiple NLSs are required to overcome Bcr–Abl binding to actin, thus 
driving it into the nucleus and causing apoptosis. 
 
Introduction 
 The causative agent for 95% of all CML cases, Bcr–Abl, is derived from the 
fusion of the breakpoint cluster region (Bcr) gene on chromosome 22 and the Abelson 
leukemia oncogene (Abl) on chromosome 9. This reciprocal translocation results in an 
abnormal, shortened chromosome — 'Philadelphia chromosome” or Ph (+) phenotype (1, 
2). The resulting Bcr–Abl fusion protein acts as an oncoprotein, and the constitutive 
activation of tyrosine kinase activity of Abl leads to cell proliferation. Although Gleevec 
is currently the “gold standard” drug of choice for Bcr–Abl positive CML (3-5), 
resistance to treatment with Gleevec occurs. This is mostly due to mutations in the Bcr-
Abl kinase domain that render it unable to bind to Gleevec (6-8). Some mutations create a 
more potent Bcr–Abl oncogene and accelerate disease progression (9). Other mechanisms 
for resistance include Bcr–Abl amplification or over expression, clonal evolution, a 
decrease in Gleevec bioavailability or cell exposure, and up regulation of drug efflux 
pumps (6, 10). Many other tyrosine kinase inhibitors (TKIs) are being studied and 
developed, with a few already approved. Nonetheless, Bcr–Abl also has the potential to 
develop resistance to these molecules. In addition, since FDA approval, potentially fatal 




possibility of developing other cancers (due to blockade of tumor suppressor p63) (12), 
and acute renal failure (13). Therefore, finding alternative strategies to Gleevec therapy 
are necessary.  
 In the cytoplasm Bcr–Abl acts as an oncogene by interacting with multiple signal 
transduction pathways that transmit anti-apoptotic and mitogenic signals (14). The key 
pathways involve ras, MAP kinases, the STAT family, PI3 kinase, and myc, among 
others (15). In the nucleus, Bcr–Abl may cause apoptosis due to nuclear Abl's ability to 
stabilize p73 and activate its pro-apoptotic functions. Vigneri and Wang have previously 
shown that nuclear entrapment of Bcr–Abl in K562 cells results in apoptosis, and requires 
an active tyrosine kinase domain to do so (2). They used Gleevec to stimulate Bcr–Abl to 
go to the nucleus (by unknown mechanism), followed by nuclear entrapment by 
leptomycin B (LMB), a general inhibitor of nuclear export. After washout of Gleevec, 
Bcr-Abl tyrosine kinase activity is reactivated, and the cells undergo spontaneous 
apoptosis. Unfortunately LMB causes neuronal toxicity and cannot be used 
therapeutically. This study attempts to address a fundamental question that remains: Does 
the apoptosis caused by nuclear entrapment of Bcr–Abl require depletion of Bcr–Abl 
from the cytoplasm, or is it sufficient to send ectopically expressed Bcr–Abl to the 
nucleus to cause apoptosis? 
 
Materials and Methods 
 
Subcloning and Construction of Plasmids 
 
 Full length Bcr–Abl was removed from pEYK3.1 retroviral vector (a kind gift 




pEGFP-C1 (Clontech, Mountain View, CA) at the EcoRI site to make EGFP–Bcr–Abl. 
The oligonucleotides 5′ -CCGGAAGCCCAAAGAAGAAGAGAAAAGTAGAAT-3′ and 
5′-CCGGATTCTACTTTTCTCTTCTTCTTTGGGCTT-3′ were ligated to pEGFP-Bcr-
Abl at the BspEI site. The oligonucleotide insert encodes for the nuclear localization 
signal (NLS) from SV40 large T antigen (amino acids PKKKRKV) and is flanked with 
the BspEI digested sequence. The ligation resulted in the formation of pEGFP-1NLS–
Bcr–Abl and pEGFP–4NLS–Bcr–Abl (a concatemer consisting of four nuclear 
localization signals). The bases encoding key residues (T65A and Y66A) in the EGFP 
chromophore (16, 17) of pEGFP–4NLS–Bcr–Abl were mutated using the QuikChange II 
Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA) to eliminate EGFP 
fluorescence (for use in some co-transfection experiments). The primers used for the 
mutagenesis were 5′ -CTCGTGACCACCCTGGCCGCCGGCGTGCAGTGCTTC- 3′ and 
its reverse complement. This plasmid encodes 4NLS–Bcr–Abl with non-fluorescent 
EGFP. 
 
Cell Line and Culture Conditions 
 Bcr-Abl positive K562 cells (human chronic myelogenous leukemia cell line), 
from our collaborator Dr. K. Elenitoba-Johnson (Univ. of Michigan), were cultured as 
suspension cells in RPMI 1640 supplemented with 10% FBS (Hyclone Laboratories, 
Logan, UT), 1% penicillin– streptomycin (100U/ml, GIBCO BRL, Grand Island, NY), 
0.1% gentamycin (Hyclone), and 1% L-glutamine (Hyclone). Cells were maintained in a 






 Transient transfections were performed using Amaxa Nucleofector II according to 
the Amaxa protocol for K562 cells. Briefly, 2×106 cells were pelleted from a cell density 
of 1–5×105 cells/mL, and then resuspended in 100 μL Amaxa Solution V. This solution 
was then added to 10 μg DNA and transfected in an Amaxa cuvette using program T-013. 
Following, 500 μL RPMI was added to the cuvette and cells were transferred to 15 mL 
RPMI and plated in a 75 cm2 flask for caspase-3 assays. Small aliquots (200 μL) of cells 
were plated into 4-well live-cell chambers for fluorescent microscopy (Lab-tek chamber 
slide system, 2 mL, Nalge NUNC International, Naperville, IL) for determination of 
transfection efficiency. For co-localization experiments where 2 plasmids were 
transfected simultaneously, 5 μg of each plasmid was used; 5 μg of a single plasmid was 
used for comparison studies. Cells were incubated for ~20–24 h before any other assays 
were performed. To calculate the transfection efficiency, four or more fields of cells were 
counted under the 40× objective. The number of transfected cells (as indicated by the 
EGFP expression; see methods below for microscope settings) was divided by the total 
number of cells to obtain transfection efficiency. 
 
Caspase-3 Activity Assay 
 The induction of apoptosis was monitored through the enzymatic activity of 
caspase-3 using the EnzChek Caspase-3 Assay Kit #1 (Molecular Probes, Eugene, OR) 
following the manufacturer's protocol. Briefly, 1.5×106 cells were pelleted and 
resuspended in 50 μL1×cell lysis buffer followed by a freeze-thaw cycle. The lysed cells 




added to one of the lysates of untransfected K562 cells. 2× substrate (50μL) solution was 
then added to 50 μL of lysate and incubated at room temperature for 30min. A standard 
curve was made using known amounts of 7-amino-4-methylcoumarin (AMC). 
Fluorescence was then measured at an excitation wavelength of 355 nm and an emission 
wavelength of 460 nm. Caspase assays were performed three or more separate times 
(n=3). Data was represented as relative fluorescence units per cell, taking transfection 
efficiencies into account. 
 
Actin Staining and Microscopy 
 K562 cells transfected with EGFP–Bcr–Abl were fixed with formaldehyde and 
stained for actin using BODIPY 558/568 Phalloidin from Molecular Probes (Eugene, 
OR) according to manufacturer's protocol. Briefly, cells were washed with PBS, pelleted, 
and resuspended in 4% formaldehyde (in PBS). Cells were incubated in formaldehyde 
solution for 10 min at room temperature and subsequently washed in PBS. Cells were 
then placed in 1 mL of 0.1% TritonX-100 (in PBS) for 5 min followed again by washing 
with PBS. The cells were then incubated with staining solution for 20 min at room 
temperature and then washed with PBS. Following staining the cells were viewed at 40× 
with an Olympus IX701F inverted fluorescence microscope (Scientific Instrument 
Company, Aurora, CO) using the HQ:TRITC filter to detect actin, and a high quantity 
narrow band GFP filter (excitation HQ480/20 nm, emission HQ510/20 nm, with beam 






DNA Staining and EGFP Microscopy 
 K562 cell nuclei were stained by the addition of 0.8 μL Hoechst 33342 (10 
mg/ml) (Invitrogen, Carlsbad, CA) to 1 mL of cells in a Lab-Tek®II 4-well live-cell 
chamber (Nalge NUNC) and incubated for 30 min at 37°C. Pictures were taken 
approximately 24h after transfection using a fluorescence microscope with high-quantity 
narrow band GFP filter (to detect EGFP) and Cyan GFP v2 filter (excitation D436/20 nm, 
emission D480/40 nm, with beam splitter 455dclp) to detect H33342. To minimize 
photobleaching of EGFP chromophore, cells were imaged using neutral density filters in 
combination with short exposure times. An air stream incubator (Nevtek ASI 400, 
Burnsville, VA) with a variable temperature control was used to maintain the microscope 
stage and the live-cell chambers at 37 °C. All filters were purchased from Chroma 
Technology (Brattleboro, VT). 
 
Cell Tracing 
 Quantitation of Bcr–Abl in the nucleus and cytoplasm was carried out by 
measuring the fluorescence intensity of EGFP, tagged to the Bcr–Abl, as previously 
described (18). All the images were analyzed using analySIS® software (Soft Imaging 
System, Lakewood, CO). 
 
Statistical Analysis 
 All experiments were done at least in triplicate (n≥3). The difference between the 
percent nuclear intensity values was analyzed using an unpaired t-test with Welch's 




assess the differences between relative fluorescence intensity values from the caspase-3 
assay. All statistics were calculated using GraphPad Prism (San Diego, CA). 
 
Results 
 When transfected into K562 cells, Bcr–Abl (pEGFP-Bcr-Abl) localizes in the 
cytoplasm and forms a distinctive ring around the cell (Figure 2.1). This localization is 
indicative of binding to actin, and is expected due to previous reports of Bcr–Abl 
localization with actin (19). Co-localization of EGFP–Bcr–Abl and actin is shown in 
Figure 2.1. 
 Additional nuclear localization signal(s) were added to EGFP-Bcr-Abl to attempt 
to overcome Bcr–Abl binding to actin. Two plasmids were created, one with 1 NLS 
subcloned to EGFP–Bcr–Abl, and one with 4 NLSs subcloned to EGFP–Bcr–Abl. When 
transfected into K562 cells, only EGFP–4NLS–Bcr–Abl localized to the nucleus (Figure 
2.2G) with the distinct absence of the actin ring surrounding the cell (compared to 2.2A, 
wt–Bcr–Abl). The 1NLS construct, while somewhat dispersed throughout the cell, still 
formed a peripheral actin ring (Figure 2.2D), just like wt–Bcr–Abl (Figures. 2.2A and 
2.1). 
 Next, cell studies demonstrating apoptosis were performed on Bcr–Abl, 4NLS–
Bcr–Abl, and 1NLS–Bcr–Abl. For comparison, Figure 2.3 shows healthy K562 cells. 
Phase contrast images show round, healthy cells (Figure 2.3, left panel), while H33342 













Figure 2.1. EGFP-Bcr-Abl localization in K562 cells. A. localization of Bcr–Abl via 
EGFP. B. Actin staining of cells. C. Overlay of EGFP–Bcr–Abl localization with 











Figure 2.2. K562 cells transfected with 0NLS-, 1NLS-, or 4NLS-Bcr-Abl. A–C. EGFP–
Bcr–Abl transfected into K562 cells; fluorescent (EGFP), nuclear staining with H33342, 
and phase contrast images, respectively. D–F. EGFP–1NLS–Bcr–Abl transfected into 
K562 cells; fluorescent (EGFP), nuclear staining with H33342, and phase contrast 
images, respectively. G–H. EGFP–4NLS–Bcr–Abl transfected into K562 cells; 
fluorescent (EGFP), nuclear stainingwithH33342, and phase contrast images, 
respectively. White arrows (H) indicate apoptotic cells undergoing massive DNA 
segmentation. Black arrows (I) indicate that these same cells have undergone cell 
shrinkage, a morphological hallmark of apoptosis (20-24). Black arrowheads (I) show 
cells undergoing zeotic/cytoplasmic blebbing. Scale bar (5 μm) representative for all 














Figure 2.3. Healthy K562 cells.  Left panel, phase contrast image. Right panel, nuclear 






healthy K562 cells are round/oval or “kidney” shaped (Figure 2.3, right panel). 
 Twenty-four hours after transfection, cytochemical analyses of apoptosis, 
including overall cell morphology (Figure 2.2C,F, and I) and DNA 
morphology/segmentation (Figure 2.2B,E, and H), were examined. 
 Morphological changes indicating apoptosis include zeotic and cytoplasmic 
blebbing, cell shrinkage, and fragmentation of cells into smaller bodies (20-24). These 
morphological changes are seen obviously in cells transfected with 4NLS–Bcr–Abl, 
comparing Figure 2.2I (apoptosis) to Figure 2.2C and F (no apoptosis). Black arrows 
indicate shrunken cells (with cell shrinkage indicating apoptosis). Black arrowheads 
(2.2I) show cells undergoing zeotic/cytoplasmic blebbing. 
  The characteristic change in nuclear morphology (DNA segmentation) is “the 
most accurate indicator of the involvement of apoptosis in the death of a cell” (22), where 
the nucleus changes shape from the normal round/oval shape into smaller, non-
homogeneous segments. As shown in Figure 2.2H, cells transfected with 4NLS–Bcr–Abl 
show this characteristic DNA segmentation into smaller pieces (white arrows), not seen 
in other cells (compare to Figure 2.2B and E), including healthy cells (Figure 2.3, right 
panel). 
 Transfected cells were also counted for DNA segmentation or nuclear 
morphology changes, an accurate indicator of apoptosis (22). As shown in Table 2.1, 
cells transfected with EGFP-4NLS-Bcr-Abl had a higher percentage of cells with 
apoptotic nuclei than EGFP–1NLS–Bcr–Abl and EGFP–Bcr–Abl. Only cells with 













Table 2.1. DNA segmentation in K562 cells transfected with EGFP-Bcr-Abl, EGFP-
1NLS-Bcr-Abl, or EGFP-4NLS-Bcr-Abl 
Construct 
Transfected 





Percentage of cells 
with segmented 
DNA 
EGFP-Bcr-Abl 178 7 3.9 
EGFP-1NLS-Bcr-Abl 154 5 3.2 







 Bcr–Abl is known to form homodimers (tetramers) (25, 26). To determine if the 
4NLS–Bcr–Abl was capable of multimerizing with Bcr–Abl, and altering its localization, 
a co-transfection (co-localization) experiment was performed. EGFP–4NLS–Bcr–Abl 
with mutated EGFP chromophore (not fluorescent) was transfected with fluorescent 
EGFP–Bcr–Abl. If the 4NLS–Bcr–Abl protein is able to drag Bcr–Abl into the nucleus, 
EGFP fluorescence will be detected in the nucleus. If 4NLS–Bcr–Abl does not drag Bcr–
Abl into the nucleus, EGFP–Bcr–Abl will remain in the cytoplasm. For this analysis, a 
semi-quantitative assay was used that measured the fluorescence intensity in the nucleus 
in the co-transfected cells vs. the singly transfected (with EGFP–Bcr–Abl) cells, 
normalized to each cell's cytoplasmic intensity. These nuclear to cytoplasmic intensities 
were termed “percent nuclear intensity.” 4NLS–Bcr–Abl did not “capture” wt–Bcr–Abl 
and drag it into the nucleus, since the nuclear intensity of wt–EGFP–Bcr-Abl did not 
change in the presence of the 4NLS–Bcr–Abl construct (Figure 2.4). This result is not 
unexpected since the presence of strong NLSs would presumably drive any protein it was 
attached to immediately into the nucleus. From this result, it was determined that 
cytoplasmic depletion of Bcr–Abl by 4NLS–Bcr–Abl was not occurring. 
 Next, the caspase-3 assay was used to determine mid-stage apoptosis. Caspases, 
from cysteine-aspartate proteases, are a group of proteolytic enzymes that perpetuate the 
apoptotic signal by cleavage of proteins such as actin, lamins, fodrin, ICAD, and PARP. 
Prior to receiving the apoptotic signal, caspases are present in cells in an inactive pro-
enzyme form. The caspase cascade starts with the activation of the initiator caspases 











Figure 2.4. Percent nuclear intensity of Bcr-Abl with and without 4NLS-Bcr-Abl. EGFP-
Bcr-Abl Percent nuclear intensity for cells transfected with EGFP-Bcr-Abl alone (right 





Both caspase-3 and caspase-7 cleave the peptide sequence DEVD, which makes it an 
ideal substrate for use in measuring apoptosis as a majority of the apoptotic signaling 
pathways converge on these effector caspases. The caspase-3 assay used measures the 
cleavage of a substrate with the amino acid sequence DEVD. Caspase-3 activity (Figure 
2.5) was determined in several treatment groups, including EGFP–4NLS–Bcr–Abl, 
EGFP–1NLS–Bcr–Abl, EGFP–Bcr–Abl, or a negative control (transfected with pGL3 
basic plasmid which has no promoter or enhancer and hence is not expressed). As shown 
in Figure 2.5, only cells transfected with EGFP–4NLS–Bcr-Abl showed a statistically 
significant increase in the caspase activity compared to the negative control.  
 
Discussion/Conclusions 
 Nuclear localization of Bcr–Abl converts it from an oncogene to an apoptotic 
factor. The nuclear localization could not be achieved without adding multiple NLSs to 
Bcr–Abl. Once additional NLSs were added to Bcr–Abl, this caused apoptosis of CML 
cells (K562 cells) measured by morphologic changes (cytoplasmic blebbing and cell 
shrinkage), DNA segmentation (nuclear morphology changes), and the caspase-3 assay. 
This critical finding shows that the change in the location of Bcr–Abl from cytoplasmic 
to nuclear dramatically alters its function.   
 Nuclear entrapment and cytoplasmic depletion of wt–Bcr–Abl may have a 
synergistic effect on cell death. The nuclear entrapment results in apoptosis via the Abl 
domain which can cause cell death by stabilizing p73 and activating its pro-apoptotic 











Figure 2.5. Effect of Bcr-Abl localization on caspase activity. Caspase-3 activity in K562 
cells transfected with EGFP-4NLS-Bcr-Abl, EGFP-1NLS-Bcr-Abl, EGFP-Bcr-Abl, or 
pGL3basic plasmid (a negative control; plasmid is promoter- and enhancer-less and 
therefore nothing is expressed). *p,0.05; n = 3. Statistical significance determined using 





interact with the signal transduction proteins involved in gene transcription, 
mitochondrial processing of apoptotic responses, cytoskeletal organization, and 
degradation of inhibitory proteins (29). Here we report that ectopically expressed Bcr–
Abl directed to the nucleus is sufficient to induce apoptosis without cytoplasmic 
depletion. However, it may be speculated that coupling cytoplasmic depletion with 
nuclear entrapment will synergistically enhance the apoptotic signal. To this end, our 
ultimate goal is to deplete wt–Bcr–Abl from the cytoplasm, and direct it to the nucleus by 
our previously described “protein switch” technology (18, 30). We exploit known 
dimerization domains (DD) of proteins to capture them and move them to a different 
subcellular compartment. An ectopically expressed “protein switch” can be designed to 
target any protein with a DD. The protein switch also contains inducible signal sequences 
to localize to a starting compartment in the cell (e.g., cytoplasm). Upon addition of 
ligand, the protein switch can move to a different subcellular compartment (e.g., 
nucleus). Our ultimate goal is to use the protein switch (18, 30) to control the subcellular 
location of Bcr–Abl, and convert Bcr–Abl from an oncogene to an apoptotic factor. 
 Alternative therapies for CML are needed, despite the “blockbuster” results with 
Gleevec. Gleevec is not a cure for CML, and patients need to take it for the rest of their 
lives. Gleevec is also known to have severe side effects including cardiotoxicity (11) and 
the possibility of developing other cancers (due to blockade of tumor suppressor p63) 
(12). Importantly, Gleevec resistance mostly occurs due to different point mutations in 
Bcr–Abl that make traditional small molecule inhibitors (like Gleevec) unable to 
bind/inhibit Bcr–Abl. In some cases, a decrease in Gleevec bioavailability/cell exposure 




 The protein switch concept is also being tested in our laboratory with the anti-
apoptotic factor survivin, and the tumor suppressor p53 (mislocalized in cancers). 
Changing localization to alter function may prove to be a new therapeutic strategy for 
many types of cancer, including CML (31). 
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THE NUCLEUAR TRANSLOCATION ASSAY FOR INTRACELLULAR 
 
PROTEIN-PROTEIN INTERACTIONS AND ITS APPLICATION 
 





 Protein interactions are critical for normal biological processes and molecular 
pathogenesis.  While it is important to study these interactions, there are limited assays 
that are performed inside the cell, in the native cell environment, where the majority of 
protein-protein interactions take place.  Here we present a method of studying protein 
interactions intracellularly using one protein of interest fused to a localization-
controllable enhanced green fluorescent protein (EGFP) construct and the other protein of 
interest fused to the red fluorescent protein, DsRed.  Nuclear translocation of the EGFP 
construct is induced by addition of a ligand, and the difference in nuclear localization 
between the induced and uninduced states of the DsRed construct provides an indication 
of the interaction between the two proteins.  This assay, the nuclear translocation assay 
(NTA), is introduced here as broadly applicable for studying protein interactions in the 
native environment inside of cells and is demonstrated using forms of the coiled-coil 





 Protein-protein interactions are an essential component of almost every cellular 
process.  These interactions regulate signaling events that result in differentiation, 
proliferation, regulation of gene transcription,  repair mechanisms, and inhibition or 
induction of apoptosis to name only a few (1).  Studying these interactions can provide 
valuable insights into the molecular mechanisms governing these cellular processes.  
Furthermore, aberrant protein interactions can lead to diseases such as cancer (2), 
diabetes (3), cystic fibrosis (4), Alzheimer’s (5), and a number of metabolic disorders (6).  
Thus, the understanding of protein interactions is also critical in the understanding of 
disease and the development of therapeutic interventions to treat them.  The majority of 
these interactions between proteins occur inside of cells, and intracellular experimental 
assays for protein-protein interactions are the most relevant.  However, currently there are 
few assays that provide a means to quantify protein-protein interactions in the native cell 
environment.  Resonance energy transfer (RET), including bioluminescence resonance 
energy transfer (BRET) (7) and Fӧrster (fluorescence) resonance energy transfer (FRET) 
(8), is one mechanism for detecting intracellular protein interactions but requires a 
specific combination of the right donor and acceptor, along with the sensitive detection of 
light emitted at specific wavelengths.  Further, the proper orientation of the donor and 
acceptor dipoles within the Fӧrster distance must be achieved for effective energy 
transfer.  The two-hybrid system (yeast or mammalian) is another assay for intracellular 
protein interactions (9), but the interaction typically takes place inside the cell nucleus 
and this assay requires the transcription/translation of a reporter protein which 




control protein).  CytoTrap® is one variation of the two-hybrid assay that allows the 
interaction to occur in the cytoplasm.  The split ubiquitin assay (10) is similar to the two-
hybrid system, but uses truncations of ubiquitin in place of transcription factor domains.  
Here we present a new method for the qualitative analysis of protein-protein interactions 
that is performed inside of cells and is based on an optimized ligand-responsive protein 
and the simultaneous quantification of fluorescence intensity from EGFP and DsRed. 
 The controlled nuclear translocation in this assay occurs through what we have 
termed a “protein switch.”  The protein switches we have developed are chimeric proteins 
consisting of three components: a nuclear export signal (NES), a nuclear localization 
signal (NLS), and ligand binding domain (LBD).  In the absence of ligand the NES 
directs the protein switch to the cytoplasm.  However, when the ligand binds the LBD it 
causes a conformational change, exposes the NLS, and the protein is redirected to the 
nucleus.  In our laboratory various combinations of these three components have been 
studied to identify the optimal combination that results in the greatest amount of nuclear 
translocation upon ligand induction (11, 12).  This nuclear translocation is concentration-
dependent and reversible if the ligand is removed (12).  One such optimized protein 
switch, used herein, consists of the NES from HIV rev, the NLS from MycA8, and the 
LBD from the rat glucocorticoid receptor containing the C656G mutation which renders 
it 10 times more sensitive to the synthetic glucocorticoid dexamethasone (13).  This 
protein switch provides an easy method for controlling the subcellular shuttling between 
the cytoplasm and the nucleus. 
 The ability to control the translocation of a protein into the nucleus has led to a 




translocation assay (NTA).  The general concept of the NTA is depicted in Figure 3.1.  A 
protein of interest is subcloned and expressed as a fusion protein with the protein switch 
and EGFP.  As a result of the protein switch, this fusion protein is responsive to ligand 
and will translocate into the nucleus upon ligand induction.  A second, non-ligand 
responsive protein tagged with DsRed is co-expressed with the protein switch construct.  
If the two proteins interact (Figure 3.1, top) the second protein will translocate into the 
nucleus along with the protein switch.  The percentage of DsRed inside the nucleus is 
quantified before and after the addition of ligand, and the difference (termed percent 
nuclear increase, PNL-PN0)/PN0*100%) is indicative of the interaction between the two 
proteins.  However, if there is little or no interaction between the two proteins (Figure 
3.1, bottom) the protein switch alone moves to the nucleus and there is no change in the 
subcellular localization of the second protein.  Fluorescent protein tags are used as a 
means of determining the cytoplasmic and nuclear localization of the two proteins 
through fluorescence microscopy, and thus the fluorescent signals from the two proteins 
expressed in the same cell need to be distinguishable via excitation/emission filters.  Two 
such fluorescent proteins are EGFP and DsRed that exhibit excitation/emission of 
480nm/510nm and 545nm/620nm, respectively.   
To demonstrate the NTA in mammalian cells (1471.1: murine adenocarcinoma, 
and Cos-7: simian kidney), we performed the assay on two forms of the coiled-coil 
domain from the breakpoint cluster region (Bcr) protein.  This domain forms an 
antiparallel coiled coil responsible for the oligomerization of Bcr (14).  Although 






Figure 3.1: The nuclear translocation assay (NTA) concept.  If the two proteins interact, 
as is the case for proteins X and Y in the top half of the diagram, protein X will cause an 
increase in the nuclear localization of protein Y upon addition of ligand (L) due to the 
ligand-responsive protein switch (PS) fused to protein X.  If two proteins do not interact, 
as is the case for proteins X and Z in the bottom half of the diagram, the protein switch 
translocates the fused protein X to the nucleus upon addition of ligand without altering 
the localization of protein Y.  The translocation of the protein switch construct is 
monitored through the fluorescence of EGFP, and the translocation of the second protein 





translocation between chromosomes 9 and 22 generates the Philadelphia chromosome 
which expresses Bcr-Abl consisting of the C-terminus of Bcr fused to the N-terminus of 
the Abelson kinase protein (Abl) (15).  The Philadelphia chromosome and Bcr-Abl are 
the cause of 95% of chronic myelogenous leukemia (CML) cases (16).  Oncogenesis 
through Bcr-Abl is dependent on the tyrosine kinase activity that is regulated through the 
oligomerization of Bcr-Abl mediated by the coiled-coil domain (17).  Reports have 
shown an isolated coiled-coil domain (or truncations thereof) can disrupt the 
oligomerization of Bcr-Abl and reduce the kinase activity and associated oncogenesis 
(18-21).  We have recently altered certain residues (manuscript in progress) of this 
domain to prevent the homo-oligomerization (i.e., coiled coil:coiled coil) and improve the 
binding to Bcr-Abl (i.e., coiled coil:Bcr-Abl).  As the wild-type coiled-coil domain 
(herein designated CC, sequence provided in supplementary materials) has no specificity 
for Bcr-Abl’s coiled coil over another exogenously added coiled coil, the homo-
oligomerization may be a limiting factor in its efficacy.  Our designed coiled coil (herein 
designated CCmut, sequence provided in supplementary materials) shows reduced homo-
oligomerization (mutant:mutant), along with the potential for enhanced hetero-
oligomerization (mutant:Bcr-Abl), to increase the binding to the coiled coil of Bcr-Abl.  
The NTA is a unique method for studying protein-protein interactions under 
intracellular conditions.  Few assays offer the ability to study these interactions in the 
cellular environment where they actually take place.  The controlled nuclear translocation 
upon addition of ligand using the protein switch provides the ability to differentiate the 
nuclear translocation from proteins that localize partially in the nucleus or small proteins 




and after ligand induction.  Thus, proteins smaller than 40kDa that can diffuse through 
the nuclear pores or nuclear localized proteins will not result in false positives.  However, 
as this assay revolves around nuclear translocation, transmembrane proteins may not be 
suitable, and nuclear localized proteins may need a modification (mutating the nuclear 
localization signal, adding a nuclear export signal, or performing the assay with only the 
binding domain rather than the full protein) for their study.  An additional consideration 
is that the cytoplasmic and nucleoplasmic environments are not the same, and an 
interaction that normally occurs in the nucleus may be altered in the cytoplasm where this 
assay originates.  Yet in spite of these few limitations, the NTA is relatively simple, does 
not involve reporter plasmids/proteins, and requires little more than the appropriate 
fusion proteins, dexamethasone, and a fluorescence microscope to perform.   
  
Materials and Methods 
Construction of Plasmids and Mutagenesis 
 The DNA encoding the coiled-coil domain was amplified through PCR from 
pEGFP-Bcr-Abl using the primers 5’- tgtaactcgagttatggtggacccggtg-3’ and 5’-
atgctctcgagaccggtcatagctcttc-3’, and subcloned into pEGFP-PS at the XhoI restriction 
enzyme site.  pEGFP-PS is an EGFP mammalian expression plasmid (pEGFP-C1, 
Clontech, Mountain View, CA, USA) with the optimized protein switch (PS) subcloned 
at the C-terminus of EGFP (12).  Using the resulting pEGFP-PS-CC plasmid as the 
template, two sequential site-directed mutagenesis reactions were performed using the 
QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA).  The 




acaaccaggagcgcttccgcatgatctacctggagacgttgctggccaagg-3’ and the reverse complement.  
For the second reaction the primers were 5’-gcgacgagcagcgggtgaaccaggagcgcttcc-3’ (and 
reverse complement) and 5’-caggagctggagcgcgccaaggcccgcattcg-3’ (and reverse 
complement). These mutations were designed to change bases encoding five amino acids 
in the coiled-coil domain to increase the number of ionic interactions in the heterodimer 
(mutant:wild type) and introduce charge-charge repulsions in the mutant homodimer 
(mutant:mutant) (manuscript in progress).  The wild type and mutant forms of the coiled 
coil were used as the templates for PCR with the primers 5’-
tgtaactcgagttatggtggacccggtg-3’ and 5’-atgctctcgagccggtcatagctcttc-3’, and subsequently 
inserted into pDsRed2-N1 (Clontech) at the XhoI site. 
 
Cell Line and Transient Transfection 
1471.1 and Cos-7 cells grow as monolayers in DMEM and RPMI (GIBCO, 
Invitrogen, Carlsbad, CA, USA) respectively, both supplemented with 10% FBS 
(Hyclone Laboratories, Logan, UT, USA), 1% penicillin-streptomycin (GIBCO), 0.1% 
gentamicin (Hyclone), and 1% L-glutamine (Hyclone).  The cells were maintained in a 
5% CO2 incubator at 37 °C.  1471.1 cells were grown to approximately 50% confluency, 
and 5 x 106 cells in 100 μL cold plain DMEM were transiently cotransfected via 
electroporation as previously described (22, 23).  Transfections were performed using the 
Electrosquare Porator ECM 830 (BTX, Harvard Apparatus, Holliston, MA, USA) with 2 
μg of EGFP-protein switch plasmid and 2 μg of DsRed plasmid along with 6 μg 
pGL3basic (Promega, Madison, WI, USA) carrier DNA for a total of 10 μg DNA.  3 




plated in complete DMEM in a 2-well live cell chamber (Lab-tek II chamber slide 
system, Nalge NUNC, Rochester, NY, USA), and incubated in a 5% CO2 incubator at 37 
°C overnight.  Cos-7 cells were seeded into a 2- or 4-well live cell chamber 24 hrs prior 
to transfection with Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) so the 
confluency was around 90% on the day of the transfection.  Transfections were carried 
out as recommended by the supplier. 
 
Ligand Induction and Fluorescent Microscopy 
 After 24 hrs, the cells were rinsed with PBS (GIBCO) followed by addition of 2 
mL complete phenol red-free DMEM (GIBCO).  The protein switch ligand 
dexamethasone (Sigma, St. Louis, MO, USA) (12)  was then added to one well at a final 
concentration of 200 nM, and the cells were incubated at 37 °C for 1-2 hrs.  0.5 μL 
H33342 nuclear dye was added to the Cos-7 cells and incubated at 37°C for another 15 
min.  Following the incubation, the transfected cells were viewed and photographed using 
an inverted fluorescence microscope, Olympus IX701F (Scientific Instrument Company, 
Sunnyvale, CA, USA) with high-quality narrow band GFP filter (excitation HQ480/20 
nm, emission HQ510/20 nm, beam splitter Q495lp, Chroma Technology Corp., 
Brattleboro, VT, USA) and high-quality TRITC filter (excitation HQ545/30 nm, emission 
HQ620/60 nm, beam splitter Q570lp, Chroma Technology Corp.).  Cells were 
photographed with a 40x or 60x objective using an F-view Monochrome CCD camera.  
Neutral density filters with 500 ms exposure time was used to minimize photobleaching.  
The microscope stage was maintained at 37 °C with a Nevtek ASI 400 Air Stream 




Quantification of the Percent Nuclear Increase 
 Quantification of the fluorescence intensity of EGFP and DsRed correlates to the 
amount of the respective exogenous protein.  The images of cells were analyzed using 
analySIS® software (Soft Imaging System GmbH, Muenster, Germany), and the amount 
of protein in the cytoplasm and the nucleus was quantified as previously described (23-
26).  The following equations were used in the quantification: 
Equation 1: 
CA
CIACI =  
Equation 2: 
NA










 Where ACI= average cytoplasmic intensity, CI=cytoplasmic intensity, CA=area 
of cytoplasm, ANI=average nuclear intensity, NI=nuclear intensity, NA=area of nucleus, 
PN=percentage nuclear, PNI=percentage nuclear increase, PNL=percentage nuclear  after 
ligand induction, PN0=percentage nuclear without ligand induction. 
 At least eight cells were analyzed from each group, and each experiment was 
performed in triplicate.  The experimental output, PNI, is a measure of how much the 
nuclear intensity increases after the addition of ligand, and values reported are the means 
± standard deviation.  As the percent nuclear increase (PNI) of the DsRed construct is 
related to the binding and PNI of the protein switch construct, PNI of DsRed was 





Results and Discussion 
 In any assay involving simultaneous expression of two distinct proteins it is 
essential to ensure both proteins are expressed at consistent levels from experiment to 
experiment and between groups in each experiment.  The NTA exhibits the ability to 
quantify the amount of protein present in each cell being studied, providing a validation 
of consistent protein expression.  For example, the experiments performed in 1471.1 
cells, all resulted in fluorescence intensities in the range of 13,000 RFU/area (no 
statistical difference at the 95% confidence level using 1-way ANOVA; data not shown).  
Further, the EGFP PNI (the ligand-responsive protein switch) should be relatively 
consistent, and can be monitored to ensure the assay is functioning properly.  As seen in 
Figure 3.2a, the nuclear fluorescence intensity from all protein-switch constructs (EGFP) 
assayed in 1471.1 cells increased in the range of 30% after the addition of ligand (no 
statistical difference at the 95% confidence level using 1-way ANOVA).  After 
confirmation that the total fluorescence intensities from both DsRed and EGFP, and the 
percent nuclear increase of EGFP are consistent, the varying levels of DsRed percent 
nuclear increase will be due to the interaction between the two proteins fused to DsRed 
and EGFP.  Example images demonstrating the localization in the absence and presence 
of ligand in 1471.1 cells are shown in Figure 3.2b.   
 The alteration of subcellular localization of a protein is a novel method of 
studying protein-protein interactions in the complex cellular milieu.  This technology 
harnesses the control over nuclear translocation provided by the protein switch, and uses 





Figure 3.2: Percent Nuclear Increase of Protein-Switch Constructs and Example Cell 
Images.  A. Percent nuclear increase of the protein switch constructs as measured by 
EGFP fluorescence.  The percent nuclear increase of the protein switch being relatively 
consistent across all groups tested indicates the percent nuclear increase of the DsRed 
construct is due to the interaction of the fusion proteins.  B. Example images of 1471.1 
cells cotransfected with EGFP-Protein Switch-CCmut and DsRed-CC.  The phase 
contrast is seen in the top row, the fluorescence from EGFP in the middle row, and 
fluorescence from DsRed in the bottom row.  The left column contains cells without 
ligand added, and the right column contains cells 2 hrs after ligand was added.  For the 
protein switch construct (EGFP), the initial localization is in the cytoplasm, and after 
addition of ligand it translocates into the nucleus.  The nuclear translocation of the DsRed 
construct is not as noticeable, but also moves into the nucleus after addition of ligand due 




negative control, EGFP-PS-CC was cotransfected with DsRed (no coiled-coil domain), as 
well as EGFP-PS (no coiled coil) cotransfected with DsRed-CC, and both resulted in 
negligible nuclear translocation after the addition of ligand (Figure 3.3, first column).  A 
particularly challenging interaction to study is the homo-oligomerization of a protein.  
When utilizing two fusion proteins to study the interaction, difficulty arises due to the 
formation of homo-oligomerized fusion proteins that compete with the hetero-
oligomerization between the two fusion proteins.  In the case of the Bcr coiled-coil 
domain, in spite of the known dimerization of this domain, the homo-oligomerization of 
the protein switch construct seems to be a limiting factor and minimal nuclear 
translocation was seen (Figure 3.3, second column).  However, when we used a mutant 
form of the coiled coil that exhibits reduced homo-dimerization, the protein switch 
construct was more available for interaction with the DsRed construct and a large nuclear 
increase was observed (Figure 3.3, third column).  The prevention of the homo-
oligomerization by the mutant coiled coil is also indicated by the absence of nuclear 
increase when the mutant coiled coil is fused to both the protein switch and DsRed 
(Figure 3.3, fourth column).  The NTA provided a novel way of demonstrating the 
enhanced binding and specificity of the mutant coiled coil as seen in Figure 3.3.  This 
data has been corroborated with a mammalian two-hybrid assay (data not shown). 
 One of the cell lines we chose to use for this assay, 1471.1, is an adherent cell line 
with easily detectable nuclei ideal for imaging fluorescent proteins via fluorescence 
















Figure 3.3: NTA results for the Bcr coiled coil and mutant coiled coil.  The mutant coiled 
coil is designed to prevent the homo-oligomerization (CCmut:CCmut) and have 
improved binding to the wild-type coiled coil.  This results in EGFP-PS-CCmut being 
more available to oligomerize with DsRed-CC, and the greatest nuclear translocation 
with this combination (CCmut:CC, third column).  PS=protein switch, CC=coiled coil, 
CCmut=mutant coiled coil.  * p<0.01, **p<0.001 compared to control (first column); 
each experiment performed in triplicate with at least eight cells analyzed per experiment.  






Further, the cell nucleus is very large (Figure 3.2b) and the nuclear membrane is easily 
detectable with a 40x objective, eliminating the need for nuclear stains and reducing the 
complexity of the assay.  We have routinely stained the nuclei of these cells with a 
Hoechst dye (H33342, similar to DAPI), and confirmed the location of the cell nuclei 
(data not shown).  To further validate the assay, we studied the same interactions in Cos-
7 cells, and very similar results were obtained as seen in Figure 3.3.   
 The protein switch designed in our laboratory originated with an idea for altering 
the subcellular localization of aberrant functioning proteins as a therapeutic intervention 
(23).  This optimized control over nuclear translocation now serves as an assay to study 
protein interactions in the intracellular matrix and can be applied to almost any protein of 
interest.  Although in some regards the NTA is similar to the membrane recruitment 
assay (27), or the translocation biosensor (28), the ability to control the translocation by 
the presence or absence of a ligand is advantageous.  Here we have demonstrated the 
NTA in murine and simian cells, but as the protein switch is translocated into the nucleus 
via importin α/β common among most organisms, other cells (including human) could be 
used to perform this assay.  After routine generation of fusion proteins consisting of the 
proteins of interest fused to EGFP-protein switch and DsRed, the NTA is simple and 
requires only a fluorescence microscope, software to quantify fluorescence intensities 
(such as Image J, freeware from the NIH) and the readily available ligand 
dexamethasone.  This assay now adds to the limited repertoire of experimental techniques 
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DISRUPTION OF BCR-ABL COILED-COIL 
 





 Oligomerization is an important regulatory mechanism for many proteins, 
including oncoproteins and other pathogenic proteins.  The oncoprotein Bcr-Abl relies on 
oligomerization via its coiled-coil domain for its kinase activity, suggesting that a 
designed coiled-coil domain with enhanced binding to Bcr-Abl and reduced self-
oligomerization would be therapeutically useful.  Key mutations in the coiled-coil 
domain of Bcr-Abl were identified which reduce homo-oligomerization through 
intermolecular charge-charge repulsion yet increase interaction with the Bcr-Abl coiled-
coil through additional salt bridges, resulting in an enhanced ability to disrupt the 
oligomeric state of Bcr-Abl.  The mutations were modeled computationally to optimize 
the design.  Assays performed in vitro confirmed the validity and functionality of the 
optimal mutations which were found to exhibit reduced homo-oligomerization and 
increased binding to the Bcr-Abl coiled-coil domain.  Introduction of the mutant coiled-




proliferation, and increased caspase-3/7 activity and DNA segmentation.  Importantly, 
the mutant coiled-coil domain was more efficacious than the wild-type in all experiments 
performed.   The improved inhibition of Bcr-Abl through oligomeric disruption resulting 
from this modified coiled-coil domain represents a viable alternative to small molecule 
inhibitors for therapeutic intervention. 
 
Introduction 
Coiled-coil domains are ubiquitous protein structural motifs found in 
approximately 10% of all eukaryotic proteins (1). Characterized by a heptad repeat 
(sequence of seven amino acids) and association of two or more α-helices, coiled-coils 
provide oligomerization capabilities (both homo- and hetero-oligomerization) useful for 
structural scaffolding and protein recognition.  Coiled-coil domains are critical for 
regulating many processes involved in the pathogenesis of various diseases (2).  Thus, 
rationally designed coiled-coils can be used as therapeutics by interfering with the 
activity of a pathogenic protein through oligomeric disruption.  One example is 
enfuvirtide (Fuzeon®), a fusion inhibitor that disrupts the helix bundle formation 
necessary for HIV-15 viral entry (3),  spawning the next-generation of rationally designed 
fusion inhibitors (4-8).  The coiled-coil reported here was designed to bind to the target 
(Bcr-Abl) better than the target protein binds to itself while exhibiting minimal homo-
oligomerization.   
 Coiled-coils are very well characterized, and the high correlation between their 
sequence and structure (9) is advantageous for rational design.  Coiled-coil 




the heptad repeat, hydrophobic packing at the “a” and “d” positions (see Figure 4.1, green 
residues) helps drive association with further stability provided by the residues at 
positions “g” and “e” which are commonly charged and interact to form salt bridges (see 
Figure 4.1, red and blue residues).  Since charged residues are routinely found at the “g” 
and “e” positions, mutating these residues in a rational manner to add salt bridges to favor 
formation of hetero-oligomers (10-12) and charge-charge repulsions to reduce the 
formation of homo-oligomers (13, 14) can change the affinity and specificity of the 
coiled-coil dimer. 
 Bcr-Abl exists primarily as a tetramer (more specifically as a dimer of dimers), 
facilitating the trans-autophosphorylation necessary to activate the tyrosine kinase 
domain (15, 16).  Oligomerization of Bcr-Abl is achieved through a coiled-coil domain at 
the N-terminus of the protein.  Bcr-Abl constructs lacking the N-terminal coiled-coil fail 
to induce chronic myelogenous leukemia (CML) in a murine model (15, 17) thus setting 
the stage for oligomeric disruption as a therapy.  Proof of concept for using the coiled-
coil domain to inhibit Bcr-Abl activity has already been demonstrated through retroviral 
transfection of the wild-type coiled-coil domain or addition of the purified protein 
attached to a cytoplasmic transduction peptide (18-22).  To further this approach, we 
designed and tested a mutant coiled-coil (CCmut2) using both computational and in vitro 
experiments.  This CCmut2 disfavors self-oligomerization (CCmut2:CCmut2) yet 
appears to bind more tightly to the target BcrAbl coiled-coil domain (CCmut2:Bcr-Abl) 
than the target’s native oligomerization partner (Bcr-Abl:Bcr-Abl), and resulted in 









Figure 4.1: Ribbon diagrams, with the corresponding helical wheel diagram below, of the 
wild-type homodimer (A), wild-type:CCmut2 heterodimer (B), and CCmut2:CCmut2 
homodimer (C).  Grey ribbon (ribbon diagrams) or dots (helical wheel diagrams) 
represents the wild-type coiled-coil domain and cyan represents CCmut2.  The side 
chains of key residues (E34, K39, S/R41, L/D45, E46, E/R48, R53, R55, and Q/E60) are 
shown as red (acidic), blue (basic), green (hydrophobic), yellow (serine), or black 
(glutamine) spheres (ribbon diagrams) or font (helical wheel diagrams).  Dotted lines 
indicate possible ionic interactions and solid lines indicate charge-charge repulsions.  
Ribbon diagrams were generated with UCSF Chimera starting with the Bcr coiled-coil 





The coiled-coil domain from Bcr-Abl consists of 72 amino acids composed of two 
α-helices (α1: residues 5-15 and α2: residues 28-67) that form an N-shaped configuration 
with two parallel helices connected by a short linker (see Figure 4.1A) (23).  Upon 
dimerization, the resulting coiled-coil has an anti-parallel orientation with α2 at the core 
and α1 latching onto the backside of the opposing α2 helix (domain swapping) (1, 23).  
The majority of the dimer interface is composed of the classic knobs-in-holes type 
hydrophobic interactions from residues at the “a” and “d” positions (24).  Further 
stabilization comes from 4 inter-chain salt bridges between residues in the α2 helices 
(Figure 4.1A), as well as packing of aromatic residues from the α1 helix and opposing α2 
helix.  As seen in Figure 4.1A, there are two uncharged residues (S41 and Q60) that are 
in the appropriate position for the formation of salt bridges with two charged residues 
(E32 and E48).  Thus, mutation of S41 and Q60 to positively charged amino acids has the 
potential to provide two additional salt bridges with Bcr-Abl (Figure 4.1B), and thus 
enhance binding.  However, while this provides more salt bridges in the hetero-oligomer, 
these mutations alone are undesirable as they allow the formation of a greater number of 
salt bridges in the homo-oligomer.  To reduce homo-oligomerization in the mutant 
coiled-coil, residues proximal to charged residues on the opposing helix were considered 
as candidates for mutation to introduce charge-charge repulsion (13, 14).  L45 and E48 
were identified as two such residues (Figure 4.1C).  In addition, previous reports have 
incorporated a C38A mutation primarily for crystallization purposes (1, 23), and this 
mutation was also studied.  Putative mutations were investigated first through molecular 
modeling and state-of-the-art biomolecular simulation and free energy analysis to 




provide a means to efficiently (and inexpensively) assess the influence of mutation.  The 
resulting optimized mutant coiled-coil (CCmut2) contains five mutations (C38A, S41R, 
L45D, E48R, and Q60E) and was further assessed in vitro.  Taken together, these results 
demonstrate the effectiveness of the mutant coiled-coil domain, and importantly, further 
illustrate the ability to rationally modify an existing coiled-coil domain to improve 
therapeutic efficacy. 
 
Materials and Methods 
 
Computational Modeling and Simulation 
The initial model structure was obtained from the crystal structure (refined to 2.2 
Å resolution) of the N-terminal oligomerization domain of Bcr-Abl (PDB ID: 1K1F, 
chains A and B) (25).  Selenomethionine residues were mutated to methionine and 
position 39 was mutated back to cysteine to maintain consistency with the natural protein.  
Amino acid side-chain mutations were introduced using Deepview (Swiss PDB Viewer) 
(26) and by hand with the LEAP module from AMBER 9 (27).    Molecular dynamics 
(MD) and free energy simulations were performed to assess the structure and stability of 
the model coiled-coil structures.  Such methods have proven useful for reproducing and 
predicting the structure of proteins, including the folding of small proteins and influence 
of amino acid side chain substitutions (28-34).  All simulations were completed using the 
AMBER modeling suite (27), the AMBER ff03 protein force field (35), with explicit 
solvent and counter-ions using standard simulation protocols, including minimization and 
~40-90 ns of MD sampling with Ewald treatments of the electrostatics (36).  For further 




deviations (RMSd) to the initial structure of the coiled-coil during the MD simulations 
can be found in Figure 4.S1 of the supplemental data.  The MD trajectory results, 
effectively the time history of the atomic motions of the model structures at different 
intervals over the simulation, were analyzed with various tools.  Quantification and 
comparison of the relative helical content was measured by calculating mean residue 
ellipticities at 222 nm (representative of helix content in CD spectra) of 5 individual 500 
ps average structures spanning the final 5 ns of simulation of each coiled-coil dimer using 
the DichroCalc program (37).  Structural helical content, or percent helicity defined as 
the number of residues in an α-helix divided by the total number of residues, was also 
calculated based on secondary structure as determined by peptide backbone Ψ and Φ 
torsions from the final 10 ns of simulation using the DSSP method (38) as implemented 
in UCSF Chimera (39).  Intrahelical hydrogen bonds (i.e. carbonyl oxygen of residue ‘i’ 
to the amine nitrogen of residue ‘i+4’) were calculated over the final 10 ns of MD with 
distances less than 3.5 Å indicative of a hydrogen bond.  To estimate the relative binding 
free energies of the coils in the dimers, MM-PBSA as implemented in AMBER (40) and 
described by Gohlke and Case (41) was applied to independent MD trajectories for the 
dimer and individual monomers.  In addition to the post-processing of MD results, 
calculations of the relative free energy of binding with respect to the wild-type dimer 
(ΔΔGbinding) were completed using more detailed thermodynamic integration (TI) 
methods for the CCmut2 dimers (42).  On the basis of a thermodynamic cycle (see 
supplemental data Figure 4.S2), the relative free energy of binding can be calculated by 
“mutating” the original protein (λ = 0) to incorporate designed amino acid side chain 




silico.  Incorporation of the five amino acid mutations considered using this approach was 
accomplished stepwise (see Figure 4.1B).  Two steps were required to incorporate all five 
mutations to form the heterodimer mutant (CC-CCmut2) and an additional two steps to 
perturb the transition dimer into the homodimer (CCmut2-CCmut2).  Similarly, two steps 
were used to incorporate the five mutations in the unbound monomer.  Relatively long (6 
ns equilibration, > 6 ns accumulation) MD simulations were performed at each λ for the 
TI.  Further technical details are provided in the supplemental data. 
 
Construction of Plasmids and Mutagenesis 
The gene encoding the coiled-coil domain from Bcr-Abl (43) was amplified via 
PCR with the primers 5’- tgtaactcgagttatggtggacccggtg-3’ and 5’-atgctctcgagaccggtcatag 
ctcttc-3’ and subcloned into the XhoI site of the plasmid pEGFP-PS, an optimized protein 
switch (PS) (44, 45) for use in the nuclear translocation assay (46), and pEGFP-C1 
(Clontech, Mountain View, CA, USA) for other experiments. These plasmids, named 
pPS-CC and pEGFP-CC respectively, were then used as the template DNA for site-
directed mutagenesis using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA, USA) to generate  five amino acid mutations (S41R, L45D, E48R, V49D, 
and Q60E). The primers used for the mutagenesis were 5’-
ggagcgctgcaaggcccgcattcggcgcgacgagcagcgggacaaccaggagcgcttccgcatgatctacctggagacgtt
gctggccaagg-3’ and the reverse complement.  Another site-directed mutagenesis was 
carried out to make C38A and D49V mutations with the primers 5’-
caggagctggagcgcgccaaggcccgcattcg-3’ (and reverse complement) and 5’-




were termed pEGFP-CCmut2 and pPS-CCmut2.  The primers 5’-
cgcaagggagctcccatcatcatcatcatcatcttgaagttctttttcaaggtcctatggtggacccggtgggcttc-3’ and 5’-
agcatggatccctaccggtcatagctcttcttttccttggc-3’ were used to PCR amplify wild-type and 
mutant coiled-coil domains and subcloned into pMAL-c2x (New England Biolabs, 
Ipswich, MA, USA) at the SacI and BamHI sites to generate pMAL-H6-PP-CC and 
pMAL-H6-PP-CCmut2 used for protein expression.  The primers 5’-
tgtaactcgagttatggtggacccggtg-3’ and 5’-atgctctcgagccggtcatagctcttc-3’ were used to PCR 
amplify both coiled-coil genes (wild-type and mutant), and each was subsequently 
subcloned into the XhoI site of pDsRed2-N1 (Clontech) to make pDsRed-CC and 
pDsRed-CCmut2.  Similarly, the primers 5’-tgtaaggcccagccggccatggtggacccggtg-3’ and 
5’-cggggcgcggccgcccggtcatagctcttcttttc-3’ were used to insert the genes into the plasmid 
pEFVP16 (mammalian two-hybrid prey vector containing the VP16 activation domain, 
obtained from Dr. T.H. Rabbitts, LIMM, Leeds, UK) at the SfiI and NotI sites to generate 
pEFVP16-CC and pEFVP16-CCmut2.  The primers 5’-tgtaagaattcatggtggacccggtg-3’ and 
5’-atgctgaattcaccggtcatagctcttc-3’ were used to insert the coiled-coils into the vector pM1 
(mammalian two-hybrid bait vector containing the Gal4 binding domain, obtained from 
Dr. T.H. Rabbitts) at the EcoRI site to generate pM1-CC and pM1-CCmut2.   
 
Cell Lines and Transient Transfection 
Cells were maintained in a 5% CO2 incubator at 37°C.  K562 (a kind gift from 
Kojo Elenitoba Johnson, Univ. of Michigan) and Cos-7 cells (ATCC) were grown in 
RPMI (GIBCO, Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Hyclone 




(Hyclone), and 1% L-glutamine (Hyclone).  K562 cells were passaged every two days 
and maintained between 0.1-1 x 106 cells/mL.  The Amaxa Nucleofector II (Lonza Group 
Ltd, Basel, Switzerland), was used to transfect 2 x 106 cells with 5-8 μg DNA in solution 
V following the manufacturer’s recommended protocol and nucleofection program (T-
013).  Cos-7 cells were passaged every 2-3 days and transfected 24 hrs after seeding the 
cells using Lipofectamine LTX (Invitrogen) as recommended by the supplier.   
 
Protein Purification and Circular Dichroism (CD) 
Fusion proteins consisting of maltose binding protein (MBP), a His-tag, a 
PreScission Protease site, and CC or CCmut2 were expressed in BL21star DE3 E. coli 
cells (Invitrogen) from pMAL-H6-PP-CC or pMAL-H6-PP-CCmut2 plasmids.  The 
proteins were purified over amylose resin (New England Biolabs) with gravity flow, 
cleaved with PreScission Protease (a kind gift from Dr. Chris Hill, Utah), and MBP-H6 
removed by purification over HisPur Cobalt resin, (Thermo Scientific, Waltham, MA, 
USA).  Reverse phase HPLC was performed as a final purification before lyophilizing the 
protein.  CC and CCmut2 purified proteins were confirmed through mass spectrometry 
(Mass Spectroscopy and Proteomics Core Facilities, U. of Utah).  CD experiments were 
performed on an Aviv 410 CD spectrometer (Biomedical Inc., Lakewood, NJ, USA).  
Measurements from 190-300 nm (1 nm steps) were taken on 10 μM protein solutions in 
PBS (50 mM sodium phosphate, 150 mM NaCl, 0.5 mM DTT, pH 7.2) in a 1 mm 
pathlength cuvette.  Three sec equilibration times were allowed prior to each 
measurement, and the signal was averaged over 3 sec.  The average of 3 scans was used 




every 2°C from 10°C to 95°C, and back down to 10°C in 10°C steps.  The protein 
concentrations used were 10 μM CC, 10 μM CCmut2, or 5 μM CC + 5 μM CCmut2.  In 
addition, a mixing cell cuvette was used with 2.5 μM CC in one chamber and 7.5 μM 
CCmut2 in the other chamber with spectra acquired prior to and post mixing.  After 
mixing and before data acquisition, the sample was incubated at 80 °C for 10 min, and 
then allowed to re-equilibrate at 10 °C. 
 
Nuclear Translocation Assay 
The nuclear translocation assay (NTA) was performed as previously described 
(46).  Briefly, this assay uses a nuclear-localization inducible protein switch fused to a 
protein of interest and measures its ability to translocate a second protein into the 
nucleus.  Here, the protein fused to the protein switch was either the coiled-coil domain 
or mutant coiled-coil domain, and its ability to translocate a cotransfected coiled-coil 
domain or mutant coiled-coil domain into the nucleus was measured.  Twenty-four hrs 
after transient transfection of Cos-7 cells, 200 nM dexamethasone, or an equal volume of 
ethanol (carrier) was added to the cells and incubated for 1 hr.  0.5 μL H33342 (nuclear 
dye) was added and incubated for another 15 min. before imaging the cells with a 
fluorescence microscope as previously described (43).  The percentage of protein 
localized in the nucleus was quantified with and without ligand to determine the nuclear 







Mammalian Two-Hybrid Assay 
The pM1-CC or pM1-CCmut2 (bait), pEFVP16-CC or pEFVP16-CCmut2 (prey), 
pG5-Fluc (reporter; obtained from Dr. T.H. Rabbitts), and pRL-CMV (for normalization; 
obtained from Dr. T.H. Rabbitts) plasmids were co-transfected in RPMI without 
antibiotics into 7.5x104 Cos-7 cells in a white 96-well plate (Cellstar, Greiner Bio-One, 
Monroe, NC, USA) in a 10:10:10:1 ratio.  Twenty-four hrs after transfection the media 
was replaced with complete RPMI, and 48 hrs after transfection both the Firefly and 
Renilla luminescence were measured using the Dual-Glo Luciferase Assay (Promega) 
reagents per the manufacturer’s recommendations.  The mean from duplicate samples 
were taken from 5 separate experiments.  pAD-SV40 and pBD-p53 (Stratagene) plasmids 
were used for the positive control, and pM1 lacking the coiled-coil gene was used as the 
negative control.  A relative response ratio was calculated by first normalizing the 
individual Firefly luminescence to the Renilla luminescence.  The negative control was 
subtracted from the mean of the duplicate experimental values, and scaled by dividing by 





Cell Proliferation and Western Blotting 
Forty-eight hrs following transfection of K562 cells with pEGFP-C1, pEGFP-CC, 
or pEGFP-CCmut2, trypan blue exclusion was used to determine cell proliferation (cell 
viability).  Cells were pelleted (3 x 106) and resuspended in 600 μL lysis buffer (62.5 mM 
Tris-HCl, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue).  
Standard western blotting procedures were followed using antibodies to detect the 




The primary antibodies (anti-pAbl(Y245): 73E5, Cell Signaling Technology; anti-
pSTAT5(Y694): E208, Abcam; anti-pCrkl(Y207): #3181, Cell Signaling Technology; 
anti-actin: mAbcam 8226, Abcam) were detected with anti-mouse (Ab6814, Abcam) or 
anti-rabbit (#7074, Cell Signaling Technology) HRP-conjugated antibodies before the 
addition of ChemiGlo (AlphaInnotech, Cell Biosciences, Santa Clara, CA, USA) 
chemiluminescent substrate and detection with a FluorChem FC2 imager 
(AlphaInnotech).  The resulting bands were quantified through densitometry and 
normalized to the β-actin bands.   
 
Colony Forming Assay 
Twenty-four hrs following transfection of pEGFP-C1, pEGFP-CC, or pEGFP-
CCmut2, K562 cells were resuspended in Iscove’s modified Dulbecco’s media (Stem 
Cell Technologies, Vancouver, BC, Canada) with 2% FBS, and 1000 cells were seeded in 
Methocult H4230 methylcellulose medium (Stem Cell Technologies) in the absence of 
cytokines.  Imatinib mesylate (IM; a kind gift from Novartis) was added to 1000 
untransfected K562 cells seeded in Methocult at the time of seeding. Each group of 
treated cells was seeded into two separate plates. Colony formation was assessed 7 days 
after seeding cells by counting colonies in a 200 µm2 area of the plate and calculating the 
mean number of colonies per treatment. Experiments were replicated at least 3 times and 
compared to control (cells transfected with pEGFP-C1).  
 
Caspase-3/7 Assay 




CCmut2, 3 x 106 K562 cells  were pelleted and resuspended in 50 μL lysis buffer 
provided in the EnzChek Caspase-3/7 Assay Kit #2 (Invitrogen).  Cells were frozen at -
80 °C, and then centrifuged at 5,000 x g for 5 min.  Lysates were transferred to a black 
96-well plate (Cellstar, Greiner Bio-One, Monroe, NC, USA), and 50 μL 2x AMC-
DEVD substrate was added and incubated at room temperature for 30 min.  Fluorescence 
was measured with excitation 342 nm and emission 441 nm on a SpectraMax M2 plate 
reader (Molecular Devices, Sunnyvale, CA, USA). 
 
Fluorescence Microscopy and DNA Segmentation 
Forty-eight hrs following transfection of pEGFP-C1, pEGFP-CC, or pEGFP-
CCmut2, K562 cells were transferred to 2-well live cell chambers, 1 µL of the nuclear 
stain H33342 was added, and the cells were incubated at 37°C for 15 min. Cells were 
then analyzed with an inverted fluorescence microscope (Olympus IX701F, Scientific 
Instrument Co., Sunnyvale, CA, USA) with high-quality narrow band GFP filter 
(excitation HQ480/20 nm, emission HQ510/20 nm, beam splitter Q4951p, Chroma 
Technology Corp., Brattleboro, VT, USA). Cells were photographed with an F-view 
Monochrome CCD camera using a 60x objective, and were selected based on EGFP 
fluorescence.  The nuclei of at least 50 transfected cells (EGFP fluorescence) per group 
were classified as either healthy (round or kidney shaped) or segmented (punctate) (47, 










Rational design, molecular modeling, molecular dynamics (MD), and free energy 
simulations were used to predict favorable attributes, specificity, and energetics in order 
to facilitate the choice of coiled-coil modifications that stabilize binding of the mutant 
coiled-coil domain with Bcr-Abl (CCmut2:CC) while destabilizing self-oligomerization 
(CCmut2:CCmut2).  Initial simulations monitored increases in α-helicity as an indirect 
correlate for improved free energy of binding of mutant pairs (49, 50) and focused on 
mutations to potentially improve salt bridge interactions, increase stability through 
formation of a disulfide bond, improve helicity in the backbone though alanine mutations 
to position “f”, and destabilizing mutations to improve specificity.   
Alanine mutations in the peptide backbone of the C-terminal coiled-coil region 
were designed at residues Gln33, Gln47, Phe54, and Thr61 to increase the α-helicity (49-
51).  Comparisons of the helicity as measured by circular dichroism and secondary 
structure between the homodimer (CCmut:CCmut) and heterodimer (CCmut:CC) 
suggested that this design actually decreases the helicity and shows poor specificity for 
the heterodimer over the homodimer (see Table 4.1, #3, CD and secondary structure) 
Visualization of the coiled-coil monomer structure suggests that the designed alanine 
mutations have disrupted local intrahelical hydrogen bonds which may affect secondary 
structure and protein folding.  
Cys38 exists as unbound free thiol in the native protein, and its close proximity to 





Table 4.1.  Overview of comparative helicity calculations for various mutations of the 
Bcr coiled-coil domain.  Helicity of simulated coiled-coil dimers using the calculated 
circular dichroism of the peptide, the percent of the residue which is defined as α-helical 
according to Ψ and Φ backbone dihedral torsions (using the DSSP method), and the 
percent of α-helical specific hydrogen bonds (< 3.5 Å) formed between i and i+4 residues 
at ps intervals over the final 10 ns of MD relative to the total number of potential 
interactions (the total number of residues minus 4).  Row #6 was the only set of 
mutations tested that indicated a more favorable homodimer than the heterodimer, and 
was termed CCmut1 and used in subsequent MM-PBSA experiments as a negative 
control.  Row #8 contains the set of mutations found to exhibit the optimal reduced 
homo-oligomerization paired with improved hetero-oligomerization and was termed 
CCmut2 for subsequent MM-PBSA and thermodynamic integration studies, as well as 












hb (%) S.D. 
1. None (wild-type) Homo -20943 858 66.6 1.7 56.6 2.7 
2. S41R, E48R, Q60E Hetero -21580 672 70.0 2.0 56.9 2.8 Homo -20961 678 66.5 2.9 59.4 2.7 
3. Q33A,Q47A, 
F54A,T61A 
Hetero -20884 477 66.3 2.5 60.6 2.5 
Homo -20787 760 65.1 2.2 56.4 3.2 
4. E52C Hetero -20521 796 67.8 2.2 55.9 2.7 
5. S41R, L45D, 
E48R, Q60E 
Hetero -20330 1329 66.8 1.9 52.9 3.0 
Homo -19398 679 66.2 2.0 56.5 2.4 
6. S41R, L45D, E48R, 
V49D, Q60E (CCmut1) 
Hetero -19696 765 67.8 2.0 56.9 2.7 
Homo -20352 671 69.1 2.5 59.2 2.8 
7. C38A, S41R, 
E48R, Q60E 
Hetero -21493 90 70.0 2.4 61.5 2.5 
Homo -21463 265 70.0 2.6 61.4 2.5 
8. C38A, S41R, L45D, 
E48R, Q60E (CCmut2) 
Hetero -21186 695 67.7 2.4 59.1 2.8 
Homo -17964 507 59.3 2.6 50.7 2.4 
9. C38A, S41R, L45D, 
E48R, V49D, Q60E 
Hetero -19651 456 64.2 2.5 54.0 2.5 






structure.  An engineered disulfide was modeled by incorporating a cysteine residue at 
position 52.  Visualization of the heterodimer and analysis of the structure helicity (see 
Table 4.1, #4, CD) suggests that the geometry of the disulfide is not ideal and introduces 
structural disturbances.   
 Three point mutations were designed in the wild-type monomer to improve 
binding to the oncoprotein: S41R, E48R, and Q60E.  When these three designed point 
mutations were modeled, helicity of the homodimer and heterodimer mutants exceeded 
the wild-type dimer (see Table 4.1, compare #1 vs. #2) suggesting improved binding due 
to more favorable electrostatic interactions.  The improved helicity of the mutant 
homodimer over the Bcr-Abl wildtype dimer may, however, result in decreased 
specificity for the heterodimer form.  Destabilizing point mutations to improve the 
heterodimer specificity included designed aspartate mutations in the hydrophobic core 
(L45D and L49D), and were evaluated as both single and double mutations.  Both 
mutations together decreased the secondary structure (and stability) of the heterodimer 
(see Table 4.1, #6 and #9), whereas L45D maintained heterodimer specificity (see Table 
4.1, #5).  The final mutation converted an exposed thiol group (Cys38) to alanine and, in 
conjunction with the four prior mutations, stabilized the heterodimer over both the mutant 
homodimer and the wild-type dimer (see Table 4.1, compare #1 vs. #8).  Thus, the 
optimal mutant coiled-coil domain (termed CCmut2) contains C38A, S41R, L45D, E48R, 
and Q60E mutations.  Specificity as measured by helicity suggests that the mutant 
homodimer (CCmut2:CCmut2) is significantly less stable than the wild-type (CC:CC) 
and the heterodimer (CC:CCmut2).   




latter being more quantitative and accurate, were subsequently used to analyze the two 
sets of mutations.  Both approaches validated the previous indications which suggested 
CCmut2 exhibits improved heterodimer stability compared to the wild-type 
oligomerization (see Table 4.2).  Further, CCmut2 is shown to have reduced homo-
oligomerization.  Together, MM-PBSA and thermodynamic integration energy 
calculations suggest improved binding and specificity of CCmut2.  
 
In vitro Experiments Validate the Design 
To substantiate the computational circular dichroism calculations, wavelength 
scans were performed on protein solutions of CCmut2, CC, and a mixture of CCmut2 and 
CC.  As seen in Figure 4.2A, all three protein solutions produced the typical pattern 
characteristic of α-helices with similar helicity.  Given the relatively small number of 
mutations that distinguish CCmut2 from wild-type CC, and since the mutations are 
designed to alter oligomerization while retaining helicity, it is reasonable to not expect 
major differences in their experimentally measured helicity.  However, the modifications 
do clearly destabilize the mutant homodimer as is made apparent in the thermal 
denaturation of the proteins (Figure 4.2B).  While CC demonstrated a melting 
temperature (Tm) consistent with previous reports of 83 °C (23), a large decrease in Tm is 
found for the CCmut2, Tm = 63 °C (Figure 4.2B), confirming the decreased stability of 
the mutant homo-oligomer.  When CCmut2 was mixed with CC in a 1:1 ratio two distinct 
melting transitions are evident (Figure 4.2B, black triangles), however a third Tm was not 
readily apparent. This suggests the CC-CCmut2 hetero-dimer is either iso-energetic with 









Table 4.2.  MM-PBSA and thermodynamic relative free energy of binding results (in 
kcal/mol).  MM-PBSA results were found by subtracting the absolute free energies of the 
unbound monomers from the calculated free energy of coiled-coil dimer using separate 
MD trajectories.  Thermodynamic integration calculations followed the scheme described 
in supplemental data Figure 4.S2 using intermediate coiled-coil dimers to build a 
consistent transition from the wild type coiled-coil dimer to the CCmut2 dimers.   Results 
from both calculations were reported relative to the wild-type coiled-coil dimer (CC-CC).   
Dimer 









CC:CC 0.0 3.2 0.0 0.0 
CC:CCmut1 11.7 3.0 - - 
CCmut1:CCmut1 25.5 0.1 - - 
CC:CCmut2 -1.3 3.1 -1.1 0.5 









Figure 4.2: Circular dichroism wavelength scans and thermal denaturation.  A) Alpha-
helices exhibit a characteristic double absorption minimum at ≈208 nm and 222 nm.  CC: 
green circles, CCmut2: blue squares, Mix: black triangles.  The lines represent the 
average from 3 scans.  B) Thermal denaturation curves in 1cm cuvette.  Ratio of CC to 
CCmut2 used in mix was 1:1.  CC: green circles, CCmut2: blue squares, Mix: black 
triangles.  C) Thermal denaturation curves in mixing cell cuvette using 2.5 μM CC and 




formation of the hetero-dimer a 3:1 (CCmut2:CC) ratio was studied in a mixing cell 
cuvette (Figure 4.2C) both before and after mixing.  The mixing shifts the curve, most 
predominantly at lower temperatures and only slightly at higher temperatures, suggesting 
the formation of a new species (as seen in Figure 4.2C).  The shift in the curve at lower 
temperatures can be accounted for by the decreased CCmut2 concentration due to 
formation of hetero-dimers.  The small difference in the curves at higher temperatures 
suggests the formation of hetero-oligomers that are nearly iso-energetic or slightly less 
stable than the CC homo-oligomers.  Consistent with the computational modeling, the 
primary improvement made through these mutations is in the specificity granted by a less 
stable mutant homo-dimer while retaining the ability to oligomerize with wild-type. 
The optimally designed mutant coiled-coil was created through site-directed 
mutagenesis on a plasmid encoding the Bcr-Abl coiled-coil for cell based in vitro 
experiments and further validation.  First, the nuclear translocation assay (NTA) (46) was 
used to study the interaction (Figure 4.3a).  This assay measures the ability of a nuclear-
inducible protein switch (PS) fused to one form of the coiled-coil domain to alter the 
nuclear localization of another form of the coiled-coil domain.  Essentially, the 
interaction between the coiled-coil domains is indicated by an increase in fluorescence in 
the nucleus.  The high level of nuclear translocation resulting from the mutant coiled-coil 
domain (Figure 4.3a, middle column) is likely to stem from both the reduced homo-
oligomerization as well as the improved binding to the wild-type coiled-coil domain.  To 
specifically address whether the designed mutations were limiting the homo-
oligomerization, the interaction between two mutant coiled-coil domains 





Figure 4.3: Binding of the homo- and hetero-dimers tested through the nuclear 
translocation assay (NTA) and mammalian two-hybrid assay.  A) Figure modified from 
Dixon and Lim (46).  The NTA measures the ability of a nuclear-inducible protein switch 
(PS) fused to a protein of interest to cause a second interacting protein to translocate into 
the nucleus, and is monitored through fluorescence microscopy (fused to EGFP and 
DsRed respectively).  The assay was performed in Cos-7 cells that do not contain Bcr-
Abl.  Each experiment was performed in triplicate with at least eight cells analyzed per 
experiment.  Statistical significance determined using one-way ANOVA with Tukey’s 
posttest.  * p<0.01, **p<0.001 compared to control (pDsRed2-N1/EGFP-PS-CC, not 
included in graph); B) Mammalian two-hybrid assay in Cos-7 cells.  Statistical 
significance determined using one-way ANOVA with Tukey’s posttest.  * p<0.01 




control (not included in graph).  These same interactions were also studied in a 
mammalian two-hybrid assay to further validate the results.  Similar to the NTA results, 
the greatest binding was found between the mutant and wild-type coiled-coil domains 
(CCmut2:CC, Figure 4.3B, 2nd column), and the homo-oligomerization between two 
mutants (CCmut2:CCmut2, Figure 4.3B, 3rd column) was not statistically distinguishable 
from the negative control (not included in graph).  Together, the NTA and two-hybrid 
results indicate the proposed mutations have reduced the homo-oligomerization of the 
mutant coiled-coil domain and improved the binding to the wild-type coiled-coil domain.   
Next, the oligomeric disruption of Bcr-Abl was indirectly measured through 
assaying the activity of Bcr-Abl.  As the oligomeric state of Bcr-Abl is correlated to its 
activity, if the oligomerization is disrupted it will cause a reduction in Bcr-Abl activity 
(decrease in phosphorylation).  After transfecting either the wild-type or mutant coiled-
coil domain into K562 cells, western blotting with an antibody that specifically 
recognizes the phosphorylated form of Bcr-Abl was used to determine the activity.  
Under identical experimental conditions, the wild-type coiled-coil domain had minimal 
effect on the level of phosphorylation of Bcr-Abl (Figure 4.4A, 3rd column), whereas the 
mutant coiled-coil domain reduced the phosphorylation level to 35% (Figure 4.4A, last 
column).  Further, the phosphorylation of two proteins known to be phosphorylated by 
Bcr-Abl, STAT5 and CrkL, was also tested.  Again, the wild-type coiled-coil domain had 
minimal effect while the mutant coiled-coil domain reduced the phosphorylation of both 
proteins (Figure 4.4B, 3rd and 4th columns).  The decreased phosphorylation of Bcr-Abl 
suggests that the mutant coiled-coil domain is capable of interacting with the endogenous 





Figure 4.4: Representative images of western blots to detect the phosphorylated form of 
Bcr-Abl (A) and two substrates of Bcr-Abl, STAT5 and CrkL (B).  The phosphorylation 
of Bcr-Abl is indicative of the tyrosine kinase activity, and is shown to be decreased by 
the addition of CCmut2 (percent p-Bcr-Abl from untreated K562 cells is indicated 
graphically).  The proteins STAT5 and CrkL are also phosphorylated when Bcr-Abl is 
active, and are secondary indicators of the Bcr-Abl activity.  Western blotting followed 
by densitometry was replicated three times on lysates from three separate transfections.  
The level of p-Bcr-Abl, as a percentage of the untreated cells, is shown graphically in A, 
and the level of p-STAT5 and p-CrkL (±st. dev.) is indicated above the representative 
images.  Statistical significance was determined using one-way ANOVA with Tukey’s 




two-hybrid experiments.  Moreover, the decreased level of phosphorylation provides 
insight into the oligomeric disruption and inhibitory potential of the mutant coiled-coil 
domain.   
Inhibition of Bcr-Abl through oligomeric disruption, as with inhibition through 
tyrosine kinase inhibitors, should relieve the upregulation of signaling pathways resulting 
in mis-regulated cell proliferation.  The effect of the coiled-coil domains on cell 
proliferation was measured through cell counts with trypan blue exclusion.  While the 
wild-type coiled-coil domain demonstrated a slight effect on the number of proliferating 
cells, the mutant coiled-coil domain was most effective at decreasing the number of 
proliferating cells (Figure 4.5A).  Furthermore, the effect on proliferation was measured 
via a colony forming assay, and again the mutant coiled-coil domain was found to cause 
the greatest reduction in cell proliferation (Figure 4.5B, column 2), similar to that seen 
with imatinib (Figure 4.5B, column 3).   
As CML cells become dependent on the signaling pathways up-regulated by Bcr-
Abl, the inhibition of Bcr-Abl and reprieve of that signaling should also induce apoptosis.  
As one indication of the ability of the coiled-coil constructs to induce apoptosis, the 
activity of caspase-3/7 was measured in a fluorimetric assay.  In a trend similar to that 
found in all previous experiments, the mutant coiled-coil domain again produced the 
greatest result, and was the only construct able to induce the activation of caspase activity 
at a statistically significant level (Figure 4.5C, 3rd column).  Similar experiments with 
CCmut2 in cells that do not express Bcr-Abl (1471.1 and Cos-7), as expected, did not 
show an increase in caspase activity (data not shown). 





Figure 4.5: Inhibition of the Bcr-Abl through expression of CCmut2 results in decreased 
proliferation of K562 cells and activation of apoptosis.  A) Proliferation of K562 cells as 
determined by cell counts with trypan blue exclusion.  B) Proliferation of K562 cells as 
determined by colony forming assays; IM, Imatinib mesylate.  C) Induction of apoptosis 
as measured through activation of caspase-3/7.  For A-C, statistical significance was 
determined using one-way ANOVA with Tukey’s posttest.  * p<0.01, **p<0.001 




was measured (47, 48).  Cells transfected with CCmut2 revealed segmented nuclei, a 
hallmark of apoptosis as shown in Figure 4.6 (column 3, arrows).  CC and control 
(EGFP) transfected cells had healthy (round) nuclei.  The percentage of CCmut2 
transfected cells demonstrating apoptosis was 29.4% compared to 4.29% for CC and 
0.75% for EGFP control.  Additionally, phase contrast images (Figure 4.6, column 1) 
demonstrated morphological changes indicative of apoptosis including zeotic blebbing, 
cell shrinkage, and cell fragmentation  (43, 48).   Finally, in a control cell line (1471.1 
cells) minimal DNA segmentation (less than 2%) was observed after EGFP, CC, or 
CCmut2 was transfected (data not shown).  The inhibition of cell proliferation and the 
induction of apoptosis illustrate the therapeutic potential of oligomeric disruption through 
this modified coiled-coil.   
 
Discussion 
Rational design, molecular modeling, MD simulation, and free energy analysis identified 
modifications to the Bcr-Abl coiled-coil to improve interaction with Bcr-Abl, while also 
reducing mutant homodimer (CCmut2:CCmut2) interactions.  The optimal set of 
mutations served as the lead, reducing the need to test an overwhelming number of 
possible mutations or combination of mutations in vitro.  The in vitro experiments 
performed with this construct confirmed the computational results and demonstrated that 
this designed mutant coiled-coil has an enhanced capability to oligomerize with Bcr-Abl.  
The design incorporated charge-charge repulsions between two mutant coiled-coil 
domains to reduce the homo-oligomerization, thereby making the mutant more available 










Figure 4.6: Fluorescence microscopy for morphological evaluation of nuclei.  Cells 
transfected with CCmut2 (bottom row) appear shrunken (column 1, arrows) or zeotic 
(column 1, arrowheads) and exhibit segmented (punctuate) nuclei (column 3, arrows), 
hallmarks of late apoptotic cells.  The far right column summarizes the percentage of 
transfected cells determined to have segmented DNA. Statistical significance was 
determined using one-way ANOVA with Tukey’s posttest.  *p<0.001 compared to 






favorable electrostatic interactions with Bcr-Abl were also introduced to increase the 
binding affinity between the mutant and Bcr-Abl.  Although further structural 
characterization could confirm that the hypothesized interactions are indeed occurring, 
both the computational modeling and in vitro experiments strongly indicate that the 
modifications to the coiled-coil domain lead to a more specific, better binding coiled-coil 
partner for Bcr-Abl. 
Although an isolated coiled-coil domain from Bcr-Abl should, in principal, 
oligomerize with Bcr-Abl, the isolated coiled-coil domain also has the ability to form 
homo-oligomers. Given that an isolated coiled-coil domain is smaller, there is likely less 
entropic penalty for formation, and therefore it should be less effective as a therapeutic 
due to the decreased effective concentration of the monomer and need for dissociation of 
the dimer for activity.  Our approach to a more potent therapeutic involved the design of 
a coiled-coil domain with reduced ability to self-oligomerize while also exhibiting 
enhanced oligomerization with the target.  This goal was confirmed through both 
computational modeling and in vitro experiments.  Alternative treatments for CML are 
still needed due to the inability to eliminate CML stem cells, resistance to small molecule 
inhibitors, and ineffective treatment of advanced stages of the disease (52-56).  Given the 
importance the coiled-coil domain has in the regulation of Bcr-Abl activity, it has long 
been hypothesized that this domain could be used therapeutically.  This modified Bcr-Abl 
coiled-coil domain has a heightened ability to inhibit the oncogenicity of Bcr-Abl and 
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Supplemental Data 
Molecular Dynamics Simulation Protocols 
The initial models of the coiled-coil proteins were solvated by surrounding the 
compound with at least a 10 Å water layer in all directions within a truncated octahedron 
using on the order of 12000 explicit TIP3P (57) waters.  Explicit Na+ and Cl- salt ions 
using the AMBER-adapted Aqvist parameters set (58) were added to neutralize the 
system.  Ionization states for the amino acids reflected the expected solvent-exposed pKa 
states at physiological pH, i.e. charged Arg, Lys, Glu, and Asp residues.  Energy 
minimization was performed for 500 steps first in the system with restrained protein 
atoms (50 kcal mol-1 Å-2) and then in an unrestrained system.  Initial minimization was 
followed by heating to 300K at constant volume over a period of 10 ps using harmonic 
restraints with a force constant of 2 kcal mol-1 Å-2 on the protein atoms. Subsequent 
unrestrained equilibration at 300K followed for 500 ps.  Bond lengths involving 
hydrogen atoms were constrained with SHAKE (59, 60) with a geometric tolerance for 




were applied using the particle mesh Ewald method (PME) with a less than 1 Å charge 
grid and cubic B-spline interpolation (36). 
All of the production molecular dynamics (MD) simulations were performed with 
a 2 fs time step and a direct space non-bonded cutoff of 10 Å with the pair list of atomic 
interactions built out to 11 Å and heuristic update of the pair list triggered when any atom 
moved more than 0.5 Å since the previous update.  During production runs, the center of 
mass translational motion of the entire system was removed after the initial velocity 
assignments and subsequently every 5000 MD steps.  Constant temperature was 
maintained with weak coupling to a heat bath with a 2 ps time constant (61).  Pressure (1 
atm) was maintained using isotropic position scaling with Berendsen weak coupling 
algorithm with a 1.0 ps pressure relaxation time (61).  Production molecular dynamics 
simulations for each peptide were completed on the 40-90 ns timescale.   
 
Analysis of the MD Trajectories 
Quantification and comparison of the relative helical content was measured by 
calculating mean residue ellipticities  at 222 nm (representative of helix content in CD 
spectra) of 5 individual 500 ps average structures spanning the final 5 ns of simulation of 
each coiled-coil dimer using the DichroCalc program (37). A Gaussian curve type was 
assumed with a bandwidth at half maximum of 12.5 nm and two backbone transitions.  
For these calculations, the Hirst et al. semi-empirical parameter set (62) was used due to 







Standard MM-PBSA methods were employed as described in the main text.  
Solvent and ion molecules were stripped from the trajectories and the approximate free 
energy of binding was calculated by subtracting absolute free energies of the monomers 
from the dimer. For the free energy of binding calculations, 250 snapshots were taken 
spanning the final 5 ns of stable simulation. Normal mode analysis calculations to 
determine the translation, rotational, and vibrational entropies of the protein were 
completed using a subset of 50 snapshots spanning the range of the original 250 snapshot 
set.  Minimization of each snapshot in the gas phase used the conjugate gradient method 
with a distance dependant dielectric screened by a dielectric constant of 4 until the RMS 
of the elements of the gradient vector were less than 10-6 kcal mol-1 Å-1.  The polar 
contributions to the solvation free energy of the protein were calculated using the 
Poisson-Boltzmann (PB) equation as implemented in Delphi II (63). For the calculations, 
two grid points per Å were used, the solute filled 80% of the grid box, and 5000 finite 
difference iterations were performed to ensure convergence of the results. Atomic parse 
radii consistent with prior Amber Delphi parameterization were used (41, 64).  For the 
nonpolar contribution to the free energy of solvation, the molecular surface area was 
calculated using the molsurf program implemented in AMBER (27) with a 1.4 Å probe 
radius (41). The surface tension proportionality constant was set to 0.00542 kcal mol-1 Å-
2, and the free energy of nonpolar solvation for a point solute b was set to 0.92 kcal mol-1. 
This is consistent with the use of Delphi as the PB solver (41).  Protein enthalpic 






Calculations of the relative free energy of binding with respect to the wild-type 
dimer (ΔΔGbinding) were completed using thermodynamic integration for the CCmut2 
dimers.  Incorporation of the five amino acid mutations was accomplished stepwise (see 
Figure 1B from the main text).  Two steps were required to incorporate all five mutations 
to form the heterodimer mutant (CC-CCmut2) and an additional two steps to perturb the 
transition dimer into the homodimer (CCmut2-CCmut2).  Similarly, two steps were used 
to incorporate the five mutations in the unbound monomer.  Transitions from the wild-
type dimer to the CCmut2 dimers were accomplished using three stages of 
thermodynamic integration at each step of the perturbation:  the removal of atomic 
charges for changing atoms, a soft core potential stage for the conversion of atom types, 
and a stage to add atomic charges to the mutated atoms.  All thermodynamic integrations 
simulations were performed using a particle mesh Ewald (PME) treatment of 
electrostatics, as previously described, with explicit solvent and neutralizing ions.    
Equilibrated structures were allowed to relax during 6 ns of molecular dynamics 
simulation followed by thermodynamic integration sampling for a minimum of 6 ns at 
each sampling point.  Convergence of thermodynamic integration sampling was 
visualized by a plateau in the ∂V/∂λ time course.  The first step transitions which 
incorporated four of the five mutations required significant sampling time exceeding 12 
ns per λ value to affirm that convergence had occurred. For thermodynamic integration 
calculations involving soft core potentials, nineteen linear sampling points of λ between 
0.05 and 0.95 were used.  Calculations involving only the removal or addition of atomic 




integration was used to sum the free energy of transitions.  Comparing this approach 
against integrating a polynomial fit of the average weighted energetic value against λ 






Supplemental Figure 4.S1:  One dimensional root mean square deviation (RMSd) of 
coiled-coil dimers derived from the Bcr protein-protein binding domain.  A) CC-CC  B) 









Supplemental Figure 4.S2.  Thermodynamic integration approaches to calculate the 
relative free energy of binding for coiled-coil dimers were based on a thermodynamic 
cycle (A).  Using this cycle the relative free energy of binding (ΔΔGbinding) can be found 
using the free energy differences found by incorporating point mutations in the dimer and 
unbound monomers;  ΔΔGbinding = ΔGbinding,B - ΔGbinding,A = ΔGA→B,dimer - ΔGA→B,monomer.  
Five point mutations were designed in each monomer using the scheme presented in (B).  
Note that CC‡ represents a transition coiled-coil that incorporates the C38A, S41R, E48R, 
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SECOND-GENERATION MODIFICATIONS TO THE BCR COILED-COIL 
 
 DOMAIN: FURTHER MUTANT HOMO-DIMER DESTABILIZATION 
 






 The oncoprotein Bcr-Abl relies heavily on oligomerization for trans-
autophosphorylation responsible for its aberrant activity (1, 2).  The formation of Bcr-Abl 
homo-oligomers is achieved through a coiled-coil domain at the N-terminus of the 
protein (3, 4).  We have previously shown that a modified version of this coiled-coil 
domain, CCmut2, exhibits improved ability to interfere with the oligomeric state of Bcr-
Abl and resulted in decreased proliferation of K562 cells and induction of apoptosis (5).  
A major contributing factor to these enhanced capabilities is the destabilization of the 
CCmut2 homo-dimers, increasing the availability to interact with and inhibit Bcr-Abl.  
Here, we identified an additional residue that could be mutated to further destabilize the 
mutant homo-dimer.  Incorporation of this modification into CCmut2 generated what we 
termed CCmut3, and resulted in further improvements in the binding properties with the 
wild-type coiled-coil domain representative of Bcr-Abl.  A separate construct containing 
one revert mutation, CCmut4, did not demonstrate improved oligomeric properties and 




capabilities, a distinguishable enhancement in effects on CML cells (versus CCmut2) was 
not detected and may be attributed to assay sensitivity or the oligomeric disruption 
already being maximized with CCmut2.  In addition to functioning as an alternative to 
tyrosine kinase inhibitors, the improved binding demonstrated by CCmut3 establishes it 
as a Bcr-Abl binding domain that may be used to redirect Bcr-Abl to alternative 
subcellular locations with interesting therapeutic implications.   
 
Introduction 
 In approximately the past decade, chronic myelogenous leukemia (CML) has 
been transformed from a deadly cancer into a manageable disease through the 
development of tyrosine kinase inhibitors (TKIs) (6, 7).  Currently, there are three 
approved TKIs for the treatment of CML; imatinib, nilotinib, and dasatinib.  Until only 
recently, imatinib has been considered the first-line therapy (8), with nilotinib and 
dasatinib reserved for cases of imatinib resistance, suboptimal outcome, or intolerability.  
Now, however, all three are FDA-approved for newly diagnosed chronic phase CML (9).  
While TKI therapy has proven effective for the management of CML, one particular 
resistant form, harboring an isoleucine mutation in the T315 gate keeper residue, 
however, is uninhibited by all of the currently approved TKIs (10-13).  Ponatinib (14, 15) 
and DCC-2036 (16) are third-generation TKIs currently in clinical trials that have been 
shown to be effective against the T315I form.  Nevertheless, TKIs are not without 
problems and are not a cure for CML (8, 9, 17, 18).  Patients will need to continually 
manage the disease by endlessly taking the TKI.  Thus, alternative approaches are still of 




 In healthy cells, the kinase activity of cellular Abelson kinase (c-Abl) is tightly 
controlled through Src Homology 3 (SH3) and SH2 domains as well as interaction with 
the myristoylated N-terminus (19-23).  Under genotoxic stress and other activating 
conditions, phosphorylation of the SH2 domain, SH2-Y-kinase linker region, and 
activation loop of the Y-kinase domain results in activation of c-Abl (24-27).  In the 
majority of CML cases, the Abl protein is fused onto the C-terminus of the breakpoint 
cluster region protein (Bcr), a fusion protein expressed from the Philadelphia 
chromosome (28-31).  In the fusion protein the myristoylation is lost, and even though 
both the SH3 and SH2 regulatory domains are retained, the autoinhibition of the Y-kinase 
domain is relieved (19).  The unregulated Y-kinase activity then phosphorylates and 
activates signaling pathways such as RAS, PI3K/AKT, and Src family kinases such as 
STAT5, to name only a few (32-34).  The net result is inhibition of apoptosis, activation 
of cell proliferation, and an altered cell adhesion and motility, all engendering growth 
advantages and cancer.   
 Key to the constitutive Y-kinase activity found in Bcr-Abl is a trans-
autophosphorylation process that phosphorylates critical activating residues (19, 35).  
This trans-autophosphorylation stems from the oligomeric state achieved through a 
coiled-coil (or oligomerization) domain at the N-terminus of the Bcr portion of the 
protein (1, 36, 37).  Bcr-Abl constructs lacking the coiled-coil domain have diminished 
transformation potential (1), validating oligomerization as a pivotal role in oncogenicity 
through Bcr-Abl.  An understanding of the correlation between the Y-kinase activity and 
oligomerization through the coiled-coil domain has inspired the use of an isolated coiled-




Formation of hetero-oligomeric structures between Bcr-Abl and the isolated coiled-coil 
domain prevents the trans-autophosphorylation necessary for constitutive activity leading 
to cancer, and is an interesting alternative to TKIs that bind at the Y-kinase domain.   
 The Bcr-Abl coiled-coil domain consists of 72 amino acids that fabricate two 
parallel α-helices connected through a short linker region (4).  The dimerization interface 
is composed primarily from the second helix (α-2), residues 28-67.  The first helix (α-1) 
functions as a swap domain and folds onto the backside of the opposing α-2 helix after 
dimerization.  This dimer subsequently dimerizes to form a tetrameric dimer-of-dimers.  
While the tetrameric interface consists primarily of aromatic and hydrophibic interactions 
and is challenging for rational design, both hydrophobic and ionic interactions contribute 
to formation of the dimer interface (3, 4).  Given that formation of dimers is a preceding 
step to formation of the tetramer, coupled with the fact that modifications to charged 
interactions in α-helices are more readily identified, analysis of the dimer interface 
permits logical modifications for improved oligomerization.   
 While it is possible to use the wild-type coiled-coil domain to interfere with the 
Bcr-Abl homo-oligomerization, the drawback is that there is no preference for interacting 
with Bcr-Abl over another isolated coiled-coil domain.  As Bcr-Abl in the cell will 
already be found in the tetrameric state, the feasibility of using the wild-type domain 
relies heavily on pushing the equilibrium towards formation of hetero-oligomers through 
increased concentration of the isolated coiled-coil domain. The ideal coiled-coil domain 
would exhibit minimal homo-oligomerization and form hetero-oligomers that are more 
stable than the Bcr-Abl oligomeric structures.  In attempt to generate a coiled-coil domain 




rationally mutated residues in the Bcr-Abl coiled-coil domain.  We previously 
demonstrated that modifications can be made to the Bcr-Abl coiled-coil domain to 
improve the oligomeric capabilities (5).  The design approach was two-fold: decrease 
homo-dimer stability through incorporation of charge-charge repulsion, and increase 
hetero-dimer stability through formation of additional salt bridges.  The resulting 
CCmut2 was found to not only have improved oligomeric properties, but further resulted 
in improved inhibition of Bcr-Abl and enhanced effects on CML cells.  In spite of the 
aforementioned bi-fold design approach, there is much evidence supporting that the 
improved oligomeric properties stem primarily from decreased stability of the mutant 
homo-dimer coupled with the retention of the ability to oligomerize with Bcr-Abl, not 
necessarily the formation of a more stable hetero-dimer.  This indicates the importance of 
reducing the formation of mutant homo-dimers to allow for interaction with Bcr-Abl. 
 In attempt to increase the hetero-dimer interaction, Q60 was mutated to glutamate 
in CCmut2 for the formation of an additional salt bridge with K39 of the Bcr-Abl coiled-
coil domain.  Notwithstanding, in the CCmut2 homo-dimer where both domains contain 
the Q60E mutation, an unintentional result is the possibility to form two sets of K39:E60 
salt bridges (Figure 5.1A).  In order to turn these undesired salt bridges that may 
contribute to stabilization of the mutant homo-dimer into charge-charge repulsions that 
can decrease the mutant homo-dimer stability, K39 was mutated to glutamate.  This 
mutation, along with the other five mutations previously described for CCmut2, was 
termed CCmut3 (Figure 5.1B and C).   






Figure 5.1.  Ribbon diagrams of the modified coiled-coil domains.  Only side chains from 
residues 39, 45, and 60 are illustrated as spheres and indicated in A.  Red 
ribbon=CCmut2, Blue ribbon=CCmut3, Green ribbon=wild-type (WT), Gray 
ribbon=CCmut4.  Yellow spheres=carbon, Red spheres=oxygen, Blue spheres=nitrogen.  
A) CCmut2 homo-dimer.  The potential two sets of K39:E60 salt bridges are modeled 
along with the D45:D45 charge-charge repulsion.  B) CCmut3 homo-dimer.  The two sets 
of K39:E60 salt bridges are now replaced with two sets of E39:E60 charge-charge 
repulsions.  The D45:D45 charge-charge repulsion is retained in the middle.  C) 
WT:CCmut3 hetero-dimer.  CCmut3 may form a K39:E60 salt bridges with WT as 
illustrated.  As WT does not have negatively charged residue in close proximity to D45 of 
CCmut3, there is no charge-charge repulsion.  D) CCmut4 homo-dimer.  Similar to 
CCmut3 homo-dimer, the two sets of E39:E60 charge-charge repulsion are again 
illustrated.  The D45:D45 charge-charge repulsion is now replaced with L45:L45 
hydrophobic interaction in the middle.  E) WT:CCmut4 hetero-dimer.  The K39:E60 salt 





incorporation of both L45D and V49D mutations, mutations aimed at decreasing homo-
dimer stability through charge-charge repuslsions, introduced a kink in the α-2 helix and 
was unfavorable.  However, making either L45D or V49D mutations alone contributed to 
the specificity of the mutant coiled-coil, and L45D was chosen for incorporation into 
CCmut2.  Residues 45 and 49 are unique among the set of possible mutations analyzed 
due to the fact that they are not located at “g” or “e” helical positions, but instead are 
located at the typical hydrophobic “d” and “a” positions.  Although the L45D mutation 
was demonstrated to contribute to the decrease in homo-dimer stability, it may have the 
drawback of decreased hydrophobic interactions in the hetero-dimer.  The additional 
charge-charge repulsion designed through the K39E mutation may obfuscate the need for 
charge-charge repulsion through the L45D mutation, and reverting the L45D mutation 
back to the original leucine may provide the benefit of better hydrophobic interactions 
with the Bcr-Abl coiled-coil domain (Figure 5.1D and E).  Thus, CCmut3 with the revert 
mutation D45L, was termed CCmut4.   
 As a second iteration of a rationally designed coiled-coil domain for improved 
binding to Bcr-Abl, we demonstrate here that CCmut3, but not CCmut4, provides further 
enhancements of the oligomerization properties.  CCmut3 produced similar effects as 
CCmut2 in inhibiting Bcr-Abl activity, decreasing CML cell proliferation, and inducing 
apoptosis in CML cells.  In addition to an alternative inhibitor of Bcr-Abl, the enhanced 
binding may further prove beneficial for other interests currently underway in our 






Materials and Methods 
Construction of Plasmids and Mutagenesis 
 The plasmids pEGFP-CC, pEGFP-CCmut2, pM1-CC, pM1-CCmut2, pEFVP16-
CC, and pEFVP16-CCmut2 were constructed as previously described (Chapter 4, Page 
78) (5).  pM1-CCmut3 and pEFVP16-CCmut3 were created through site-directed 
mutagenesis using pM1-CCmut2 and pEFVP16-CCmut2 as the templates, respectively.  
The mutagenic primers were 5’-GCTGGAGCGCGCCGAGGCCCGCATTCGG-3’ and 
5’-CCGAATGCGGGCCTCGGCGCGCTCCAGC-3’.  pM1-CCmut4 and pEFVP16-
CCmut4 were created through site-directed mutagenesis using pM1-CCmut3 and 
pEFVP16-CCmut3 as the templates, respectively.  The mutagenic primers were 5’- 
CCGCATTCGGCGCCTGGAGCAGCGGGTGAAC-3’ and 5’-GTTCACCCGCTGCTC 
CAGGCGCCGAATGCGG-3’.  The genes encoding CCmut3 and CCmut4 were then 
amplified through PCR using pM1-CCmut3 and pM1-CCmut4 as the templates, 
respectively, and the primers 5’-TGTAACTCGAGTTATGGTGGACCCGGTG-3’ and 
5’- ATGCTCTCGAGACCGGTCATAGCTCTTC-3’.  The PCR products were then 
inserted into pEGFP-C1 (Clontech, Mountain View, CA, USA) at the XhoI restriction 
site.  To create pmCherry-Bcr-Abl the gene encoding Bcr-Abl was digested out of 
pEGFP-Bcr-Abl (39) with EcoRI (New England Biolabs, Ipswich, MA, USA), and 
inserted into pmCherry-C1 (Clontech).   
 
Cell Lines and Transient Transfection 
The cells used all experiments were either K562 (model Ph+ CML cells, a kind 




ATCC), and were grown in RPMI (GIBCO, Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% FBS (Hyclone Laboratories, Logan, UT, USA), 1% penicillin-
streptomycin (GIBCO), 0.1% gentamicin (Hyclone), and 1% L-glutamine (Hyclone) and 
maintained in a 5% CO2 incubator at 37 °C.  K562 cells were passaged every two days 
and maintained between 0.1-1 x 106 cells/mL.  The Amaxa Nucleofector II (Lonza Group 
Ltd, Basel, Switzerland), was used to transfect 2 x 106 cells with 5-8 μg DNA in solution 
V using nucleofection program (T-013) following the manufacturer’s recommended 
protocol.  Cos-7 cells were passaged every 2-3 days and transfected 24 hrs after seeding 
the cells using Lipofectamine LTX (Invitrogen) as recommended by the supplier.   
 
Mammalian Two-Hybrid Assay 
 An in depth description of how the mammalian two-hybrid assay was carried out 
is described elsewhere (Chapter 4, Page 81) (5).  In short, pM1-CC (or mutant), 
pEFVP16-CC (or mutant), pG5-Fluc (Promega, Madison, WI, USA), and pRL-CMV 
(Promega) plasmids were co-transfected into Cos-7 cells in a 10:10:10:1 ratio.  pAD-
SV40 and pBD-p53 (Stratagene, Agilent Technologies Inc., Santa Clara, CA, USA) 
plasmids were used for the positive control, and pM1 lacking the coiled-coil gene was 
used as the negative control.  Forty-eight hrs after transfection both firefly and renilla 
luminescence were measured using the Dual-Glo Luciferase Assay (Promega) reagents 
per the manufacturer’s recommendations.  The mean from duplicate transfections were 
taken from five separate experiments.  A relative response ratio was calculated using the 







 ).  For ease of comparing to the wild-type coiled-coil interaction, the 
results were then normalized to the wild-type interaction. 
 
Confocal Microscopy and Co-localization 
 Twenty-four hrs after seeding K562 cells into 4-well live-cell chambers (Lab-tek 
chamber slide system, Nalge NUNC International, Naperville, IL, USA) they were 
transfected with Lipofectamine LTX (Invitrogen).  At least 24 hrs after transfection the 
cells were imaged.  All images of cells were acquired on an Olympus IX81 FV1000-XY 
confocal microscope equipped with 405 diode, 488 argon, and 543 HeNE lasers using a 
60X PlanApo oil immersion objective (NA 1.45) using Olympus FluoView software.  
Excitation and emission filters were as follows: EGFP, 488 nm excitation, emission filter 
500-530 nm; mCherry, 543 nm excitation, emission filter 555-655 nm.  Images were 
collected in sequential line mode.  The exposure settings and gain of laser were kept 
constant and below detected pixel saturation for each group of cells.  No crosstalk was 
observed between channels as determined by excitation with either the 488 nm or 543 nm 
laser lines, independently, while collecting fluorescence in both channels.  Pixel 
resolution was kept at 1024 x 1024 with maximum of 2.5X digital zoom.  Prior to 
statistical co-localization analysis all images were corrected for background noise (i.e., 
mean background intensity outside of cells). All experiments were completed in triplicate 
(n ≥ 3). Region of interests (ROIs) were created around whole cells.  Image and statistical 
analysis was performed with JACoP in ImageJ (http://rsb.info.nih.gov/ij) (40).  Costes’ 






 48 hrs following transfection of K562 cells with pEGFP-C1, pEGFP-CC, pEGFP-
CCmut2, or pEGFP-CCmut3, 5 mL of cells were pelleted and resuspended in 0.5 mL of 
1x annexin binding buffer (Invitrogen).  Immediately before flow cytometry analysis, 0.5 
μL of 7-aminoactinomycin D (7AAD, Invitrogen, 1 mg/mL) and 5 μL annexin V 
conjugated with allophycocyanin (annexin-APC, Invitrogen) were added to the cells.  
Flow cytometric analysis was performed on a FACSCantoII analyzer (Becton Dickinson, 
Franklin Lakes, NJ, USA) using BD FACSDiva v6.1.3 (BD) software.  Both EGFP and 
7AAD were excited with a blue laser with 488 nm wavelength, while APC was excited 
with a red laser with 635 nm wavelength.  The fluorescence detector used for EGFP was 
530/30 nm, the detector for 7AAD was 660/20 nm, and the detector for APC was 660/20 
nm.  The untransfected cells were excluded from analysis through gating on the EGFP 
fluorescence, and the percentage of transfected, apoptotic cells was quantified through 
combining the number of cells that stained positively for annexin-APC only (Q2) with 
the number of cells that stained positively for annexin-APC and 7AAD (Q4).  All four 
plasmids were transfected three separate times for separate analysis (n = 3). 
 
Cell Proliferation and Western Blotting 
 The cell proliferation and western blotting were carried out as previously 
described for CCmut2 (Chapter 4, Page 82) (5).  Briefly, 48 hrs following transfection 
into 2.5 x 106 K562 cells trypan blue exclusion was used to determine the number of 
viable cells.  For western blots, cell pellets were resuspended in 200 μL lysis buffer/106 




PVDF membrane, the membrane was probed with primary antibodies (anti-pAbl(Y245): 
73E5, Cell Signaling Technology; anti-pSTAT5(Y694): E208, Abcam; anti-pCrkl(Y207): 
#3181, Cell Signaling Technology; anti-actin: mAbcam 8226, Abcam), followed by 
HRP-conjugated secondary antibodies (Ab6814, Abcam) or anti-rabbit (#7074, Cell 
Signaling Technology) before the addition of ChemiGlo (Alpha Innotech, Cell 
Biosciences, Santa Clara, CA, USA) chemiluminescent substrate and detection with a 
FluorChem FC2 imager (AlphaInnotech).  Densitometry was performed on the phospho-
bands and normalized to β-actin.  Plasmids were transfected three separate times, and a 
western was performed on each lysate for analysis (n = 3).   
 
Colony Forming Assay 
 The colony forming assay was carried out as previously described (Chapter 4, 
Page 83) (5).  In short, 24 hrs following transfection into K562 cells, 1000 cells in 
Iscove’s modified Dulbecco’s media (Stem Cell Technologies, Vancouver, BC, Canada) 
with 2% FBS were seeded in Methocult H4230 methylcellulose medium (Stem Cell 
Technologies) in the absence of cytokines.  Each group of treated cells was seeded in 
duplicates, and colony formation was assessed seven days after seeding cells by counting 
colonies in a 200 µm2 area of the plate. Experiments were repeated at least three times 
and compared to control (cells transfected with pEGFP-C1).  
 
Caspase-3/7 Assay 
 Caspase-3/7 assays were performed as previously described (Chapter 4, Page 83) 




and 3 x 106 cells were resuspended in 50 μL EnzChek Caspase-3/7 lysis buffer (kit #2, 
Invitrogen).  Cells were frozen at -80 °C, thawed, and the cell debris removed by 
centrifuged at 5,000 x g for 5 min.  Lysates were mixed with 50 μL 2x AMC-DEVD 
substrate in a black 96-well plate (Cellstar, Greiner Bio-One, Monroe, NC, USA), and 
incubated at room temperature for 30 min. before measuring the fluorescence with 
excitation 342 nm and emission 441 nm on a SpectraMax M2 plate reader (Molecular 
Devices, Sunnyvale, CA, USA).  Lysates from three separate transfections for each 
plasmid were assayed for caspase-3/7 activity (n = 3). 
 
Fluorescence Microscopy & DNA Segmentation 
 A detailed description of the fluorescence microscopy and DNA segmentation can 
be found elsewhere (Chapter 4, Page 84) (5).  In short, 48 hrs following transfection 
K562 cells were transferred to 2-well live cell chambers, 0.3 µL H33342 (nuclear dye, 
Invitrogen) was added, and the cells were incubated at 37°C for 15 min. Cells were then 
analyzed with an inverted fluorescence microscope (Olympus IX701F, Scientific 
Instrument Co., Sunnyvale, CA, USA) with high-quality narrow band GFP filter 
(excitation HQ480/20 nm, emission HQ510/20 nm, beam splitter Q4951p, Chroma 
Technology Corp., Brattleboro, VT, USA) equipped with an F-view Monochrome CCD 
camera.  Fields of view for imaging were selected based on EGFP fluorescence (blinded 
to nuclei), and were imaged with a 40X oil immersion objective.  The nuclei of at least 50 
transfected cells (EGFP fluorescence) per group were classified as either healthy (round 
or kidney shaped) or segmented (punctate) (42, 43) and the percentage of cells with 





 Site-directed mutagenesis was performed on the mammalian two-hybrid plasmids 
pM1-CCmut2 and pEFVP16-CCmut2 to create CCmut3 constructs.  The resulting 
CCmut3 constructs were then mutated through site-directed mutagenesis to create the 
corresponding CCmut4 plasmids.  Subsequently, mammalian two-hybrid assays were 
carried out in Cos-7 cells.  For the hetero-dimer interactions, both possible fusion 
constructs were assayed (i.e. pM1-CC/pEFVP16-CCmutX and pM1-CCmutX/pEFVP16-
CC).  While the same trend was observed regardless of which fusion construct was the 
wild-type, slightly higher values were obtained when the wild-type were fused to the 
DNA binding domain (pM1).  As illustrated in Figure 5.2A, the greatest interaction 
resulted from the hetero-dimer between CCmut3 and the wild-type coiled-coil domain 
(CC) (Figure 5.2A, third column).  Equally important, the CCmut3:CCmut3 interaction 
(homo-dimer) resulted in negligible binding (Figure 5.2A, fourth column).  Although it is 
difficult, if not impossible, in this assay to separate out the binding contributions from 
increased availability versus increased affinity, the design to decrease the stability of the 
mutant homo-dimer did correlate to an increased ability to bind wild-type as predicted.  
The result from the CCmut3 hetero-dimer and homo-dimer together indicate the 
improved interaction exhibited by CCmut3.   
 Although the CCmut4 hetero-dimer did result in a slightly greater interaction than 
wild-type (all results are normalized to the wild-type CC:CC interaction, Figure 5.2A, 
fifth column), the CCmut4 homo-dimer produced an almost equivalent result (Figure 






Figure 5.2. Mammalian two-hybrid assay.  A) Relative response ratios were first 
determined for each interaction, and then normalized to the wild-type homo-
oligomerization (CC:CC) to indicate the relative binding efficiency.  CCmut2, CCmut3, 
and CCmut4 hetero-dimers resulted in a greater interaction than the wild-type, as did the 
CCmut4 homo-dimer.  CCmut2 and CCmut3 homo-dimer interactions were negligible.  
Assays were repeated five times, and values indicated are the means ± S.D.  Statistics 
were performed on the values without normalizing to CC so as to include the wild-type 
interaction in the statistics.  Statistical significance was determined by one-way ANOVA 
with Tukey’s posttest.  *p<0.05, ***p<0.001.  B) The quotient of the hetero-dimer 
interaction divided by the homo-dimer interaction (absolute value) is graphed for all three 
mutants.  This ratio provides a means of indicating the preferential binding to CC over 





generating a preferential binding towards wild-type.  Whereas the other mutations 
designed for charge-charge repulsion are found on the helix at “g” and “e” postions and 
may more readily adopt rotamer conformations that position the like charges away from 
each other, the L45D mutation is in the hydrophobic core where such rotamer flexibility 
may be more limited.  As demonstrated from the dramatic differences between CCmut3 
and CCmut4, the L45D mutation is critical.   
 As both the hetero-dimer and homo-dimer formations are critical in evaluating the 
improvements made through the mutations, the quotient of the hetero-dimer and homo-
dimer can be used to more easily compare the overall effect.  Figure 5.2B reports these 
quotients for CCmut2, CCmut3, and CCmut4.  Although the quotient for CCmut2 
indicates it is a favorable domain for interacting with Bcr-Abl (at least the wild-type 
coiled-coil domain of Bcr-Abl), the best set of mutations are those comprising CCmut3.  
While CCmut4 may interact favorably with wild-type (Figure 5.2A, fifth column), it does 
not exhibit any preferential binding (Figure 5.2B, third column) and did not result in any 
improvement as compared to the wild-type domain.  Following these results, CCmut4 
was dropped from further analysis due to the lack of improvement in oligomerization 
properties.   
 While the mammalian two-hybrid assays are a quantitative method of studying 
the effects of the mutations, these assays were carried out with the isolated coiled-coil 
domains and not full-length Bcr-Abl.  To validate the modifications also correlate to the 
binding to Bcr-Abl, co-localization experiments were performed in K562 cells.  A 
rigorous analysis for determining co-localization was employed, Costes’ co-localization 




localization was aimed at simply confirming the interaction with the full-length protein, 
and not necessarily at distinguishing their binding affinities.  Nevertheless, CCmut3 was 
found to exhibit a much higher degree of co-localization with Bcr-Abl than the other two 
(Figure 5.3), and further validated the improved oligomeric properties.  Not surprisingly, 
there was no difference between CC and CCmut2 (Figure 5.3).  These co-localization 
results confirm the CCmut3 set of mutations have improved the ability to interact with 
Bcr-Abl inside a live cell.   
 Analysis of the oligomeric disruption of Bcr-Abl was further explored to confirm 
the interaction of CCmut3.  As Bcr-Abl trans-autophosphorylation is dependent on the 
coiled-coil domain, the formation of hetero-oligomers between a coiled-coil domain and 
full-length Bcr-Abl should reduce the phosphorylation of Bcr-Abl.  As a measure of the 
phosphorylation state of Bcr-Abl, western blotting was carried out probing K562 lysates 
with an antibody that recognizes the phosphorylated form of Bcr-Abl.  As seen in Figure 
5.4A, the phosphorylation of Bcr-Abl was the least after transfection of CCmut3.  A 
secondary measure of the phosphorylation of Bcr-Abl, and its corresponding kinase 
activity, is the phosphorylation of Bcr-Abl substrates such as STAT5.  The 
phosphorylation of STAT5 was also the least after transfection of CCmut3 (Figure 5.4A).  
The western blot results correlate with both the mammalian two-hybrid and co-
localization data.   
 Next, the improved Bcr-Abl binding of CCmut3 was analyzed for its effect on 
CML cells.  As CML cells are dependent on Bcr-Abl signaling for growth, inhibition of 





Figure 5.3.  Co-localization with Bcr-Abl.  Representative images of either EGFP or 
coiled-coil domain are seen in the left column (cyan).  Representative images of Bcr-Abl 
distribution are seen in the middle column (magenta).  Heat maps indicating the co-
localization of the two fluorophores are seen in the right column with co-localization 
scale at the bottom (red highest) followed by the co-localization coefficient.  The mean 
co-localization coefficient was determined from at least three cells per transfection, and 
repeated four times.  The values reported are the means ± S.E.M.  Statistical significance 





Figure 5.4.  Effects of CCs on Bcr-Abl and proliferation of K562 cells.  A) A western 
blot indicating the phosphorylation of Bcr-Abl (top, p-Bcr-Abl) and STAT5 (middle, p-
STAT5).  B) Viable K562 cells were counted 48 hrs following transfection.  The number 
of proliferating cells was normalized to the number resulting from the EGFP transfection.  
Each construct was transfected a minimum of three times.  Values reported are means ± 
S.D.  Statistical significance was determined by one-way ANOVA with Tukey’s posttest.  
*p<0.05.  C) Colony forming units were counted 7 days after seeding 103 transfected 
K562 cells into methylcellulose medium.  The mean from three separate 200 μm2 areas 




monitored in a simple fashion through performing cell counts after treatment of the cells.  
48 hrs following transfections of either EGFP, CC, CCmut2, or CCmut3 into a CML 
model cell line (K562), cell counts were performed using trypan blue exclusion.  As seen 
in Figure 5.4A, the proliferation of the cells decreased in the order of EGFP, CC, 
CCmut2, and CCmut3.  Although indirect, this provides evidence of the disruption of 
Bcr-Abl oligomerization resulting in inhibition of its signaling.  
 As an alternative method of measuring cell proliferation, a colony forming assay 
was performed.  Twenty-four hrs following transfection of the plasmids into K562 cells, 
103 cells were seeded into methylcellulose medium and incubated at 37°C for seven days 
before counting the colony forming units in a 200 μm2 area.  Both CCmut2 and CCmut3 
were found to produce the fewest number of colonies, indicative of the decrease in cell 
proliferation.  Notwithstanding, there was no difference in the number of colonies after 
transfection of CCmut2 or CCmut3.  The results achieved by CCmut2 and CCmut3 were 
comparable to the result after treating K562 cells with 0.5 μM imatinib, demonstrating 
the therapeutic potential.   
 Further exploration of the effects on CML cells was carried out though analysis of 
the induction of apoptosis.  First, flow cytometry was used to analyze the number of cells 
with externalized phosphatidylserine, an established marker of apoptosis.  As seen in 
Figure 5.5A, the level of cell death incrementally increased in the order of CC, CCmut2, 
and CCmut3.  Although the statistical significance compared to the EGFP control was 
greater for CCmut3 than for CCmut2, there was not a statistical significance between 






Figure 5.5.  Annexin-APC/7AAD staining and caspase-3/7 assays.  A) 48 hrs following 
transfection into K562 cells phosphatidylserine externalization was assessed through flow 
cytometry.  After gating on EGFP fluorescence to select only the transfected cells, the 
number of 7AAD-/Annexin+ cells (Q2, early apoptosis) was combined with the 
7AAD+/Annexin+ cells (Q4, late apoptosis) and used to determine the percentage of 
apoptotic cells.  The values reported are the means ± S.D. from three separate 
transfections.  Statistical significance was determined by one-way ANOVA with Tukey’s 
posttest.  *p<0.05, **p<0.01.  B) Forty-eight hrs following transfection into K562 cells 
the activation of caspase-3/7 was analyzed in the cell lysates through a fluorescence-
based assay.  Values reported are the means ± S.D. from three separate transfections.  
Statistical significance was determined by one-way ANOVA with Tukey’s posttest.  




caspase-3/7 was also measured.  A substantial increase in caspase-3/7 activity was 
observed after transfection of either CCmut2 or CCmut3 (Figure 5.5B).  Again, there was 
no statistical difference between the caspase-3/7 activities resulting from the CCmut2 or 
CCmut3 transfected cells.   
 Analysis of the cell morphology is an alternative method of studying the induction 
of apoptosis.  Healthy K562 cells are relatively large, round cells with kidney shaped (or 
round) nuclei (Figure 5.6A, top row).  Apoptotic cells, however, exhibit very distinct 
morphological signs readily detectable through microscopy.  Some morphological signs 
of apoptosis include cell shrinkage (as opposed to necrotic cells that may expand), 
cytoplasmic blebbing, echnoid spikes, and nuclear segmentation (42, 43).  Of these signs, 
nuclear segmentation is one indication that can be quantified (each individual cell 
determined to have either a normal or segmented nucleus) as a measurement of the 
induction of apoptosis.  Forty-eight hrs after the transfection of the plasmids into K562 
cells, the nuclei are stained with H33342, and the cells are photographed on a 
fluorescence microscope.  The fields of view photographed are selected based on the 
EGFP fluorescence, while being blinded to the nuclear stain, and reduces biased selection 
of nuclei.  Representative images are illustrated in Figure 5.6A.  The percentage of 
transfected cells with segmented nuclei is graphed in Figure 5.6B.  Similar to the cell 
proliferation, and flow cytometry, an incremental effect was observed on nuclear 
segmentation with CC, CCmut2, and CCmut3.  Nevertheless, CCmut2 and CCmut3 
produced similar results.  Thus, the flow cytometry, caspase assay, and nuclear 
segmentation together demonstrate the ability of the modified coiled-coils to inhibit Bcr- 






Figure 5.6. Nuclear segmentation of K562 cells.  A) Representative images of K562 cells 
48 hrs after transfection of EGFP (top row) or CCmut3 (bottom row).  The left column 
depicts the phase contrast images, with an example of cell shrinkage indicated with a 
black arrow.  The middle column depicts the fluorescence from EGFP.  The right column 
depicts the nuclei, with examples of nuclear segmentation indicated by the white arrows.  
Scale bars are included in the bottom right corners.  B) Results from the quantification of 
nuclear segmentation.  The percentage of transfected cells with segmented nuclei was 
determined from three fields of view and repeated with cells transfected three separate 
times.  Values reported are the means ± S.D.  Statistical significance was determined by 






 Analysis of the structure of the Bcr-Abl coiled-coil domain, and the previously 
designed CCmut2, guided the identification of residues 39 and 45 as interesting possible 
mutations.  Incorporation of a K39E mutation into CCmut2 produced CCmut3.  
Subsequently, reverting the CCmut3 L45D mutation back to leucine produced CCmut4.  
The effects of these modifications on the oligomerization properties were studied through 
a mammalian two-hybrid assay in Cos-7 cells and compared to CCmut2.  While CCmut3 
yielded impressive improvements in the binding capabilities, CCmut4 was found to bind 
almost equivalently to another CCmut4 as it binds CC.  The binding results from CCmut4 
indicate the importance of the L45D mutation in preventing homo-oligomerization.  
These binding results, including both CCmut3 and CCmut4, further support the idea that 
decreased homo-dimer stability is a major driving force in the improved oligomerization 
with Bcr-Abl.  The mammalian two-hybrid assay using isolated coiled-coil domains was 
then followed by co-localization with full-length Bcr-Abl.  CC, CCmut2, and CCmut3 
were all found to colocalize with Bcr-Abl, with CCmut3 resulting in the greatest degree 
of co-localization.  The improved binding of CCmut3 to Bcr-Abl also decreased the 
phosphorylation of Bcr-Abl, a parameter indicative of Bcr-Abl’s oligomeric state and 
activity.  These binding studies validated the additional mutation used in CCmut3 led to 
enhanced oligomeric properties and demonstrated its usefulness as a Bcr-Abl binding 
domain.   
 The improved binding by CCmut3 was then tested for its effect on CML cells.  
Cell proliferation was first measured through cell counts and colony forming assays 




the cell proliferation, but there was no statistical difference between CCmut2 and 
CCmut3.   
 CCmut3 was also demonstrated to induce apoptosis in K562 cells as measured 
through 7AAD staining, activation of caspase-3/7, and hallmark morphological signs of 
apoptosis.  Both the decreased cell proliferation and the induction of apoptosis are 
indirect evidence of the ability of CCmut3 to interfere with the homo-oligomerization of 
Bcr-Abl.  Due to the fact that CCmut3 does not contain the Y-kinase domain necessary 
for activation through trans-autophosphorylation, the binding between CCmut3 and Bcr-
Abl results in inactivation of Bcr-Abl and induction of apoptosis in CML cells.   
 These results can be divided into two distinct categories of experiments: testing 
the binding, and testing the effect the construct has on CML cells.  The analysis of the 
binding revealed a marked improvement in CCmut3, even over the proven CCmut2.  
Nevertheless, this improved binding did not correlate to enhancements over CCmut2 in 
effects on CML cells.  This may be explained by insufficient assay sensitivity to 
distinguish a modest difference, indicating the improvement is only marginal.  An 
alternative explanation lies in the idea that the disruption of Bcr-Abl oligomerization is 
already maximized with the binding capabilities of CCmut2.  If this is the case, any 
improvements in binding with an alternative coiled-coil domain would not instigate 
enhancements in the effect on CML cells.  This theory is supported by the inability to 
increase the effect of CCmut2 on CML cells through combinatorial treatment with 
CCmut2 and a TKI (unpublished data D.W.W.).   
 Although use of CCmut3 for interfering with the oligomeric state of Bcr-Abl is an 




our laboratory is the use as a capture motif for escort of Bcr-Abl to alternative subcellular 
locations.  As opposed to a passive induction of apoptosis when Bcr-Abl is inhibited, we 
are seeking an active induction of apoptosis that may lead to a more potent therapeutic 
strategy.  With this goal in mind, the improved binding properties are of utmost interest.  
This work establishes CCmut3 as an efficient binding partner to Bcr-Abl with 
implications in inhibiting Bcr-Abl as well as other interesting therapeutic strategies that 
require tight binding to Bcr-Abl. 
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RATIONALLY DESIGNED BCR-ABL CAPTURE 
 





 The fusion of the breakpoint cluster region (BCR) and Abelson kinase (Abl) 
proteins generates a highly characterized oncoprotein responsible for the majority of 
chronic myelogenous leukemia (CML) cases (1-3) attributable to the aberrant signaling 
through the tyrosine kinase domain (4-7).  In addition to the constitutive kinase activity 
generated by the fusion of these two proteins, a further consequence is the exclusive 
cytoplasmic localization of Bcr-Abl (8, 9).  Bcr-Abl in the cytoplasm allows for 
oncogenic signaling which leads to proliferation of cells.  However, nuclear localization 
of Bcr-Abl leads to apoptosis (10-12).  The purpose of this work was to develop capture 
motifs capable of binding endogenous Bcr-Abl and escorting it to the nucleus.  Binding 
domains for capture of Bcr-Abl were generated, and subsequently incorporated into a 
controllable nucleo-cytoplasmic shuttling protein switch (13) or attached to four nuclear 
localization signals (12).  Targeting Bcr-Abl at domains with known interactions that 




C-terminus), we isolated intracellular domain antibodies (iDabs) that bind Bcr-Abl.  In 
addition to the co-localization with Bcr-Abl, the best isolated iDab (ABI7) and a 
rationally designed coiled-coil domain (CCmut3) provoked a redistribution of the 
subcellular localization of Bcr-Abl.  These binding domains were then tested for their 
ability to escort Bcr-Abl into the nucleus using the protein switch (13) or attachment of 4 
NLSs.  Although RIN1, ABI7, and CCmut3 all produced similar co-localization with 
Bcr-Abl, CCmut3 was the only domain found to produce efficient nuclear translocation 
of Bcr-Abl, implicating the region of Bcr-Abl being bound, and possibly the resulting 
Bcr-Abl conformation, are important factors for nuclear translocation and not mere 
binding affinity alone.  This newly found capability to escort Bcr-Abl into the nucleus 
has the potential of turning the causative agent, Bcr-Abl, against the cancer cell for 
induction of apoptosis and may provide a potent means of treating CML, even forms 
resistant to the current and future tyrosine kinase inhibitors (TKIs). 
 
Introduction 
 As the gene product resulting from the first abnormal chromosome found to be 
responsible for a specific disease (the Philadelphia chromosome) (14), the oncoprotein 
Bcr-Abl has been extensively investigated (15, 16).  This thorough research has turned a 
previously fatal cancer, chronic myelogenous leukemia (CML), into what is now a 
chronically manageable disease (17, 18).  The turning point in the treatment of CML was 
the identification of STI-571 (imatinib, or Gleevec®), a small molecule inhibitor of Bcr-




as well as the progression from the chronic phase of the disease into the deadly blast 
crisis (19-21).   
 On the molecular level, Gleevec® binds Bcr-Abl at the tyrosine kinase domain 
and prevents phosphorylation of its substrates (22, 23), an event critical to the activation 
of numerous signaling pathways resulting in upregulation of proliferation, inhibition of 
apoptosis, altered cell adhesion and motility, and inhibition of DNA repair (15), all 
contributing to the oncogenesis through Bcr-Abl.  Due to the essential role of the tyrosine 
kinase activity in the pathogenesis, the inhibition by Gleevec® has proven to be a 
remarkable treatment for CML.  Nevertheless, numerous mutations in Bcr-Abl have been 
described which render resistance to Gleevec® (24-27), and second generation tyrosine 
kinase inhibitors (TKIs) such as AMN107 (nilotinib, Tasigna®) and BMS-354825 
(dasatinib, Sprycel®) have already been approved for the treatment of Gleevec®-resistant 
forms of CML.  One resistant form, containing the T315I mutation, remains elusive to all 
currently approved TKIs (28-31), although AP24534 (Ponatinib) and DCC-2036 have 
been demonstrated to be effective against the T315I mutation and are currently in clinical 
trials (32-36).  Still, TKIs do not cure CML, and alternative therapeutics are still of 
interest for the potential to eliminate the necessity of a life-long treatment. 
 It is well established that the fusion between Bcr and Abl transforms the regulated 
tyrosine kinase activity from c-Abl into constitutive tyrosine kinase activity in Bcr-Abl.  
This activity, as described above, has received rightly due attention and has been the 
focus of much research for CML.  In addition to the misregulated kinase activity, it is 
also well established that this fusion also results in a spatial misregulation at the 




nucleus and plays distinct roles in each subcellular compartment (37-40).  This spatial 
control is important for the role of c-Abl in cell differentiation, division, adhesion, and 
response to stress signals.  In contrast, Bcr-Abl is found to localize exclusively in the 
cytoplasm where it can be positioned in proximity to the signaling proteins controlled by 
its activated kinase domain.  The combination treatment of Gleevec® and the nuclear 
export inhibitor Leptomicin B (LMB) have demonstrated the ability to relocate Bcr-Abl 
to the nucleus, where Bcr-Abl induced apoptosis (11).  We have also demonstrated that 
an exogenous Bcr-Abl construct can be directed to the nucleus through incorporation of 
nuclear localization signals (NLSs), and established that the induction of apoptosis was 
dominant over the endogenous Bcr-Abl oncogenic signaling as cytoplasmic depletion of 
the endogenous Bcr-Abl was not observed (12).  Thus, relocalizing Bcr-Abl to the 
nucleus is a potent method of inducing apoptosis and may be an interesting alternative 
intervention strategy.  However, LMB cannot be used clinically due to neuronal toxicity 
(41), and treatment with an exogenous Bcr-Abl would also be problematic.  In order to 
harness the apoptotic potential of Bcr-Abl, an alternative method of repositioning the 
protein is needed. 
 Numerous proteins are found to shuttle between the cytoplasm and nucleus under 
normal biological conditions.  One of the most notable examples is steroid hormone 
receptors which are found to localize in the cytoplasm in the absence of hormone (42-44).  
Upon binding of the hormone and the associated conformational change, the receptor 
dimerizes and transports into the nucleus where it is a transactivator of various genes.  
Previous work in our laboratory has exploited the controlled conformational change of 




incorporation of both a nuclear export signal (NES) and a nuclear localization signal 
(NLS), generated a small (32 kDa) chimeric protein with nucleo-cytoplasmic shuttling 
control through the addition or removal of the synthetic glucocorticoid dexamethasone 
(dex) (13).   The LBD employed is from the rat glucocorticoid receptor and contains one 
point mutation, C656G, delivering 10 times more sensitivity to dex (42).  This protein, 
termed the protein switch, localizes to the cytoplasm in the absence of dex due to the 
NES.  When dex is added, the conformational change causes the NLS to become 
dominant and the protein switch moves to the nucleus.  This translocation is reversible, 
and the protein switch relocalizes to the cytoplasm if dex is washed out (13, 45, 46).   
 The controlled translocation into the nucleus afforded by the protein switch may 
be applied to escorting Bcr-Abl into the nucleus through incorporation of a Bcr-Abl 
binding motif.  The ideal binding motif for incorporation into the protein switch will 
exhibit high affinity and specificity, will be stable inside of cells, and will be small in 
size.  These are all attributes of intracellular domain antibodies (iDabs) (47-56).  While it 
is commonplace for heavy and light chain variable fragments to be connected through a 
small peptide linker in the scFv format for use in epitope recognition inside of cells, the 
iDab is a further simplification of an antibody and consists of only one variable domain 
(from either the heavy or the light chain).  As the entire structure is only one domain, the 
iDab eliminates the necessity for a linker and is half the size of an scFv.  The iDab has 
been demonstrated to function in the absence of any disulfide bonds (54), and is the 
minimal antibody portion that retains the high affinity and specificity typical of 
antibodies.  A simple method for isolation of an iDab that will bind to an intracellular 




is based on yeast two-hybrid screening of iDab libraries.  In the first round of screening, 
libraries consisting of randomized CDR3 regions (ranging from 8 to 21 amino acids total 
in CDR3) are screened.  Affinity maturation is achieved through creation of a sublibrary 
by taking the CDR3 sequences identified in the first round of screening and randomizing 
CDR2.  This process can be repeated a third time for further maturation by randomizing 
CDR1 and another round of screening.  While one limitation of typical yeast two-hybrid 
screens is the small number of clones that can be screened (as compared to other methods 
such as phage display), through creation and screening of sublibraries as described in the 
IAC3 protocol, it is theoretically possible to screen up to 1018 clones (57).  This method 
has been used to generate iDabs that bind LMO2, RAS, RAF, and p53 with high affinity 
(57, 58).   
 Using the IAC3 technology it is possible to not only target a specific protein, but 
target a specific region of the target protein through screening the libraries against that 
particular domain or region of interest.  In line with the goal of escorting Bcr-Abl to the 
nucleus, we took the approach that competing with interactions that anchor Bcr-Abl in 
the cytoplasm may render it more available for transport into the nucleus.  In this fashion, 
the iDab may not solely allow for the capture of Bcr-Abl, but interfere with an interaction 
contributing to the cytoplasmic localization, and through both mechanisms yield a higher 
degree of nuclear translocation.  Although the list of proteins that interact with Bcr-Abl is 
lengthy, one of particular interest is actin as it has been demonstrated to play a leading 
role in the cytoplasmic localization of Bcr-Abl (59-61).  As the actin binding domain 
(ABD) is found at the C-terminus and is contributed by the Abl portion, we also wanted 




are routinely found together and function to bind inositolphospholipids at the inner 
surface of the membrane (62-67).  Although the Bcr-Abl DHPH domains are less studied 
and documented in the literature than the ABD, the interaction with phospholipids 
provides another plausible contribution to cytoplasmic retention.  We thus chose the 
ABD and DHPH domains as the Bcr-Abl subdomains for targeting iDabs, and used these 
domains as the baits in the screens. 
 An alternative binding approach is a rationally designed coiled-coil domain based 
on the coiled-coil domain of Bcr-Abl (68).  Through formation of a dimer-of-dimers, 
Bcr-Abl is found as a tetramer (69, 70).  This oligomerization is achieved through the 
coiled-coil (or oligomerization) domain at the N-terminus, and this domain is another 
possible way of binding Bcr-Abl.  Recently, we have designed mutations in this coiled-
coil domain to improve the interaction with Bcr-Abl as an alternative binding motif for 
controlled nuclear escort (68).  Unpublished data in our laboratory indicate a set of 
mutations, containing one additional mutation than the previously published CCmut2, 
results in superior interaction with Bcr-Abl, and has been termed CCmut3.  In addition to 
the iDab and CCmut3, we also compared the functionality of the Abl binding domain 
from RIN1, a known Bcr-Abl interactor, as a binding motif for nuclear escort.  This RIN1 
domain has been demonstrated to be an efficient binding partner for Bcr-Abl, interacting 
with the SH3/2 domains and contributing to maintaining Bcr-Abl in a constitutively 
active state (71-73).  The regions of Bcr-Abl targeted by these four binding domains are 










Figure 6.1. Bcr-Abl domains and the targeting regions of the binding domains.  CCmut3 
binds the coiled-coil domain, DBI binds the DHPH domains, RIN1 binds the SH3/SH2 
domains, and ABI binds the ABD.  Thus, two Bcr and two Abl domains are targeted with 
these binding domains.  CC = coiled-coil domain, S/T kinase = serine/threonine kinase 
domain, DH = Dbl homology domain, PH = pleckstrin homology domain, SH3 = Src 
homology 3 domain, SH2 = Src homology 2 domain, Y kinase = tyrosine kinase domain, 
DBD = DNA binding domain, ABD = actin binding domain, CCmut3 = coiled-coil 
mutation set 3, RIN1 = Abl binding domain from RIN1, DBI = DHPH binding iDab, ABI 





to overcome the interactions generating the cytoplasmic retention of Bcr-Abl, and this 
guided our selection of these distinct regions for targeting Bcr-Abl.  Although 4NLS-
CCmut3 resulted in efficient nuclear translocation of Bcr-Abl, the effect was enhanced 
through combining 4NLS-ABI7 and 4NLS-CCmut3. 
 In this report, the IAC3 technology was employed for identifying iDabs targeting 
Bcr-Abl at regions complimentary to where CCmut3 and RIN1 target Bcr-Abl.  Next, the 
effect the expression of these domains had on the subcellular localization of Bcr-Abl was 
analyzed.  In attempt to move Bcr-Abl into the nucleus, the best iDab, as well as CCmut3 
and RIN1, were subcloned into the protein switch.  The nuclear translocation afforded by 
these protein switch constructs was then compared to the translocation resulting when the 
protein switch was replaced with four constitutively active nuclear localization signals. 
 
Materials and Methods 
Cell Lines and Transformation/Transfection 
 First round IAC3 screening was carried out in L40 yeast cells (T.H. Rabbitts, 
L.I.M.M., Leeds, UK; MATa, leu2-3, his3Δ200, trp1Δ1, ade2, LYS2::(LexA-op)4-HIS3, 
URA3::(LexA-op)8-lacZ).  Second round IAC3 screening was carried out in AH109 yeast 
cells (T.H. Rabbitts; MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, 
LYS2::GAL1UAS-GAL1TATA-HIS3, MEL1, GAL2UAS-GAL2TATA-ADE2, ura3::MEL1UAS 
-MEL1TATA-lacZ).  Transformation into yeast cells was performed by a lithium 
acetate/carrier DNA/PEG precipitation method as described in the IAC3 protocol (57).  
Briefly, an overnight culture grown in YC (for transformation of bait) or YC-W (for 




YPD to an optical density at 600 nm (O.D.600) ~0.6.  The cells were harvested by 
centrifugation and washed in sterile water three times.  After the final wash, the cells 
were resuspended in TE-LiAc and maintained on ice.  The plasmid DNA being 
transformed (bait plasmid or library) was mixed with salmon sperm DNA and the DNA 
mixture was added to the cells and vortexed for 30 sec.  A fresh solution of 
TE/PEG/LiAc was added and the cells were votexed again before incubating at 30 °C for 
30 min.  Following the incubation DMSO was added and the cells were heat shocked at 
42 °C for 15 min with swirling every 2 min.  After incubating the cells on ice for 2 min, 
sterile water was added and the cells harvested by centrifugation.  The pellet was washed 
in water and then resuspended in TE before plating onto 9 cm YC-W (transformation of 
bait) or 25 x 25 cm YC-WLH (transformation of library) plates.  For library screens, 
serial dilutions were made and plated onto 9 cm YC-WL plates to calculate the 
transformation efficiency.  The plates were grown at 30 °C for 2-3 days.   
 Mammalian two-hybrid assays were performed in murine adenocarcinoma 1471.1 
cells, and fluorescence microscopy was performed in simian kidney Cos-7, or human 
lymphoblasts K562 (CML model cells expressing Bcr-Abl).  1471.1 cells were grown as 
monolayers in DMEM (GIBCO, Invitrogen, Carlsbad, CA, USA), and Cos-7 and K562 
cells were grown in RPMI (GIBCO, Invitrogen) as monolayers and in suspension, 
respectively.  Both DMEM and RPMI were supplemented with 10% FBS (Invitrogen), 
1% pen/strep/L-glu (Invitrogen), and 0.1% gentamicin (Invitrogen).  1471.1 cells were 
transfected using Lipofectamine 2000 (Invitrogen) following the recommended protocol 
from the manufacturer.  Cos-7 cells were transfected with Fugene HD (Promega, 




cells were nucleofected using Solution V and the Amaxa Nucleofector II (Agilent 
Technologies Inc., Santa Clara, CA, USA) on program T-013. 
 
Construction of Plasmids and Libraries 
 The genes encoding the Dbl Homology/Pleckstrin Homology (DHPH) and actin 
binding (ABD) domains were amplified through PCR using the primers (DHPH) 5’-
ACACACACGAATTCGGCTTGGAGATGAGAAAATGGGTCCTG-3’ and 5’-
CAACCCCAGAATTCCTTCTTCTGCTGCTCCCGGATG-3’ and (ABD) 5’-TATGTCT 
AGAATTCGCAGGGGACCAGCCGTCTTC-3’ and 5’-CACTCCACGAATTCCTCAG 
CCACTGTCATGGGTATG-3’ for insertion into the yeast two-hybrid vectors pBTM116 
(used in first round screening) and pBD-Gal4-Cam (used in second round screening) at 
the EcoRI site to create fusions with the LexA and Gal4 DNA binding domains 





3’) and a linker region between the DH and PH domains (5’- AATTCGGCGGTGGGGG 
ATCCGGCGGTGGGGGATCCTCCAGCATCAATGAGGAGATCACACCCCGACGG
CAGTCCG-3’ and 5’- AATTCGGACTGCCGTCGGGGTGTGATCTCCTCATTGATG 
CTGGAGGATCCCCCACCGCCGGATCCCCCACCGCCG-3’) were annealed and 
inserted into the pBD-Gal4-Cam vector at the EcoRI site.  The first round iDab libraries 




these libraries is described in detail in the IAC3 protocol (57).  For generation of the 
sublibrary used in the second round of screening, the plasmids encoding the positively 
interacting iDabs identified in the first round were extracted from the yeast cells and 
pooled together for use as the template DNA in a PCR to amplify the CDR3 region using 
the primers VHCDR2Fw (5’- ATATACTATGCAGACTCTG-3’) and VP162R (5’-
CAACATGTCCAGATCGAA-3’).  For the DHPH iDabs, those extracted from screening 
library #4320 and #4325 were kept separate and used to generate two sublibraries.  
Another PCR was performed to randomize the bases encoding CDR2 using the primers 
EFFP2 (5’-GGAGGGGTTTTATGCGATGG-3’) and 5RCDR2 (5’-
CAGAGTCTGCATAGTATATMNNMNNMNNMNNMNNACTAATGTATGAAACC
CAC-3’).  A third PCR was performed using the products from the previous two PCRs as 
the template and the EFFP2 and VP162R primers, fusing the entire iDab sequences 
together.  The product from the final PCR was digested with SfiI and NotI and ligated 
into the yeast two-hybrid pVP16 vector to generate fusions to the VP16 activation 
domain.  The ligation reaction was transformed into MegaX DH10BTM T1R 
ElectrocompTM cells (Invitrogen) via electroporation.  The transformed cells were plated 
onto five 25 cm x 25 cm LB plates containing ampicillin, grown overnight, and then 
harvested by scraping.  The plasmids were isolated with a Qiagen EndoFree Plasmid 
Maxi kit (Qiagen, Hilden, Germany) and used as the sublibrary for second round 
screening.  The ABD and DHPH sequences were digested out from the pBTM116 
plasmids, gel purified, and ligated into the mammalian two-hybrid plasmid pM1 for 
fusion to the Gal4 DNA binding domain.  The plasmids encoding the iDabs isolated after 




the mammalian two-hybrid plasmid pEFVP16 for fusion to the VP16 activation domain.  
The ABI7 iDab was amplified through PCR from pEFVP16-ABI7 with the primers 5’- 
TGCTATCGTCGACATGGCCGAGGTGCAGCTGTTG-3’ and 5’- TTTACCTGTCGA 
CCTAGCTCGAGACGGTGACCAGGGTTC-3’ and inserted into pEGFP-C1 (Clontech, 
Mountain View, CA, USA), pPS (protein switch fused to EGFP) (13), p4NLS (containing 
4 SV40t antigen nuclear localization signals fused to EGFP, created through removal of 
Bcr-Abl from p4NLS-Bcr-Abl (12) and re-ligation of the plasmid), and pmCherry-C1 at 
the SalI site.  RIN1 was amplified through PCR from a plasmid containing the human 
RIN1 gene (NM_004292, OriGene, Rockville, MD, USA) with the primers 5’- 
TGCTATCGTCGACATGGAAAGCCCTGGAGAGTCAGGC-3’ and 5’- TTTACCTGT 
CGACCTAGTACCCCACTGAGCTCTCCCTCC-3’ and inserted into pEGFP-C1, pPS, 
p4NLS, and pmCherry-C1 at the SalI site.  pEGFP-CCmut3 was created through site 
directed mutagenesis of CCmut2 (68) using the primers 5’- CCGCATTCGGCGCCTG 
GAGCAGCGGGTGAAC-3’ and 5’-GTTCACCCGCTGCTCCAGGCGCCGAATGCG-
G-3’.  CCmut3 was then amplified through PCR and inserted into pEGFP-C1, pPS, 
p4NLS, and pmCherry-C1 at the XhoI sites.  The gene encoding Bcr-Abl was digested 
from pEGFP-Bcr-Abl (12) with EcoRI and inserted into the EcoRI site of pmCherry-C1 
(Clontech).   
 
X-gal Assay 
 Colonies growing on the YC-WLH plates from the library screens were picked 
and streaked onto a 9 cm YC-WLH master plate and incubated at 30 °C for 2-3 days.  A 




30 °C for 15 min.  The membrane was then flash frozen in liquid nitrogen, allowed to 
thaw, and then placed on top of a filter paper soaked in X-gal solution (0.334 mg/mL X-
gal, 0.1M sodium phosphate, 0.01M KCl, and 1mM MgSO4, 0.27% (v/v) β-
mercaptoethanol, pH 7.0) in a 15 cm petri dish.  After incubation at 30 °C for 3 hours, 
blue colonies were marked.   
 
Mammalian Two-Hybrid Assay 
 Twenty-four hrs after seeding 5 x 104 1471.1 cells into a white 96-well plate 
(Cellstar, Greiner Bio-One, Monroe, NC, USA), the media was replaced with DMEM 
with 10% FBS and without antibiotics, and pM1-ABD or pM1-DHPH was cotransfected 
with pEFVP16-iDab, pG5-Fluc (Promega), and pRL-CMV (Promega) in a 10:10:10:1 
ratio using Lipofectamine 2000.  Twenty-four hrs after transfection the firefly and renilla 
luminescence were measured on PlateLumino (Stratec Biomedical Systems) luminometer 
using the Dual-Glo Luciferase Assay (Promega) reagents following the manufacturer’s 
recommendations.  The mean from duplicate samples were taken from three separate 
experiments.  pAD-SV40 and pBD-p53 (Stratagene) plasmids were used for the positive 
control, and pM1 was used as the negative control.  The fold-induction of the 
luminescence was calculated by subtraction of the luminescence intensity from the 
negative control and normalizing to the renilla luminescence.   
 
Confocal Microscopy and Co-localization 
 Twenty-four hrs after transfection into Cos-7 cells seeded in 4-well live cell 




captured with a FV1000-XY (Olympus) confocal microscope using a 60X PlanApo oil 
immersion objective (NA 1.45) and Olympus FluoView software.  mCherry was excited 
at 543 nm (HeNe laser), and a 555-655 nm emission filter was used to select the emitted 
light.  EGFP was excited at 488 nm (Argon laser), and a 500-530 nm emission filter was 
used to select the emitted light.  Images were collected in sequential line mode.  The 
exposure settings and gain of laser were kept constant below the detected pixel saturation, 
and no bleed-through was observed between channels.  Pixel resolution was kept at 1024 
x 1024 with maximum of 2.5X digital zoom.  For each field of view, six images were 
taken in the z-plane.  Image analysis was performed using ImageJ software (freeware, 
NIH) after converting the images to eight-bit format.  The background fluorescence was 
quantified for each image by selecting a region of interest (ROI) that did not contain 
cells.  This background fluorescence was subtracted from each of the images through use 
of a plugin set to subtract the mean background fluorescence plus three times the standard 
deviation in the background.  Using ROI manager, the parallel images were duplicated 
and then analyzed for co-localization with the JACoP plugin (http://rsb.info.nih.gov/ij) 
(74).  The quantitative co-localization coefficient was generated with Costes’ automatic 
threshold (75).  All experiments were repeated at least three times.   
 
Fluorescence Microscopy and Nuclear Translocation 
 The day before transfection between 2 x 105 and 3 x 105 Cos-7 cells were seeded 
in each well of a 2-well live cell chamber (Lab-tek II chamber slide system, Nalge 
NUNC, Rochester, NY, USA).  Twenty-four hrs following cotransfection of pmCherry-




was replaced with phenol red free RPMI, and 10 μL EtOH (control) was added to one 
replicate and 10 μL of 20 μM dex was added to the other.  After 2-4 hr incubation at 37 
°C, 0.5 µL of 10 mg/mL H33342 (nuclear stain) was added, and the cells were incubated 
at 37°C for 15 min. Cells were then analyzed with an inverted fluorescence microscope 
(Olympus IX701F, Scientific Instrument Co., Sunnyvale, CA) with high-quality narrow 
band GFP filter (excitation HQ480/20 nm, emission HQ510/20 nm, beam splitter 
Q4951p, Chroma Technology Corp., Brattleboro, VT), high-quality TRITC filter 
(excitation HQ545/30 nm, emission HQ620/60 nm, beam splitter Q570lp, Chroma 
Technology Corp.).  Cells were photographed with an F-view Monochrome CCD camera 
using a 60x objective.  During the microscopy the cells were maintained at 37 °C with an 
air stream incubator (Nevtek ASI 400, Burnsville, VA) with temperature control.  
Twenty-four hrs after cotransfection of pmCherry-Bcr-Abl and either p4NLS, p4NLS-
ABI7, p4NLS-CCmut3, or p4NLS-RIN1 the cells were imaged using the same 
microscopy settings and conditions.  Following the  quantification of the amount of Bcr-
Abl in the nucleus as previously described (13, 45, 76, 77), the amount of Bcr-Abl that 











 The overall results of the IAC3 screenings are depicted in Figure 6.2.  Two 
libraries, one consisting of nine and the other consisting of 14 amino acids randomized in 
CDR3, were screened with both the ABD and DHPH baits.  For the ABD, 29 colonies 












Figure 6.2.  Overview of IAC3 screens against ABD and DHPH baits.  Two libraries were 
screened in the first round.  20 and 15 constructs were isolated using the ABD and DHPH 
as baits, respectively, from a library that contained nine amino acids randomized in 
CDR3.  Zero and 14 constructs were isolated using the ABD and DHPH as baits, 
respectively, from a library that contained 14 amino acids randomized in CD3.  After 
generation of sublibraries by randomizing the bases encoding CDR2, the top 12 binders 
were isolated for each bait.  Mammalian two-hybrid assays then identified the top three 





determined to be weaker interactions due to their faint blue result and were eliminated to 
give a total of 20 colonies that were used for creation of the sublibrary.  For the DHPH, a 
much larger number of colonies (159 total) were validated to exhibit true interactions via 
the X-gal assay.  However, the pool was limited to the darkest X-gal results, and 25 were 
used in creation of the sublibrary.  For the DHPH bait, two sublibraries were created, one 
from the preys extracted from the VP16*-(VH9rdm) screen, and one from the preys 
extracted from the VP16*-(VH14rdm) screen.  The sizes of the sublibraries were 
estimated to be approximately 7 x 106.  The second round of screening produced more 
than 800 colonies for both the ABD and DHPH targets.  50 of the largest colonies were 
chosen for validation in the X-gal assay.  From the 50 assayed for each bait, the top 12 
were selected.  The sequences of these 24 are tabulated in Tables 6.1 and 6.2 along with 
consensus sequences for each.  Although no strong consensus is observed, none is truly 
expected given that each individual iDab may bind at different regions of the target 
domain.   
 The sequences of these 24 iDabs were then subcloned into pEFVP16 to generate 
fusion constructs with the VP16 activation domain in a mammalian expression plasmid 
for further validation in a mammalian two-hybrid assay.  As this assay provides a 
luminescent readout, the binding affinities can be compared relative to each other for 
determination of the highest affinity binder.  As seen in Figure 6.3, the ABD screens 
produced better binders overall, with clone A7 exhibiting the greatest binding.  Although 
none of the DHPH binders demonstrated highly efficient binding, the top candidate, D5, 









Tables 6.1.  Amino acid sequences (one-letter code) of the CDR2 and CDR3 regions of 
the ABD binding iDabs (ABIs) isolated in the screens.  The amino acid (or type of amino 
acids) in at least 6 of the constructs was termed the consensus amino acid at that position 
and are in red font and summarized in the bottom row.  The sequence of CDR1 was not 
randomized for screening and is the same for all constructs: GFTFSTFS.  The amino 
acids at positions 1, 2, and 8 of CDR2 were not randomized and are #1-I,#2-S,#8-I.  The 
amino acids at positions 1, 2, 12, 13, and 14 of CDR3 were not randomized and are #1-R, 
#2-G, #12-F, #13-D, and #14-Y.   
 
ABI CDR2 CDR3 
Position  3  4  5  6  7  3-11 
A1  P  S  G  T  L  PLWSFVRMS  
A2  Q  S  G  R  L  PLWSFVRMS  
A4  K  D  G  K  A  PLWSFVRMS  
A5  P  S  G  Y  S  PLWSFVRMS  
A7  K  C  G  H  V  PLWSFVRMS  
A8  D  T  G  R  A  PLWSFVRMS  
A14  R  T  S  K  T  RF  
A26  A  T  G  G  A  PLWSFVRMS  
A37  A  K  G  N  N  PLWSFVRMS  
A45  G  K  G  D  S  PLWSFVRMS  
A46  Q  T  G  S  T  PLWSFVRMS  
A50  A  N  S  R  T  PLWSFVRMS  










Table 6.2.  Tables 6.1.  Amino acid sequences (one-letter code) of the CDR2 and CDR3 
regions of the DHPH binding iDabs (DBIs) isolated in the screens.  The amino acid (or 
type of amino acids) in at least 6 of the constructs was termed the consensus amino acid 
at that position and are in red font and summarized in the bottom row.  The sequence of 
CDR1 was not randomized for screening and is the same for all constructs: GFTFSTFS.  
The amino acids at positions 1, 2, and 8 of CDR2 were not randomized and are #1-I,#2-
S,#8-I.  The amino acids at positions 1, 2, 12, 13, and 14 of CDR3 were not randomized 
and are #1-R, #2-G, #12-F, #13-D, and #14-Y.   
 
DBI CDR2 CDR3 
Position  1  2  3  4  5  3-11 
D2  E  C  L  D  L  RF  
D5  D  T  A  N  E  TFFRPPVRA  
D8  P  C  C  R  E  TFFRPPVRA  
D9  E  Y  G  S  D  TFFRPPVRA  
D12  G  E  S  K  D  TFFRPPVRA  
D13  S  M  G  E  D  TFFRPPVRA  
D15  K  G  W  C  L  GG  
D29  D  T  S  H  E  TFFRPPVRA  
D32  S  A  S  E  Q  TFFRPPVRA  
D33  D  D  S  G  V  TFFRPPVRA  
D34  P  D  S  K  E  TFFRPPVRA  
D37  G  C  G  R  D  TFFRPPVRA  












Figure 6.3.  Mammalian two-hybrid assays.  Blue columns = ABD binding iDabs (ABI), 
red columns = DHPH binding iDabs (DBI).  Based on these mammalian two-hybrid 
results, the top ABI (ABI7) and the top DBI (DBI5) were selected for further analysis by 





binding to phospholipids may prove beneficial, and the lack of knowledge regarding the 
relationship between the mammalian two-hybrid result and the ability to translocate Bcr-
Abl justifies further exploration.   
 The IAC3 screening and mammalian two-hybrid assays were performed using the 
isolated ABD or DHPH domains.  To confirm these interactions carried over to the full-
length Bcr-Abl protein, and to compare their ability to bind Bcr-Abl with CCmut3 and 
RIN1, co-localization studies were performed with each binding domain and mCherry-
Bcr-Abl in Cos-7 cells.  A rigorous method for analysis of co-localization, the use of 
Costes’ automatic threshold to determine Costes’ coefficient of co-localization (75), was 
utilized.  In this method, fluorescence signals originating from the same location 
(indicating the interaction between the proteins fused to them) will result in a value 
greater than 0.5.  Noninteracting proteins will generate values close to zero or negative.  
As seen in Figure 6.4, ABI7, CCmut3, and RIN1 all demonstrated co-localization with 
Bcr-Abl and confirmed the interactions of these binding motifs with the full protein under 
biological conditions inside of cells.  In agreement with the mammalian two-hybrid 
result, DBI5 did not result in efficient co-localization (below 0.5 co-localization 
coefficient with Costes’ automatic threshold) with Bcr-Abl.  As no iDab was isolated that 
efficiently interacted with the DHPH region of Bcr-Abl, as determined by the mammalian 
two-hybrid and co-localization with Bcr-Abl, and due to the other three binding domains 
functioning superiorly, the DBIs were not analyzed further.   
 The ABD was selected as a target for the potential advantage of competing with 







Figure 6.4.  Co-localization between Bcr-Abl and the binding domains.  Binding domains 
are in the left columns (cyan), and Bcr-Abl is in the middle column (magenta).  
Colormaps are illustrated in the right column with the key at the top of the column 
(highest co-localization = red).  The co-localization coefficients are indicated to the right 
of the colormaps.  The mean co-localization coefficient was determined after analyzing at 
least three cells, and the experiment was repeated three times.  The values reported are 
the means ± S.E.M.  Statistical significance was determined by one-way ANOVA with 





of ABI7 with Bcr-Abl, a marked redistribution of the subcellular localization pattern was 
observed.  Alone, Bcr-Abl forms a distinct localization pattern similar to the pattern 
resulting from actin staining, indicating its interaction with actin (Figure 6.5a).  However, 
when ABI7 is coexpressed along with Bcr-Abl this localization pattern shifts to one of 
punctuate dots throughout the cytoplasm (Figure 6.5b).  This observation may be 
explained by ABI7 preventing Bcr-Abl from binding actin in the same fashion as 
normally occurs, and may provide evidence for the hypothesized benefit of rendering 
Bcr-Abl more available for nuclear translocation.  Recently it has been demonstrated that 
the ABD plays a joint role, along with the tyrosine kinase domain, in regulating the NLSs 
found in Bcr-Abl (59).  A further potential implication of targeting the ABD may be a 
shift to the NLS-active conformation resulting in nuclear accumulation.  Although ABI7 
did cause an altered localization pattern of Bcr-Abl in the cytoplasm, no substantial 
increase in nuclear localization was observed.  Interestingly, when CCmut3 was co-
expressed with Bcr-Abl a dramatic change in the localization pattern occurred, and Bcr-
Abl was found to be diffuse throughout the entire cytoplasm and no longer localized to 
any particular region (Figure 6.5C).  This prominent shift may be reflective of the change 
from tetrameric Bcr-Abl to monomeric Bcr-Abl, and the correlated Bcr-Abl 
conformations.   
 In attempt to use the binding motifs for translocation of Bcr-Abl into the nucleus, 
they were each subcloned into plasmids as fusions with the localization controllable 
protein switch (13).  One potential advantage of using the protein switch for translocating 






Figure 6.5  Redistribution of Bcr-Abl subcellular localization.  A) EGFP-Bcr-Abl 
expressed alone in Cos-7 cells.  Bcr-Abl localizes at actin and forms a pattern 
characteristic of actin filaments.  B) EGFP-Bcr-Abl and mCherry-ABI7.  ABI7 affects 
Bcr-Abls interaction with actin, and results in a distinct localization pattern.  C) EGFP-
Bcr-Abl and mCherry-CCmut3.  CCmut3 causes a Bcr-Abl to become diffuse throughout 




protein.  This allows equilibration time for the interaction between the target protein and 
the protein switch before any attempt of translocation.  After cotransfecting (in duplicate) 
mCherry-Bcr-Abl with a protein switch construct, ethanol (carrier) or dex was added and 
fluorescence microscopy used to image the cells 2-4 hrs postligand induction.  The 
percentage of Bcr-Abl inside the nucleus was determined in the presence of ethanol or 
dex and used to determine a percent nuclear increase (PNI) upon ligand induction.  
Attempts to move Bcr-Abl with one binding domain (protein switch fused to either 
CCmut3, ABI7, or RIN1) did not produce any nuclear Bcr-Abl (data not shown).  
However, when two binding domains were used (two separate protein switch constructs 
with different binding domains cotransfected) it was possible to find cells with Bcr-Abl 
inside the nucleus.  Some examples are illustrated in Figure 6.6.  Nevertheless, the 
majority of the cells did not have noticeable Bcr-Abl inside the nucleus.  While 
identifying cells with nuclear Bcr-Abl may demonstrate that Bcr-Abl can be moved with 
this system, the fact that this occurred on a limited basis indicates the inefficiency of the 
system as applied to Bcr-Abl.  As both protein switch constructs are fused to EGFP it is 
impossible to distinguish cells transfected with only one of the protein switches from 
those transfected with both protein switch constructs, a fact that may explain why Bcr- 
Abl could be found in the nucleus of some limited cells.  A further note is the level of 
protein switch that translocated into the nucleus.  After incorporation of the binding 
domain into the protein switch there was a decrease in the nuclear translocation, which 
may be reflective of the interaction with Bcr-Abl as well as some interference from the 






Figure 6.6.  Nuclear translocation using the protein switch.  Left column = EGFP 
fluorescence from protein switch; Middle column = Nuclei (H33342); Right column = 
mCherry from Bcr-Abl.  Outlines of the nuclei are included for reference in all images.  
A) Combination of PS-ABI7 and PS-CCmut3.  B) Combination of PS-ABI7 and PS-




 To increase the force driving nuclear localization and simplify the approach to 
move Bcr-Abl, the binding motifs were subcloned into a plasmid containing 4 strong 
NLSs (from SV40t antigen).  These constructs, in contrast to protein switch constructs 
that were only marginally nuclear even in the presence of dex, were exclusively localized 
to the nucleus (Figure 6.7A-D, green fluorescence).  Nevertheless, 4NLS-ABI7 and 
4NLS-RIN1 were unable to cause a nuclear accumulation of Bcr-Abl (Figure 6.7B and 
C).  CCmut3, on the other hand, caused the majority of Bcr-Abl to translocate to the 
nucleus (Figure 6.7D, and Figure 6.8).  The percentage of Bcr-Abl inside the nucleus 
upon cotransfection with the 4NLS constructs was quantified and is indicated in Figure 
6.8.  While one possible explanation for the inability of 4NLS-ABI7 and 4NLS-RIN1 to 
translocate Bcr-Abl is that their interaction with Bcr-Abl is not strong enough, all of the 
binding domains generated statistically indistinguishable co-localization coefficients.  
That only one of these binding domains exhibited the ability to translocate Bcr-Abl 
supports the concept that the region of Bcr-Abl where the binding domain interacts is also 
a critical factor.   
 In spite of the fact that minimal Bcr-Abl translocated with 4NLS-ABI7, the 
combination of 4NLS-ABI7 and 4NLS-CCmut3 did result in enhanced nuclear 
accumulation of Bcr-Abl and only minimal levels were detected outside of the cytoplasm 
(Figure 6.8C, D, and E).  This validates the concept that binding Bcr-Abl through 











Figure 6.7.  Nuclear translocation using 4NLS-binding motif constructs.  Bcr-Abl is 
shown in red (mCherry), and the 4NLS construct is shown in green (EGFP).  Images 
were taken at 60X magnification, and the scale bar is indicated in the lower right corner.  
A) mCherry-Bcr-Abl and 4NLS (no binding domain).  Bcr-Abl localizes in the cytoplasm 
with actin.  4NLS is exclusively nuclear.  B) mCherry Bcr-Abl and 4NLS-RIN1.  Bcr-
Abl remains cytoplasmic and 4NLS-RIN1 localizes to the nucleus.  C) mCherry-Bcr-Abl 
and 4NLS-ABI7.  Bcr-Abl does not accumulate in the nucleus as does 4NLS-ABI7.  D) 
mCherry-Bcr-Abl and 4NLS-CCmut3.  As indicated by the overlapping green and red 







Figure 6.8 Representative images of nuclear Bcr-Abl resulting from 4NLS-CCmut3, and 
quantification of nuclear Bcr-Abl from all 4NLS constructs.  A) To more clearly show 
the nuclear accumulation of Bcr-Abl upon cotransfection with 4NLS-CCmut3, an image 
of only the red fluorescence (Bcr-Abl) is shown.  B) The image shown in (A) is shown 
with the nuclear stain (H33342, blue).  C) Resulting Bcr-Abl localization after 
transfecting 4NLS-ABI7 with 4NLS-CCmut3.  D) Image from (C) with nuclear stain.  E) 
The percentages of Bcr-Abl found in the nucleus after cotransfection with the indicated 
constructs was quantified and graphed.  At least five cells from each experiment were 
imaged and analyzed.  Each construct was cotransfected with pmCherry-Bcr-Abl three 
times.  Statistical analysis was determined by one-way ANOVA with Tukey’s posttest.  





 Both the aberrant tyrosine kinase activity and the cytoplasmic localization are 
important outcomes of the fusion between the Bcr and Abl proteins.  Current CML 
treatments target the tyrosine kinase activity, and an interesting alternative that has not 
been highly explored is repositioning Bcr-Abl into the nucleus where it is known to be an 
activator of apoptosis.  In this report we have demonstrated the ability to escort Bcr-Abl 
to the nucleus through Bcr-Abl-binding domains.   
 In order to compliment the regions of Bcr-Abl already targeted by CCmut3 and 
RIN1, we screened for iDabs that would bind at the ABD and DHPH.  While the protocol 
outlined for IAC3 describes the screening of 17 libraries in the first round, followed by 
screening sublibraries in subsequent second and third rounds of screening, we were able 
to identify an iDab with efficient binding to Bcr-Abl through screening of only two 
libraries in the first round and one sublibrary.  This demonstrates the versatility and 
usefulness of the IAC3 technology.  As speculated, this iDab (ABI7) caused a 
redistribution of Bcr-Abl from its regular localization pattern indicating the ability to 
interfere with actin interactions.  However, ABI7 was unable to efficiently translocate 
Bcr-Abl to the nucleus without CCmut3.  Further affinity maturation of ABI7 could be 
performed through creation of a randomized CDR1 sublibrary and additional screening.  
Nevertheless, the combination of 4NLS-ABI7 and 4NLS-CCmut3 produced remarkable 
accumulation of Bcr-Abl in the nucleus.   
 Attempts to move Bcr-Abl to the nucleus with the protein switch were 
unsuccessful with one binding domain, but through two protein switches fused to two 




transported into the nucleus.  The numerous interactions and large size of Bcr-Abl make 
it a challenging protein to redirect to alternative subcellular localizations, and other 
proteins may be more readily translocated.  However, the incorporation of the binding 
domains into the protein switch decreased the nuclear translocation, a factor contributing 
to the inefficient translocation of Bcr-Abl.  This finding highlights the potential need to 
optimize the protein switch with the binding domain fused to it.  The strength of the NES 
and NLS used in the protein switch could be re-optimized as well as the linker fusing the 
protein switch to the binding domain and terminus where the binding domain is fused to 
the protein switch.   
 In stark contrast to the protein switch constructs, 4NLS-CCmut3 and 4NLS-ABI7 
+ 4NLS-CCmut3 produced an impressive re-localization of Bcr-Abl to the nucleus.  We 
have long speculated on the advantage and need for some mean-residency time in the 
location of the target protein to allow the interaction to occur.  This mean-residency time 
is afforded by the controlled translocation in the protein switch.  However, that a 4NLS 
construct (4NLS-CCmut3) was the only construct tested to demonstrate efficient nuclear 
accumulation of Bcr-Abl strongly supports the claim that mean-residency time is not 
needed.  CML cells where Bcr-Abl is present, and not entirely being co-translated with 
4NLS-CCmut3, may exhibit a different dynamic wherein the mean-residency time is 
more important.  Dismissal of the usefulness of the protein switch based on these 
experiments is not entirely justified, and further exploration into the ability to translocate 
endogenous Bcr-Abl in CML cells will be needed.   
 In these experiments four binding domains that bind Bcr-Abl at distinct regions 




efficient co-localization with Bcr-Abl resulted in efficient nuclear translocation of Bcr-
Abl.  This indicates the binding affinity is not the only consideration, and may not be the 
most important consideration, in determining the ability to translocate Bcr-Abl.  
Speculatively, the resulting Bcr-Abl conformation upon being bound by the binding 
domain may contribute to the ability of one domain to translocate Bcr-Abl and not 
another.  RIN1 interacts with the SH3/2 domains of Bcr-Abl, and is known to bind in 
such a way that Bcr-Abl is maintained in an active conformation (71, 73, 78, 79).  This 
active conformation is correlated with protein interactions thought to cause cytoplasmic 
retention and inhibition of the Bcr-Abl NLSs (59).  However, CCmut3 binds the coiled-
coil domain and interferes with the oligomeric state of Bcr-Abl (68-70, 80).  The homo-
oligomerization of Bcr-Abl is directly correlated with Bcr-Abl activity, and the formation 
of hetero-oligomers with CCmut3 decreases its activity (unpublished data).  This inactive 
conformation may relieve the cytoplasmic retention as well as activate the Bcr-Abl NLSs.  
Thus, it is easy to speculate on why CCmut3 was able to translocate Bcr-Abl and RIN1 
was not, in spite of the high affinity of RIN1 for Bcr-Abl.  As demonstrated with these 
binding domains, not only binding, but binding Bcr-Abl in an inactive conformation, is 
critical to the ability to translocate Bcr-Abl.   
 Capture and escort of Bcr-Abl to the nucleus is an interesting concept for turning 
the disease causing agent against the diseased cells.  Here we demonstrate Bcr-Abl can be 
redirected to the nucleus by NLSs attached to a Bcr-Abl binding domain.  Further, this 
work validates CCmut3 as an efficient binding partner of Bcr-Abl which can be used for 
controlling the subcellular localization of Bcr-Abl.  Capture and escort of Bcr-Abl would 




cytoplasmic depletion.  This ability of CCmut3 to translocate Bcr-Abl has great potential 
for potent induction of apoptosis in CML cells, and may extend to the ability to induce 
apoptosis in resistant CML cells and also CML stem cells.  This is the subject of future 
work in our laboratory. 
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Addition of 4 Nuclear Localization Signals, But Not 1, Sends 
Bcr-Abl to the Nucleus and Induces Apoptosis 
 This body of work is hinged on the ability of nuclear Bcr-Abl to induce apoptosis.  
Bcr-Abl exhibits numerous interactions that have been implicated in its cytoplasmic 
retention (1-7), and translocating Bcr-Abl to the nucleus is a formidable challenge.  To 
demonstrate that signal sequences can be used to control the subcellular localization of 
Bcr-Abl, and to demonstrate that nuclear Bcr-Abl causes apoptosis in a model cell line 
(K562) of chronic myelogenous leukemia (CML), the strong SV40 nuclear localization 
signal (NLS) was subcloned to Bcr-Abl.  When expressed in K562 cells this protein 
construct did not localize to the nucleus, indicating the interactions anchoring Bcr-Abl in 
the cytoplasm were stronger than one SV40 NLS.  The importin α/β hetero-dimer 
provides the driving force for nuclear localization upon recognition of the SV40 NLS by 
importin α (8-11).  The strength of this NLS may be increased by having more than one 
importin α to bind Bcr-Abl, a possibility achieved by conjugating multiple NLSs to Bcr-




the nucleus, demonstrating that the factors causing cytoplasmic retention can be 
overcome through multiple NLSs.  This finding provides proof that signal sequences can 
be used to manipulate the subcellular localization of Bcr-Abl. 
 Previously it had been reported that nuclear entrapment of Bcr-Abl could be 
achieved through the combination treatment of leptomycin B (LMB) and imatinib (12, 
13).  After washout of imatinib, but not LMB, Bcr-Abl induced apoptosis (13).  As LMB 
inhibits all nuclear export through CRM1 and thus affects numerous proteins and cellular 
processes (14, 15), we sought further validation that nuclear Bcr-Abl induces apoptosis 
and used the 4NLS-Bcr-Abl construct in K562 cells as a model system.  This construct of 
Bcr-Abl, which localizes to the nucleus, was shown to activate caspase-3/7 after transient 
transfection into K562 cells.  Further demonstration of the induction of apoptosis was 
shown through morphological evaluation of the K562 cells.  Apoptotic cells exhibit 
morphological phenomena observable through microscopy such as cell shrinkage, 
cytoplasmic blebbing, echnoid spikes, and DNA segmentation (16, 17).  K562 cells 
expressing 4NLS-Bcr-Abl (determined through fluorescence from EGFP that was fused 
to the construct) demonstrated an increase in all of these hallmark signs for apoptosis.  In 
particular, DNA segmentation was quantified in the transfected cells, and 4NLS-Bcr-Abl 
was found to cause higher levels of DNA segmentation than 1NLS-Bcr-Abl or EGFP.  
One difficulty in these experiments, specifically the caspase assay, was the low 
transfection efficiency of the large Bcr-Abl plasmids into K562 cells.  Unpublished data 
from our laboratory (J. Constance) involved flow cytometry to analyze the transfected 
cells for induction of apoptosis based on annexin V binding to phosphatidylserine.  This 




experiments validate that sending Bcr-Abl to the nucleus is a viable method for inducing 
apoptosis in CML cells. 
 An important question with these experiments is whether or not the endogenous 
Bcr-Abl was affected by the localization of the exogenous, nuclear Bcr-Abl.  As Bcr-Abl 
forms tetramers through a coiled-coil domain at the N-terminus of the protein (18-21), it 
is possible for 4NLS-Bcr-Abl to oligomerize with the endogenous Bcr-Abl and drag it to 
the nucleus along with it.  To assess if the localization of the endogenous Bcr-Abl might 
be altered by 4NLS-Bcr-Abl, we tested whether the localization of an exogenous EGFP-
Bcr-Abl construct would become more nuclear upon cotransfection with 4NLS-Bcr-Abl.  
Since 4NLS-Bcr-Abl was also fused to EGFP, we mutated EGFP to inactivate the 
fluorophore.  We found the nuclear percentage of EGFP-Bcr-Abl transfected alone to be 
indistinguishable from the nuclear percentage resulting from cotransfection with 4NLS-
Bcr-Abl.  The inability to alter the localization of EGFP-Bcr-Abl indicates the 
endogenous Bcr-Abl is unlikely to be altered.  An interesting observation about the 
inability of 4NLS-Bcr-Abl to alter the localization of endogenous Bcr-Abl, coupled with 
the ability of 4NLS-Bcr-Abl to induce apoptosis in K562 cells, is that there is competing 
signals in the cell.  While the endogenous cytoplasmic Bcr-Abl signals for cell 
proliferation and the inhibition of apoptosis (22, 23), 4NLS-Bcr-Abl signals for 
apoptosis.  The fact that 4NLS-Bcr-Abl was found to induce apoptosis in cells containing 
endogenous Bcr-Abl demonstrates the potent activation of apoptotic signaling by nuclear 
Bcr-Abl.  Jointly, this validates the potential of any method for translocating Bcr-Abl to 
the nucleus, as all indications are for a high potency when removal of oncogenic 





The Use of the Protein Switch for a Nuclear Translocation Assay 
for Live-Cell Protein-Protein Interactions 
 While the protein switch technology has therapeutic potential for altering the 
subcellular localization of mislocalized proteins responsible for disease (24), a further use 
is for studying protein interactions inside a live cell.  Protein interactions are a critical 
part of biological functions (25), and misregulation of these interactions is connected to 
many diseases (26-28).  Thus, studying protein interactions is central to a basic 
understanding of biological processes as well as drug development.  Regardless, there are 
limited assays for studying protein interactions inside a live cell; an essential aspect of 
studying the interactions in a state that most closely mimics the conditions under which 
the interactions normally occur. 
 The ability to control a protein’s translocation from the cytoplasm to the nucleus 
is a valuable tool.  Through genetic engineering a protein can be fused to the protein 
switch to impart the ability to control the nucleo-cytoplasmic shuttling to that protein.  
This cytoplasmic and nuclear localization can easily be monitored, and quantified, 
through the fluorescence from EGFP which is tagged to the protein switch.  Proteins that 
interact with that protein can then be studied through subcloning of a second construct 
consisting of the interacting protein fused to a distinguishable fluorophore such as DsRed 
or mCherry.  This second protein construct is not responsive to dexamethasone, the 
protein switch ligand.  However, if an interaction occurs between the two proteins, the 
second protein will translocate into the nucleus along with the first protein that is fused to 




interaction.  This concept, termed the nuclear translocation assay (NTA) was 
demonstrated in chapter two of this dissertation through the interaction between different 
forms of the coiled-coil domain from Bcr-Abl. 
 In addition to this assay adding to the limited repertoire of methods to study 
protein interactions in live cells, an advantage is the confirmation that both of the 
necessary constructs (EGFP-protein switch-protein 1 and DsRed-protein 2) were 
transfected into the same cell and are being expressed at similar levels.  This is a built-in 
feature of this assay as it is necessary to quantify the fluorescence intensities of both 
proteins in order to determine the percentage of the proteins that is in the nucleus.  It is 
typical for cell-based assays to validate the protein expression on a population of cells 
through a method such as a western blot.  The correlated assumption is the expression in 
the cell population provides evidence regarding the expression level for each protein at an 
individual cell level.  Cotransfection of two fluorescent proteins readily confirms this 
assumption is not always true, as cells are identified with one or the other fluorescent 
protein and not both.  The NTA does not rely on this assumption, and only cells 
expressing both constructs are analyzed.   
 Other advantages of this assay include that it does not require secondary reporter 
constructs, does not involve an enzymatic reaction, and does not need any kind of added 
substrate.  This design simplifies the experimental set up, and reduces the necessary 
reagents to include only the plasmids, mammalian cells, a method for transfecting the 
cells, and a fluorescence microscope.   
 In summary, the NTA was demonstrated to be a useful way to quantify protein 




fluorescent proteins fused to the proteins of interest, but other methods could also be 
employed.  One such possibility is to fuse the proteins to a transcription factor that would 
control the expression of a reporter molecule such as luciferase when the transcription 
factor is in the nucleus.  Efforts to create this type of assay are ongoing.   
 
The Rational Design of a Coiled-Coil Domain for Binding Bcr-Abl 
 With the dual purposes of binding Bcr-Abl for nuclear translocation and 
inhibiting Bcr-Abl through disruption of its oligomeric state, a modified form of the 
coiled-coil domain from Bcr-Abl was designed.  The design entailed the identification of 
uncharged residues that are in an appropriate position to form a salt bridge with a charged 
residue on the opposing helix.  These residues, if mutated to the appropriately charged 
residue, may allow the formation of additional salt bridges between the central helices in 
the mutant/wild-type dimer and result in a more stable interaction.  To reduce the stability 
of the undesired mutant homodimer, charged residues were also incorporated where they 
would be positioned in proximity to a residue with the same charge on the opposing 
mutant helix.  Thus, charge-charge repulsion would destabilize the mutant homo-dimer.  
The initially proposed mutations (S41R, L45D, E48R, V49D, and Q60E) were modeled 
by Scott Pendley from the Cheatham Laboratory, wherein it was discovered that 
incorporating both L45D and V49D mutations generates an undesirable kink in the 
central helix.  However, one or the other mutation was demonstrated to provide some 
specificity along with an additional C38A mutation.  The optimal set of mutations was 
determined to be C38A, S41R, L45D, E48R, and Q60E.  This set of mutations was 




integration and MM-PBSA) and found to form less stable homo-dimers while retaining 
the ability to oligomerize with the wild-type domain.   
 To test experimentally the design of these mutations, we carried out site-directed 
mutagenesis on a plasmid encoding the wild-type coiled-coil domain to generate the 
mutant coiled-coil domain, CCmut2.  Two distinct binding assays, mammalian two-
hybrid and nuclear translocation (NTA), were used to validate the modifications made.  
Both assays indicated the interactions followed the order CCmut2:CCmut2 < CC:CC < 
CCmut2:CC.  This interaction pattern fits the proposed model wherein the modifications 
reduce the tendency to form mutant homo-dimers and simultaneously provide additional 
stabilization to the hetero-dimer.  Nevertheless, the apparent increase in the hetero-dimer 
interaction may also be explained by similar wild-type homo-dimer and mutant/wild-type 
hetero-dimer binding affinities coupled with reduced mutant association rendering it 
more available to bind the wild-type domain.  Regardless of whether the mutant is truly 
able to bind the wild-type with greater affinity, or simply appears to have a more 
favorable interaction due to the increased availability, these data indicate the mutations 
made in the coiled-coil domain do result in an improved oligomerization domain with 
increased efficacy for interacting with Bcr-Abl. 
 Oligomerization is important for the trans-autophosphorylation responsible for 
maintaining Bcr-Abl, specifically its tyrosine kinase domain, in a constitutively active 
state (18, 19, 29, 30).  The oligomerization between CCmut2 and Bcr-Abl would then 
interfere with the oligomeric state of Bcr-Abl, prevent the trans-autophosphorylation, and 
shift Bcr-Abl into an inactive state.  Indeed, we found that after transiently transfecting 




This residue is phosphorylated through trans-autophosphorylation, and its 
phosphorylation is pivotal for the tyrosine kinase activity of Bcr-Abl (31).  Numerous 
studies have used the phosphorylation of this residue as an indicator of the inhibition of 
Bcr-Abl, and the ability of CCmut2 to cause a decrease in Y245 phosphorylation 
demonstrates the ability to disrupt the Bcr-Abl oligomeric state leading to inhibition of 
Bcr-Abl.  The inhibitory effects of CCmut2 were further demonstrated by the reduction in 
phosphorylation of two substrates phosphorylated by Bcr-Abl, STAT5 and CrkL (32, 33).  
Importantly, the decreased phosphorylation of all three proteins was a significant 
improvement from that resulting from the wild-type coiled-coil domain.   
 The inhibition of Bcr-Abl signaling by CCmut2 was then monitored through the 
decreased proliferation of the CML cells.  CCmut2 was found to decrease the number of 
proliferating cells as measured through both a colony forming assay and cell counts using 
trypan blue for exclusion of dead cells.  While the wild-type coiled domain did not result 
in a statistical significant decrease in the proliferation of the K562 cells, CCmut2 was 
found to decrease the proliferation at a statistically significant level. 
 Just as tyrosine kinase inhibitors are found to induce apoptosis in CML cells, the 
inhibition of Bcr-Abl by CCmut2 should also result in apoptosis of CML cells.  The 
induction of apoptosis was measured through activation of caspase-3/7, and CCmut2 
produced an increase in active caspase-3/7 in K562 cells.  The fact that CCmut2 is 
functioning through inhibition of Bcr-Abl was further demonstrated by repeating the 
caspase-3/7 measurements in two cell lines that do not express Bcr-Abl, 1471.1 and Cos-
7.  No increase in caspase activity was observed in these cells, providing some evidence 




through morphological evaluation of the K562 cells (16, 17).  Cells transfected with 
CCmut2 showed signs of apoptosis such as cell shrinkage, cytoplasmic blebbing, and 
DNA segmentation.  The percentage of transfected cells with segmented DNA was 
calculated for quantification of the induction of apoptosis, and again CCmut2 
demonstrated an improved ability to induce apoptosis in the CML cells.  In a cell line 
lacking Bcr-Abl (1471.1) negligible DNA segmentation was observed after transfection 
of EGFP, CC or CCmut2.  Both the caspase and DNA segmentation assays show the 
specific induction of apoptosis in CML cells.   
 As a final bridge between the computational modeling identifying the optimal set 
of mutations and the in vitro experimental work, circular dichroism was used to study the 
mutations created in the coiled-coil domain.  First, both CC and CCmut2 were expressed 
in E. coli as fusion constructs with maltose binding protein (MBP) and six residues of 
histidine (his-tag, H6).  Wavelength scans produced almost identical spectral patterns for 
CC, CCmut2, or a mixture of CC and CCmut2, all exhibiting the characteristic pattern of 
α-helices.  Thermal denaturation of CC produced a melting temperature (Tm) of 83 °C in 
agreement with other published reports.  The Tm of CCmut2 was determined to be 63 °C 
by thermal denaturation, confirming the decreased stability of CCmut2 homo-oligomers.  
The thermal denaturation of CCmut2 mixed with CC did not produce a Tm higher than 83 
°C.  If the hetero-dimer has a Tm similar to CC, it may be difficult to distinguish with 
certainty.  The absence of a higher hetero-dimer Tm in combination with a lower homo-
dimer Tm for CCmut2, may conform to the list of results from other experiments if the 
hetero-dimer is isoenergentic with CC homo-dimers.  The CD data thus provide insight 




improve oligomerization, as substantiated through the in vitro experiments, through an 
increased availability to interact with CC due to decreased CCmut2 stability. 
 In summary, five mutations were identified in the Bcr-Abl coiled-coil domain.  
These mutations resulted in improved oligomerization with Bcr-Abl, and efficiently 
disrupted the oligomeric state of Bcr-Abl.  Disruption of Bcr-Abl oligomerization 
reduced the phosphorylation of Bcr-Abl, decreased the proliferation of K562 cells, and 
induced apoptosis in cells expressing Bcr-Abl, but not cells that do not express Bcr-Abl.  
These findings demonstrate the therapeutic capabilities of CCmut2, and also validate 
CCmut2 as an efficient binding domain for use in binding Bcr-Abl for translocation to the 
nucleus.   
 
Second Generation Modification to the Coiled-Coil Domain: CCmut3 
 While the modifications made to the coiled-coil domain improved 
oligomerization with Bcr-Abl, it seems the improvements stemmed largely from the 
decreased stability of the mutant coiled-coil rendering it more likely to interact with Bcr-
Abl.  The design for creating decreased stability was incorporation of charge-charge 
repulsion between the helices of the dimer interface.  In the course of studying CCmut2, 
an additional residue, K39, was identified as an additional position that could be mutated 
to create charge-charge repulsion and further destabilize the mutant homo-dimer 
formation.  Based on the structure of the wild-type coiled-coil domain, residue 39 is in a 
position on the helix to interact with residue 60.  For CCmut2 where residue 60 is 
glutamate, this could mean an additional two salt bridges (two sets of K39:E60) could 




form undesired salt bridges into possible charge-charge repulsion in the mutant homo-
dimer.  This additional mutation to CCmut2 was termed CCmut3. 
 The additional mutation was created in a plasmid encoding CCmut2 to create 
CCmut3, and mammalian two-hybrid assays were performed to determine the effects of 
the additional mutation.  CCmut3 was found to have an increased interaction with the 
wild-type coiled-coil domain, and minimal interaction with another CCmut3.  This 
finding confirms the additional mutation improves the oligomerization, at least at the 
domain level.   
 Co-localization analysis was then performed to verify the interaction with full-
length Bcr-Abl.  Although this method is not quantitative in terms of binding affinity, it is 
a useful way of confirming the interaction with Bcr-Abl inside of a mammalian cell.  
Interestingly, both wild-type and CCmut2 were found to co-localize at similar levels with 
Bcr-Abl.  However, CCmut3 demonstrated the greatest co-localization with Bcr-Abl, 
further validating it as the best coiled-coil domain for oligomerizating with Bcr-Abl.   
 The increased binding by CCmut3 was also assessed for increased effect on CML 
cells.  First, the proliferation was measured through colony forming assays and cell 
counts with trypan blue exclusion of dead cells.  In both assays, CCmut2 and CCmut3 
resulted in similar decrease in cellular proliferation.  The improved binding through 
CCmut3 did not correlate with an improved effect on the growth rate of the cells. 
 Induction of apoptosis by CCmut3 was also studied in CML cells through flow 
cytometry, DNA segmentation, and caspase-3/7 activation.  The number of cells that 
stained positively with 7-aminoactinomycin D (7AAD) was quantified through flow 




order of EGFP < CC < CCmut2 < CCmut3 as desired.  Nevertheless, in spite of CCmut3 
exhibiting an improvement over CCmut2 in the statistical probability between EGFP (p < 
0.001 vs p < 0.05, respectively), there was not a statistical difference between CCmut2 
and CCmut3.  Similarly, when apoptosis was measured through activation of caspase-3/7 
and DNA segmentation there was no statistical significance between CCmut2 and 
CCmut3. 
 From these studies we can conclude that the additional mutation did improve the 
ability to oligomerize with Bcr-Abl.  However, the improved binding properties did not 
translate into a further decrease in cell proliferation or enhancement of the induction of 
apoptosis.  Failure to improve the cellular effect may be explained by the disruption of 
Bcr-Abl oligomerization already being maximized with CCmut2.  If this is the case, 
further advancement in binding properties would not result in an improved effect on the 
cell proliferation or induction of apoptosis.  Alternatively, the assay sensitivity may not 
be sufficient to distinguish the difference between CCmut2 and CCmut3.  The ultimate 
goal entailing the modified coiled-coil domain is for capturing Bcr-Abl for translocation 
to the nucleus, and for this purpose the binding is critical.  The improvement in binding 
demonstrated by CCmut3, regardless of the inability to act as a more potent inhibitor of 
Bcr-Abl activity, will be important to achieve this goal. 
 
Isolation of Intracellular Domain Antibodies for Capture of Bcr-Abl 
 An alternative approach for binding Bcr-Abl is through isolation of an 
intracellular domain antibody (iDab) (34, 35) that targets Bcr-Abl.  Antibodies exhibit 




truncations have been made, particularly the scFv format, that are useful for epitope 
recognition intracellularly (36-39), but the iDab is an even smaller portion that has been 
shown to retain high binding affinity and specificity without the need for a peptide linker 
(34, 40).  In addition, iDabs are stable inside of cells, do not require any disulfide bridge, 
and can be expressed at high levels in mammalian cells (35, 41).   
 The procedure for isolation of an iDab has been termed intracellular antibody 
capture (IAC) technology (35, 42).  The IAC protocol was followed to isolate iDabs that 
bind Bcr-Abl at either the actin binding domain (ABD) or Dbl homology/pleckstrin 
homology (DHPH) region.  The first round of screening, involving screening libraries 
with randomized amino acids in the third complementarity determining region (CDR3), 
was performed in the laboratory of Dr. Rabbitts at the Leeds Institure of Molecular 
Medicine (LIMM) at Leeds University.  Although access to the libraries was limited to 
the time while I was in the Rabbitts laboratory, 20 and 25 hits were identified for the 
ABD and DHPH targets respectively.  These products from first round screening were 
then used for generation of sublibraries with amino acids in CDR2 randomized.  The 
sublibraries were then screened in the Lim laboratory where the top 12 ABD and DHPH 
binders were sequenced and subcloned into plasmids for mammalian two-hybrid 
screening.  Through the mammalian two-hybrid screening four iDabs were identified as 
the top binders, three that bind to the ABD and one that binds to the DHPH region.  
Overall, the top binding iDab was found to be ABD binding iDab #7 (ABI7). 
 Coupled with the goal of using the iDab as a capture motif for translocating Bcr-
Abl to the nucleus, the ABD was chosen as the target region of Bcr-Abl in attempt to 




we found that when ABI7 was co-transfected with mCherry-Bcr-Abl the resulting 
localization pattern of Bcr-Abl was altered.  Under normal conditions mCherry-Bcr-Abl 
is found to localize at the actin filaments in a distinct pattern of lines.  However, this 
pattern was altered and mCherry-Bcr-Abl was found at distinct punctuate structures when 
coexpressed with ABI7.  As Bcr-Abl interacts with both F-actin and G-actin (44), the 
resulting localization pattern may be indicative of a shift from interacting with both forms 
to one or the other.  While the exact details of this distinct localization pattern remains to 
be further elucidated, it does provide evidence ABI7 is able to compete with actin 
binding to a certain extent and may cause Bcr-Abl to become more available for 
translocation. 
 
The Use of Capture Motifs for Escorting Bcr-Abl to the Nucleus 
 The final work of this dissertation was to test the ability of the generated binding 
domains to capture Bcr-Abl and allow for translocation to the nucleus.  As the analysis of 
the nuclear translocation will be performed through fluorescence microscopy, cells that 
facilitate imaging and that do not express Bcr-Abl, Cos-7, were chosen for the 
experiments.  Two approaches of translocating Bcr-Abl to the nucleus were tested: 
incorporation of the binding domain into the inducible protein switch (46, 47), and 
attachment of nuclear localization signals directly to the binding domain.  Along with 
CCmut3 and ABI7, the top binding domains generated in this dissertation, the previously 
established Bcr-Abl binding domain from RIN1 (48-50) was also tested and compared 
with the translocation capabilities of CCmut3 and ABI7.  Prior to testing the ability to 




Bcr-Abl through colocalization analysis (51).  All three constructs (CCmut3, ABI7, 
RIN1) were found to colocalize with Bcr-Abl indicating their interaction inside a live 
cell.  However, DBI5, the top DHPH binding iDab, was just below the typical threshold 
used for determining colocalization.  This is likely representative of the weak interaction 
of this binding domain, confirming the modest binding result from the mammalian two-
hybrid assays.  Due to the evident weak interaction of DBI5 and all other DHPH binding 
iDabs, these binding domains were not tested further. 
 The first approach to translocate Bcr-Abl to the nucleus was under the ligand-
inducible control of the protein switch.  One advantage of this approach is the capability 
to grant mean residence time for the equilibration of the interaction between the binding 
domain and Bcr-Abl in the cytoplasm.  Nevertheless, the incorporation of the binding 
domains into the protein switch was found to decrease the nuclear translocation of the 
fused protein switch construct, and thus reduced the potential to escort Bcr-Abl to the 
nucleus along with it.  Negligible Bcr-Abl was found to accumulate in the nucleus after 
ligand induction with these protein switch constructs. 
 As all three of these binding domains interact with a different region of Bcr-Abl, 
it is possible to use multiple protein switch constructs to bind Bcr-Abl through multiple 
locations and increase the potential for nuclear translocation.  Accordingly, two protein 
switch constructs were co-transfected with Bcr-Abl and the resulting nuclear 
translocation was tested.  In the majority of the cells negligible Bcr-Abl was found to 
translocate to the nucleus.  However, it was possible to find some cells with minimal 
nuclear translocation.  As both of the protein switch constructs were fused to EGFP, it 




transfected into the cells.  After identification of cells with apparent nuclear translocation 
of Bcr-Abl, the percentage of Bcr-Abl in the nucleus was quantified.  The combination of 
protein switch-ABI7 and protein switch-CCmut3 was the only combination to result in a 
statistical significant accumulation of Bcr-Abl in the nucleus.  Although this was a biased 
screen and represents an inadequate method for translocation of Bcr-Abl, it did 
demonstrate a slight feasibility of translocating Bcr-Abl to the nucleus. 
 In a much simpler approach, the binding domains were fused to four strong 
nuclear localization signals, the signal from SV40.  Although these constructs are not 
ligand-inducible, and thus there will not be any mean residency time for binding in the 
cytoplasm, these constructs were found to localize almost exclusively in the nucleus.  
This is in stark contrast to the protein switch constructs, where even the optimized protein 
switch without incorporation of a binding domain is readily detectable in the cytoplasm 
even after ligand induction (47).  Regardless, both 4NLS-ABI7 and 4NLS-RIN1 were 
unable to cause a nuclear accumulation of Bcr-Abl.  This finding may be due to the 
minimal time to interact with Bcr-Abl associated with the rapid nuclear accumulation of 
these constructs, or insufficient binding to overcome the opposing interactions leading to 
cytoplasmic retention of Bcr-Abl.  However, in astounding fashion, 4NLS-CCmut3 
resulted in the majority of Bcr-Abl translocating to the nucleus.  The fact that CCmut3 
was able to translocate Bcr-Abl to the nucleus, but not ABI7 or RIN1, may indicate how 
Bcr-Abl is bound is important, and not merely how tightly it is bound.  Further 
examination of the binding affinities of these domains will be required to fully make this 
conclusion.  This study demonstrated, for the first time, it is possible to escort Bcr-Abl to 




LMB was previously found to trap approximately 25% of Bcr-Abl in the nucleus, an 
amount that was sufficient for induction of apoptosis (13).  4NLS-CCmut3 was found to 
cause approximately 70% of Bcr-Abl to translocate to the nucleus, demonstrating the 
potential for an even more potent induction of apoptosis.   
 
Future Work 
Simplifying CCmut3: Testing Helix 2 
 The coiled-coil domain from Bcr-Abl is 72 amino acids long and consists of two 
parallel helices connected by a short loop (20, 21).  The first of these helices, termed α-1 
and found at the N-terminus, is a short helix of 11 amino acids, residues 5-15.  The 
second helix, α-2, is composed by residues 28-67, and contains the bulk of the residues 
found at the dimer and tetramer interface.  Consistent with α-2 being at the core of the 
oligomerization, an α-2 peptide composed of residues 23-72 has been shown to be useful 
for inhibiting Bcr-Abl through interfering with its oligomeric state (52, 53).  In this work, 
we have shown that the coiled-coil domain can be improved by mutating certain residues 
to achieve enhanced oligomeric properties (54).  All of the residues mutated for enhanced 
oligomerization are found within the α-2 helix.  Thus, a CCmut3 peptide can be 
constructed similar to the previous α-2 peptide, and compared for efficacy against full-
length CCmut3 and wild-type α-2 peptide.  Both the inhibitory effects on Bcr-Abl and the 
ability to translocate Bcr-Abl to the nucleus should be studied with this smaller construct.  
Even if the CCmut3 peptide does not demonstrate enhanced efficacy, and is only 




smaller, may be more easily internalized into cells, synthesized synthetically, and may be 
more readily translated into a useful therapeutic.   
 In addition to a CCmut3 peptide consisting of residues 23-72 as has been 
demonstrated for wild-type CC, further truncations such as residues 28-67, or even 30-65, 
should also be tested.  Residues 23-27 and 68-72 are not part of the helix and are not 
likely to be important in the oligomerization and the corresponding efficacy of the 
peptide.  A peptide consisting of 30-65 has been used to study the structure of the Bcr 
coiled-coil domain (20, 21), and should also be tested as potentially the minimal peptide 
to retain binding capabilities.  An interesting strategy that has not previously been 
attempted for this peptide is to add residues at the termini for stabilization of the helix 
cap.  Aspartate residues at the N-terminus provide stabilization to the N-cap through both 
hydrogen bonding and interactions with the helix dipole (55-58).  If only α-2 is used as 
the peptide (residues 28-67), the N-terminal residue is valine which is slightly 
destabilizing for the N-cap.  This residue could be mutated to aspartate, or an additional 
aspartate could be added before this valine to help stabilize the N-cap of the helix.  At the 
C-terminus of the helix is a lysine.  Although lysines are mildly stabilizing to the C-cap, 
either this lysine could be mutated to the more stabilizing glycine, or an additional 
glycine could be added to the C-terminus for added stabilization of the C-cap (58-60).  In 
addition to the incorporation of residues for N- and C-capping of the helix, the termini of 







Continuation of Affinity Maturation Screening of Bcr-Abl-Binding iDabs 
 Although one iDab, ABI7, has been identified with reasonable affinity for Bcr-
Abl, various approaches for further affinity maturation can be explored.  This may be of 
particular interest for the DHPH binders as the isolated iDabs thus far have demonstrated 
only weak interaction with Bcr-Abl.  As further analysis of the ability to induce apoptosis 
through 4NLS-CCmut3 unfolds it may be discovered that alternative binding strategies 
that do not interfere with Bcr-Abl oligomerization will be needed.  A simultaneous dual 
binding approach at the ABD and DHPH regions could be a viable alternative with 
improvements in the affinity of these iDabs.   
 One of the easiest methods to identify an iDab with higher affinity for Bcr-Abl 
would be to rescreen the sublibraries with increased concentration of 3-amino-1,2,4-
triazole (3-AT).  3-AT is an inhibitor of the HIS3 gene product (35), the gene controlled 
through the interaction between the iDab and the bait (ABD or DHPH).  By increasing 
the concentration of 3-AT in the screening plates, weaker interactions that activate the 
pathway to a lesser extent can be inhibited.  This allows for the identification of the 
higher affinity interactions.  Before the sublibraries were screened, the auto-activation of 
the HIS3 gene was assessed, and it was determined that 2 mM 3-AT was sufficient to 
eliminate the auto-activation.  Only this minimal amount, 2 mM, was then used in the 
screens, leaving ample range for increasing the concentration to screen out the weak 
interactions and identify the high affinity interactions.  As approximately 800 colonies 
grew on the screening plates with 2 mM 3-AT for both ABD and DHPH baits, increasing 
the 3-AT concentration would reduce the number of colonies down to a range where all 




 More extensive approaches could also be undertaken to identify an iDab with 
higher affinity for Bcr-Abl.  The protocol outlined for IAC of iDabs entails the screening 
of 15 libraries in the first round of screening (35).  Time constraints only allowed access 
to these libraries for a short period of time while in the Rabbitts laboratory, and resulted 
in the ability to screen only 3 of the 15 libraries.  The remaining libraries could be 
generated in the Lim laboratory, or a possible agreement could be made with the Rabbitts 
laboratory to continue screening their libraries either in the Lim Laboratory or at the 
LIMM.  A more extensive screening with the all of the potential sequences of CDR3 
should allow for the identification of iDabs with higher affinity for Bcr-Abl.   
 Further affinity maturation of the iDabs could also be achieved through 
randomization of CDR1 in the creation of a sublibrary for use in another round of 
screening.  Typically IAC3 consists of all three rounds, screening for the optimal binding 
sequences of CDR3, CDR2, and CDR1.  Continuation of the third round of screening for 
the optimal CDR1 sequences would increase the affinity of the current iDab constructs.   
 
Translocating Endogenous Bcr-Abl to the Nucleus 
 While this work has shown that mCherry-Bcr-Abl, when co-transfected, could be 
translocated to the nucleus with 4NLS-CCmut3, further exploration of the ability to 
translocate endogenous Bcr-Abl to the nucleus will need to be confirmed.  The 
experimental design wherein the mCherry-Bcr-Abl was shown to translocate to the 
nucleus along with EGFP-4NLS-CCmut3 may prove easier than translocating the 
endogenous Bcr-Abl.  The major difference being that endogenous Bcr-Abl will already 




Abl will not only have to compete with the oligomerization of Bcr-Abl, but overcome the 
other interactions causing the cytoplasmic localization.  This is a dramatic difference with 
the experiment, wherein the Bcr-Abl was being translated simultaneously with 4NLS-
CCmut3.  This may allow an equal opportunity for 4NLS-CCmut3 to bind Bcr-Abl while 
homo-oligomerization and other protein binding occur, and result in a more facile nuclear 
translocation of Bcr-Abl.  As the ultimate goal is to translocate endogenous Bcr-Abl to 
the nucleus, the ability to do so will need to be confirmed without relying on exogenously 
added Bcr-Abl constructs. 
 One possible experimental design that may correlate more closely to the ability to 
translocate endogenous Bcr-Abl, while using mCherry-Bcr-Abl for ease of monitoring 
the nuclear translocation, is to sequentially transfect mCherry-Bcr-Abl and then 4NLS-
CCmut3.  In this fashion mCherry-Bcr-Abl would be allowed to form the typical 
interactions resulting in the cytoplasmic retention.  Twenty-four hrs later the same cells 
could then be transfected with 4NLS-CCmut3, and 24 hrs later the subcellular 
localization of Bcr-Abl determined through fluorescence microscopy.  This would 
demonstrate the ability of 4NLS-CCmut3 to compete with the cytoplasmic interactions 
and cause a relocalization of Bcr-Abl into the nucleus.   
 Nevertheless, this would not replace the testing of endogenous Bcr-Abl in CML 
cells, and immunocytochemistry will need to be performed to study the subcellular 
distribution of endogenous Bcr-Abl after transfection of 4NLS-CCmut3.  Analysis of the 
subcellular distribution of Bcr-Abl through an immunocytochemical approach has 
already been performed in K562 cells (2), and can be followed after transfection of 




the nucleus can be determined and more appropriately compared with the previous result 
obtained by the combination treatment of imatinib and LMB (13).  If less than 25% of 
Bcr-Abl is translocated into the nucleus by 4NLS-Bcr-Abl, the result obtained with 
imatinib and LMB, alternative approaches may need to be explored for increasing the 
nuclear translocation.  Some strategies for achieving this purpose may include 
combinations of binding domains that bind different regions of Bcr-Abl, pretreatment of 
cells with CCmut3 or ABI7 (no NLSs) followed by treatment with 4NLS-CCmut3, and 
combination treatment with imatinib and 4NLS-CCmut3.  Additionally, the 14-3-3 
inhibitor BV02 (7, 63) could be used in combination with 4NLS-CCmut3 to release Bcr-
Abl from 14-3-3 interactions that are also thought to play a role in cytoplasmic retention.   
 
Characterization of the Induction of Apoptosis by Nuclear Bcr-Abl 
 While translocating Bcr-Abl to the nucleus was a major component of this 
project, the ultimate goal is to use nuclear Bcr-Abl to induce apoptosis.  The induction of 
apoptosis by Bcr-Abl following translocation to the nucleus by CCmut3 will warrant 
extensive investigation through multiple experimental approaches.  Some apoptosis 
assays that could be carried out are the analysis of annexin-APC/7AAD staining via flow 
cytometry, activation of caspases such as caspase-3/7, evaluation of cellular morphology 
(such as cell shrinkage, cytoplasmic and zeotic blebbing, echnoid spikes, and DNA 
segmentation), mitochondrial membrane potential (JC-1 assay), cytochrome C release 
(western blot or ELISA), and PARP cleavage (western blot).  An important aspect of 
analyzing the induction of apoptosis through 4NLS-CCmut3 will be the comparison to 




simultaneous evaluation with 4NLS-CCmut3 will provide a reference to the standard of 
approved CML treatment.   
 The first step will be to demonstrate the induction of apoptosis in CML model 
cells such as K562, KU812, BaF3p210, and 32Dp210.  As 4NLS-CCmut3 functions through 
altering the localization of Bcr-Abl, cells that do not contain Bcr-Abl should not be 
affected.  The induction of apoptosis should also be measured after transfecting 4NLS-
CCmut3 into cells that do not contain Bcr-Abl to demonstrate both the safety of 4NLS-
CCmut3 as well as confirm the mechanism of action does in fact depend on Bcr-Abl.   
 After it has been demonstrated in model cell lines that 4NLS-CCmut3 can escort 
Bcr-Abl to the nucleus where it induces apoptosis, CML patient samples should be tested.  
These patient samples provide the closest simulation for therapeutic efficacy in CML 
patients.  A critical aspect of validating the therapeutic potential of 4NLS-CCmut3 will 
be to demonstrate efficacy in these patient samples.  However, a limiting factor is the 
access to these patient samples, and only after careful vetting of the nuclear translocation 
of Bcr-Abl and the induction of apoptosis is the use of the limited supply of CML patient 
samples warranted.   
 
Testing the Ability to Translocate Resistant Forms of Bcr-Abl 
and the Ensuing Induction of Apoptosis 
 One of the current problems in CML therapy is the ability to treat TKI resistant 
forms of Bcr-Abl (64-66).  Although ponatinib and DCC-2036 are currently in clinical 
trials and have been demonstrated to inhibit Bcr-AblT315I (67-69), there are no currently 




the coiled-coil domain, none of the currently described mutations found in the SH3, SH2, 
or tyrosine kinase domains should have any effect on the ability of CCmut3 to bind Bcr-
Abl (70-72).  As a result, 4NLS-CCmut3 should have similar efficacy on Bcr-Abl and all 
of the resistant forms of Bcr-Abl.  The ability to translocate resistant forms of Bcr-Abl to 
the nucleus, and the resulting induction of apoptosis, should be confirmed 
experimentally.  Moreover, it has been shown that oligomeric disruption of Bcr-AblT315I 
does not abrogate the kinase activity as is found for unmutated Bcr-Abl (52, 73).  Thus, if 
the kinase activity is involved in the induction of apoptosis when Bcr-Abl is localized in 
the nucleus, Bcr-AblT315I may be a more potent inducer of apoptosis than other forms of 
Bcr-Abl.  In an interesting twist, the only form of Bcr-Abl that is currently untreatable 
may turn out to be the form which 4NLS-CCmut3 has the highest efficacy against.   
 Currently our lab has BaF3 cells stably transfected with Bcr-AblT315I.  This is an 
apt model for studying the ability to translocate Bcr-AblT315I to the nucleus.  After the 
nuclear translocaion has been confirmed, similar apoptosis assays as were carried out 
with unmutated Bcr-Abl could be performed.  Other cell lines containing Bcr-Abl with 
other resistant mutations could also be used to demonstrate the ability of 4NLS-CCmut3 
to escort Bcr-Abl to the nucleus, and the ability of nuclear Bcr-Abl to induce apoptosis, 
regardless of the particular mutation.  Although extremely difficult to obtain, patient 
samples from CML patients with Bcr-AblT315I would be an important demonstration of 
the efficacy of escorting this particular form of Bcr-Abl to the nucleus and the ensuing 
induction of apoptosis.  Demonstration that 4NLS-CCmut3 can cause induction of 




will validate 4NLS-CCmut3 as a potential strategy for treatment of resistant forms of 
CML.   
 
Induction of Apoptosis by Nuclear Bcr-Abl in CML Stem Cells 
 Although TKIs effectively manage CML, they are not curative (74, 75).  At the 
root of the problem resulting in their inability to cure CML is the fact that they do not 
induce apoptosis in the CML stem cells (76).  This inability to induce apoptosis in the 
stem cells is not due to a lack of Bcr-Abl expression in these cells (77), nor is it due to 
their inability to inhibit Bcr-Abl in these cells (78).  Intriguingly, inhibition of Bcr-Abl in 
the CML stem cell does not have the same effect as inhibition in the more mature cells.  
One theory explaining this phenomenon is that these quiescent stem cells are not yet 
dependent on Bcr-Abl signaling.  Regardless of the reasoning for TKIs not affecting the 
stem cells, it is likely that active induction of apoptosis by nuclear Bcr-Abl will be 
effective in the stem cells.  If indeed nuclear Bcr-Abl induces apoptosis in the CML stem 
cells, it would demonstrate the potential to turn a disease requiring a life-long 
management regimen into a curable disease.  With enormous ramifications few other 
approaches, if any, can claim, this therapeutic intervention strategy must be explored.   
 CML stem cells are typically defined as those cells exhibiting a CD34+ and CD38- 
phenotype (79).  Addition characteristics have also been used in attempt to accurately 
identify the homogenous population of CML stem cells.  Such attempts include low side 
scatter, high expression of aldehyde dehydrogenase (79), efflux of Hoescht dye (80), and 
non-responsiveness to cytokines (80), to name a few.  Nevertheless, through FACS it is 




strict homogenous population of the stem cells, they are enriched with the stem cells and 
can be used as a model system for the stem cells.  Studies in this population of cells will 
be a critical component of validating the therapeutic potential of nuclear Bcr-Abl.  Again, 
apoptosis assays such as the ones already mentioned could be used to test the induction of 
apoptosis in these cells.  A potential limitation, however, may be the low number of the 
CD34+/CD38- cells in the sample, requiring the use of assays with high sensitivity that 
can be performed on minimal numbers of cells.  As flow cytometry will be used to sort 
the cells, some possibilities involve apoptosis analysis via flow cytometry.  This affords 
the ability to treat the entire sample and analyze the effects on different subpopulations of 
cells simultaneously on the flow cytometer.   
 While the exact mechanism of inducing apoptosis after Bcr-Abl is transported to 
the nucleus remains to be further elucidated, the current understanding is that it involves 
activation of p73 (81-85).  As a p53 family member, p73 is a robust tumor suppressor and 
recently has gained interest as a target for cancer intervention (86).  Activation of p73 
results in activation of the pro-apoptotic proteins PUMA, Bax, and p21 (87).  These 
signaling pathways are also found in hematopoietic stem cells, and hence the CML stem 
cells, indicating that activation of p73 by nuclear Bcr-Abl should have the same effect on 
all Bcr-Abl-containing cells, including the stem cells.  This immensely important 
hypothesis will justify extensive exploration.   
 
Internalization of 4NLS-CCmut3 with a Cell Penetrating Peptide 
 One of the biggest challenges that will need to be overcome in order to allow the 




a formidable challenge for macromolecular therapeutics such as 4NLS-CCmut3.  One 
avenue that is currently being explored is the use of a leukemia-specific cell penetrating 
peptide (CPP) (88).  This CPP, the nine amino acid sequence CAYHRLRRC, was 
identified through screening involving phage display and the specific internalization into 
leukemia and lymphoma cells.  Although CCmut3 is not expected to exhibit toxicity in 
healthy cells that do not contain Bcr-Abl, specific delivery to only leukemic cells will add 
an additional level of safety.   
 As opposed to a typical ligand-receptor based approach to targeting the 
leukemia/lymphoma cells, this CPP was identified while screening for peptides 
internalized through macropinocytosis (88).  Interestingly, the identified peptide 
consisted of sequences identified as a lymph-node homing motif (CAY) and an arginine 
rich sequence (RLRR) typical of cell penetrating peptides.  The dual functionality was 
demonstrated to result in substantially greater internalization into leukemia and 
lymphoma cells than other non-leukemia/lymphoma cells.  Inclusion of this CPP at a 
terminus of CCmut3 may provide the means for internalization, but will need further 
validation for larger constructs as it was only demonstrated through conjugation to a 
peptide of 14 amino acids.  As an alternative to CAYHRLRRC, another leukemia-
specific CPP has recently been identified that could be explored for internalization of 
CCmut3 (89).   
 As mentioned, there is no reason to expect CCmut3 to exhibit toxicity on cells 
that do not contain Bcr-Abl, and studies thus far confirm this finding.  Hence, a leukemia-
specific internalization may not be necessary, and if a nonspecific CPP can deliver a 




alternative CPPs should be tested and compared for a more comprehensive analysis to 
guide the selection.  Obvious choices include the commonly studied HIV trans-activator 
of transcription (Tat) (90-95) and the third helix from Antennapedia homeodomain 
(pAntp) (96-98).  These CPPs have been used to deliver a variety of cargos, including 
proteins, of various sizes into a range of cells and cell types.   
 Alternatively to the internalization of CCmut3 protein with a CPP, the gene 
encoding CCmut3 could be delivered with a viral vector.  Adenoviral vectors, specifically 
serotype 5 (Ad5), are one of the most common viral vectors used in clinical trials (99-
102), and are a reasonable choice due to improvements reducing immunogenicity along 
with the epi-chromosomal delivery to both dividing and non-dividing cells.  Other 
options, such as lentiviral vectors, offer the ability to integrate into the host cell genome 
with continued protein expression in daughter cells but come with an added risk for 
insertional mutagenesis (103, 104).  While no gene therapeutic is currently approved for 
use in the US, numerous clinical trials are underway.  Moreover, two gene therapeutics 
have been approved for head-and-neck cancer in China (105, 106), Gendicine (SiBiono) 
(107) and Oncorine (Shanghai Sunway Biotech) (108), and may be a possible indication 
of technological advancements leading to future US approval of a gene therapeutic.  
Given the immense potential of viral vectors for gene therapeutics, this mechanism of 








Use of CCmut3 or iDabs for Transport of Bcr-Abl 
to Other Subcellular Compartments 
 This body of work has focused on generating binding domains to allow the 
translocation of Bcr-Abl to the nucleus where it is an active inducer of apoptosis.  
Directing Bcr-Abl to other subcellular compartments may also prove therapeutically 
relevant.  Two subcellular locations of interest are the proteasome and the mitochondria, 
and methods to target Bcr-Abl to these areas are being explored by Rian Davis and 
Jonathan Constance, respectively.  Efficient removal of Bcr-Abl by triggering its 
degradation by sending it to the proteasome may be an alternative to inhibiting its 
activity.  Based on the activity of c-Abl, translocating Bcr-Abl to the mitochondria should 
result in phosphorylation of protein kinase C delta (PKCdelta) and subsequent induction 
of apoptosis (109, 110).  Both of these projects are underway in the Lim Laboratory and 
may be facilitated by the increased ability to capture Bcr-Abl with the binding domains 
generated in this dissertation.   
 Although signals targeting the proteasome are not as straight forward as other 
locations such as the nucleus, there are methods to target a protein to the proteasome for 
degradation.  One approach is through the N-end rule, a correlate between the half-life of 
a protein and the residue at the N-terminus of the protein (111-114).  These so-called 
degradation signals, or degrons, involve either acetylation or arginylation of the residue at 
the N-terminus.  Conjugation of the Bcr-Abl binding domain to a sequence known to be 
acetylated or arginylated may direct the complex to the proteasome for degradation in a 
similar fashion as 4NLS-CCmut3 directs Bcr-Abl to the nucleus.  An alternative strategy 




be poly-ubiquitinated by ubiquitin ligase and directed to the proteasome after binding to 
ligand (115-117).  Hence, the ER LBD may serve as a proteasomal protein switch.  A 
Bcr-Abl binding domain could be incorporated into this proteasomal protein switch, and 
after addition of ligand will escort Bcr-Abl to the proteasome for degradation.   
 Associated with the pivotal role in energy production, the mitochondrion is a 
highly-characterized cellular compartment.  Correspondingly, the signals directing 
proteins to the mitochondrion are also highly-studied.  Various mitochondrial targeting 
signals (MTS) have been described, including separate signals for targeting the outer 
membrane (118), the inner membrane (119, 120), the intermembrane space (121), and the 
matrix (122).  To date, in our laboratory the mitochondrial matrix has been efficiently 
targeted through use of the signal from ornathine transcarbamylase (OTC), 
MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQ (122), the outer membrane has 
been targeted by either the signal from Tom20, MVGRNSAIAAGVCGALFIGYCIYFD 
RKRRSDPN(123), or from Bcl-XL, RGPGIQKGPGEIQQMVPDRHDRGRRGAAGQP 
VQQKX , and the innermembrane space has been targeted by the signal from 
SMAC/Diablo.  Similar to the NLSs, these MTS could be incorporated into the binding 
domain to allow capture of Bcr-Abl followed by redirection to the mitochondrion.  In a 
more elaborate system, Jonathan Constance has designed a cryptic MTS (cMTS) that 
only results in mitochondrial relocation after phosphorylation by Bcr-Abl.  The optimized 
cMTS exhibits a tight interaction with Bcr-Abl, and no additional binding domain may be 
necessary.  Use of the cMTS would allow translocation of Bcr-Abl to the mitochondria 




 In addition to the future use of the binding domains generated in this dissertation 
for translocating Bcr-Abl to other subcellular compartments, the demonstration that Bcr-
Abl can be escorted to the nucleus provides proof-of-concept that an exogenously added 
protein can be used to redirect the subcellular localization of Bcr-Abl.  The fact that Bcr-
Abl can be moved to the nucleus indeed signifies it can be moved to other compartments 
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